# Plasma multi-omics analysis reveals very long chain ceramides as 

 validated biomarkers of Friedreich's ataxiaAuthors: Dezhen Wang, ${ }^{1}$ M. Grazia Cotticelli, ${ }^{2}$ Blanca E. Himes, ${ }^{3}$ David R. Lynch, ${ }^{4}$ Clementina Mesaros ${ }^{1 *}$

## Affiliations:

${ }^{1}$ Department of Systems Pharmacology and Translational Therapeutics and Center for Excellence in Environmental Toxicology, University of Pennsylvania; Philadelphia, PA, 19104, USA.
${ }^{2}$ Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia; Philadelphia, PA, 19104, USA.
${ }^{3}$ Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania; Philadelphia, PA, 19104, USA.
${ }^{4}$ Departments of Neurology and Pediatrics, Children's Hospital of Philadelphia; Philadelphia, PA, 19104, USA.

* Corresponding author. Email: mesaros@upenn.edu.

One Sentence Summary: New plasma lipids biomarkers of Friedreich's Ataxia (FRDA) were validated using a discovery-validation design with two independent cohorts.


#### Abstract

Friedreich's Ataxia (FRDA) is an autosomal neurodegenerative disease caused by the deficiency of the protein frataxin. Frataxin is a critical enzyme in the assembly of iron-sulfur clusters that are cofactors for several metabolic enzymes. To identify metabolic features that could be used as potential biomarkers for FRDA in plasma, we performed a multi-omics analysis using a discovery-validation cohort design. We combined metabolomics, lipidomics and proteomics from several liquid chromatography-high resolution mass spectrometry platforms. The analyses revealed that FRDA patients compared to healthy controls and unaffected carriers had dysregulated sphingolipids metabolism, phospholipid metabolism, citric acid cycle, amino acid metabolism, and apolipoprotein metabolism. Using an ROC, the decreased very long chain ceramides can distinguished FRDA patients from healthy controls with AUC from 0.75 to 0.85 . Using induced pluripotent stem cell differentiated cardiomyocytes (iPSC-CMs), we demonstrated that frataxin deficiency preferentially affected ceramide synthase (CerS2), enriching long chain ceramides, and depleting very long chain ceramides. The ceramide metabolism was differentially regulated in two of the affected tissues in FRDA: heart and muscles. A machine-learning model improved the prediction of FRDA using the combination of three plasma metabolites (AUC > 0.9). In conclusion, decreased very long chain ceramides are reliable plasma biomarkers for FRDA patients.


Keywords: Friedreich's Ataxia (FRDA), metabolomics, lipidomics, ceramide, biomarker

## INTRODUCTION

Friedreich's Ataxia (FRDA) is an autosomal recessive neurodegenerative disease characterized by progressive mobility loss, impairment of speech, ${ }^{1}$ and eventual loss of vision ${ }^{2}$ and hearing 3. Individuals with FRDA exhibit clinical manifestations of ataxia, hypertrophic cardiomyopathy, scoliosis, and diabetes mellitus ${ }^{4-7}$. Cardiac complications are the major cause of early death in FRDA ${ }^{8}$. Most disease alleles in FRDA have a guanine-adenine-adenine (GAA) repeat expansion in the first intron of the disease gene $F X N$, this repeat leads to the silencing of the $F X N$ gene and decreased frataxin protein levels ${ }^{9,10}$. Frataxin acts in the assembly of iron-sulfur (Fe-S) clusters, which are important for iron homeostasis and optimal functions of metabolic enzymes for citric acid cycle, electron chain transport, and fatty acid breakdown ${ }^{11-14}$. Defective mitochondrial metabolism and mitochondrial functions are observed in different models of FRDA ${ }^{15-17}$ including $\mathrm{Fe}-\mathrm{S}$ containing aconitase and respiratory chain complexes ${ }^{18}$ that result in a failure of energy (ATP) production ${ }^{19,20}$. Frataxin-deficient cardiomyocytes present altered thiol-redox state and a decrease content in pyruvate dehydrogenase (PDH A1) ${ }^{21}$ and decreased pyruvate oxidation and increased fatty acid oxidation was observed in platelets from FRDA patients ${ }^{22}$. Frataxin deficiency influences the peroxisome-proliferator activator receptor gamma (PPAR $\gamma$ )/PPAR $\gamma$ coactivator 1 alpha (Pgc1a) pathway in cellular and animal models, which is linked to mitochondrial biogenesis and lipid metabolism ${ }^{23}$. Frataxin reduction induces iron accumulation and enhances the sphingolipid/PDK1/Mef2 pathway, which triggers neurodegeneration in fly and mouse models ${ }^{24,} 25$. As discussed in a 2019 summary of FRDA biomarkers ${ }^{26}$, metabolic dysfunctions are significant features of FRDA patients, but larger population studies are necessary to discover and validate actionable biomarkers. A recent study ${ }^{27}$ uncovered dysregulation in the one carbon metabolism in plasma from FRDA patients. A common feature of all previous human studies is the limited number of FRDA patients and the lack of validation of the new finding in an independent cohort.

To understand the pathophysiology of FRDA, a high-throughput and large-scaled screening strategy could be employed to investigate the metabolic dysfunctions of FRDA and discover new biomarkers. Metabolomics and proteomics-based profiling provide a useful tool to unravel such biomarkers. Omics profiling have been widely used for biomarker discoveries, drug response prediction, and pathogenesis-related pathway revelation for other diseases ${ }^{28-30}$. Recently, ceramide levels were shown to be accurate biomarkers of adverse cardiovascular disease outcomes in human serum ${ }^{31}$.

To identify potential blood biomarkers in FRDA, we performed metabolomics, lipidomics, and proteomics analysis using discovery-validation design in two independent cohorts of fasting plasma samples. Our results showed that very long chain ceramides distinguish FRDA patients from healthy controls. We further investigated the ceramide metabolism in human induced pluripotent stem cell derived cardiomyocytes (iPSC-CMs) using high-resolution mass spectrometry (HRMS) lipidomics and isotope tracing assays, and consistently found that frataxin deficiency disrupted ceramide synthesis and preferentially enriched long chain ceramides but depleted very long chain ceramides. Using several cell lines from different affected tissues in FRDA patients, we demonstrated that ceramide metabolism was tissue specific differentially regulated. Our study provides new validated plasma biomarkers for

FRDA patients, and these biomarkers could be potential therapeutic targets.

## RESULTS

## Experimental design and targeted multi-omics workflow

To identify metabolic features that can be used for potential biomarkers in FRDA plasma, we developed independent targeted metabolomics, lipidomics and proteomics workflows using ultra-high performance liquid chromatography-high resolution mass spectrometry (UHPLCHRMS), and measured hundreds of metabolites, lipids, and proteins (Fig. 1A).
Using pooled plasma samples (Supplementary Table 1) or standard solutions, we build-up reliable $\mathrm{MS}^{2}$ spectral libraries by analyzing pooled samples in a data-dependent acquisition (DDA) mode. We included more than 50 internal standards ( ${ }^{13} \mathrm{C},{ }^{2} \mathrm{H}$, or chain length analogs) (Supplementary Table 2) in combination with quality controls (QC) for locally estimated scatterplot smoothing (LOESS) to normalize for signal intensity drift. Next, well annotated (see experimental part), metabolites, lipids, and peptides were used to generate scheduled window-based inclusion lists for each individual omics experiment (Supplementary Table 3-5) for targeted analysis (Supplementary Fig. 1-3).

To validate the reproducibility and the robustness of our workflows, we separately processed and analyzed 10 technical replicates formed from pooled plasma samples for each of the workflow for metabolomics, lipidomics, and proteomics. We analyzed all the samples in full scan (FS) and parallel reaction monitoring (PRM) modes providing untargeted profiling in combination with more specific targeted quantification without significantly compromising the data acquisition speed. Excellent chromatographic reproducibility was observed for the positive (Fig. 1B) and negative (Fig. 1C) modes for the lipidomics workflow. For all the analyses, we combined the positive and negative mode data. Metabolomics analysis included 123 metabolites and Pearson correlation showed high coefficients ( $\mathrm{R}^{2}, 0.97-1$ ) between 10 technical replicates for metabolomics (Fig. 1D). For lipidomics (Fig. 1E) and proteomics (Fig. $1 F$ ), even higher correlation coefficients ( $\mathrm{R}^{2}>0.99$ ) were observed for the 10 technical replicates, indicating the high reproducibility of the workflow for these assays. To test the reproducibility of all the tested features, we calculated the coefficient of variance (CVs) for all quantified metabolites, lipids, and peptides. For metabolomics, three metabolites had CVs higher than $30 \%$, and 14 metabolites had CVs higher than $20 \%$ (Fig. 1G). For lipidomics, out of 630 lipids, only four metabolites showed CVs higher than $20 \%$ (Fig. 1H). For proteomics, four peptides had CVs higher than $30 \%$, and 12 peptides had CVs higher than 20\% (Fig. 1I). All these preliminary technical data demonstrated that our approach using a targeted multiomics workflow is a robust method for biomarker identification.

## Metabolomics and lipidomics analysis revealed dysregulated metabolism in FRDA.

Using this targeted multi-omics workflow, we performed both metabolomics and lipidomics analysis using the discovery set of EDTA fasting plasma samples that included 15 controls and 33 FRDA patients (Supplementary Table 1). Those samples were collected between 2012-2019 as part of a Natural History study at the Children's Hospital of Pennsylvania. The average age of the FRDA patients was $25.6 \pm 8.1$ and the age of the controls was not significantly different $32.7 \pm 11.0$. This discovery set also included 11 unaffected carriers, with a significantly different
age, as the carriers are usually parents or relatives of the FRDA patients. All groups were balanced on sex as shown in Supplementary Table 1. We visualized the data distribution globally by principal component analysis (PCA). A clear but partial separation of the FRDA group (light blue) from the Control/Carrier groups was observed on the PC1 (Fig. 2A), indicating the metabolic features correlated with disease condition. Most small molecule analytes showed small CVs in our QCs (Supplementary Fig. 4). To identify significantly changed metabolites and lipids, we performed pairwise comparison using a $t$-test. There were no significantly different metabolites between the Control and Carrier groups in the volcano plot from Fig. 2B, which suggests that the Carriers are not metabolically different compared with controls. However, more than 30 metabolites or lipids had a false discovery rate (FDR) $<0.05$ and were dysregulated in the FRDA patients in comparison with healthy controls (Fig. 2C). We next applied multivariate statistical analysis method (least square discrimination analysis (PLS-DA)) to calculate the contribution of metabolites or lipids to model discrimination between the Control and FRDA groups (variable importance in projection-VIP). We found that all the metabolites having significant $P$ values also showed higher VIP values (Fig. 2D). To visualize the distribution of the top 50 metabolites or lipids ( $\mathrm{FDR}<0.1$ ), we plotted these as a heatmap for carriers, controls, and FRDA patients (Fig. 2E). To detect the functional groups of metabolites that changed in FRDA patients, we performed correlation analysis on the amount of top 50 compounds (FDR $<0.1$ ). The compounds can be categorized into several groups based on their structure and biological data. On the basis of partial correlation relationships, we build the metabolite correlation network (Fig. 2F and Supplementary Fig. 5) that showed three major clusters. The largest cluster was composed of multiple ceramides, and high intra-correlations were observed for these ceramides. The second largest cluster was the phospholipid cluster, composed of phosphocholines (PC), lyso-PC (LPC), phosphatidic acids (PA), phosphoinositols (PI), and lyso-PI (LPI).

## Pathway analysis revealed abnormal sphingolipid metabolism in FRDA

We further examined the pathway changes by performing Metabolite Set Enrichment Analysis (MSEA). For lipids, ceramides, PCs, and PIs had the highest enrichment ratio (Fig. 3A). For metabolites, the most enriched ones were categorized into purine metabolism, citric acid cycle, and amino acid metabolism (Fig. 3B). To quantify the metabolic pathway activity, we performed PCA for each mapped KEGG pathway, and calculated PC1 score as the proxy of pathway activity (Fig.3C). Hierarchical clustering showed three main clusters of metabolic pathways. The downregulated pathways (cluster 1) in FRDA patients were mainly lipid metabolism related pathways, including sphingolipid metabolism, glycerophospholipid metabolism, and glycerolipid metabolism. The upregulated pathway (cluster 3) in FRDA patients included the citric acid cycle, amino acid metabolism, and fatty acid degradation. We then performed statistical analysis for several top altered pathway using pathway activity score (scaled PC1 score). Consistent with the results from MSEA, sphingolipid metabolism and glycerophospholipid metabolism decreased in plasma from FRDA patients, while citric acid cycle and amino acid metabolism were increased Fig. 3D).

Decreased very long chain ceramides distinguished FRDA patients from healthy controls Ceramides were the most affected metabolites (lipids) in FRDA patients in this first discovery
experiment. The long chain ceramides (C16 and C18 fatty acyl chain) showed no significant differences between FRDA patients and healthy controls (Fig. 4A, top left), while very long chain ceramide (C22 - C26 fatty acyl chain) were significantly decreased in FRDA patients (Fig. 4A). These differential regulations resulted in the increased ratio of long chain ceramide to very long chain ceramides (C16/C24 and C16/C26) (Fig. 4B), being an indicator of higher cardiometabolic risk as previously shown in non-FRDA patients ${ }^{32,}{ }^{33}$. To test the very long chain ceramides abilities to distinguish FRDA patients from healthy controls, we plotted the receiver operating characteristic (ROCs) analysis using different ceramides as predictor. All very long chain ceramides showed good predictive capacities with area under the curve (AUC) values from 0.75 to 0.85 (Fig. 4C).

## Validation of very long chain ceramides as FRDA biomarkers in plasma

To validate the discovery results an independent cohort of EDTA fasting plasma was collected. The new cohort was collected between 2020-2022with plasma isolated within 1 h after draw in a research lab (as opposed to the clinical lab that did the isolation for the discovery cohort with no known timing associated between draw and isolation). This validation set did not sample from carriers as we detected no metabolic biomarkers that differentiated Carriers from the Controls (Fig. 2B). The validation set had similar numbers of controls and FRDA patients (Fig. 4D) as the discovery set (Supplementary Table 1). In the validation set, we found that very long chain ceramides were also significantly decreased in the FRDA patients (Fig. 4E and Supplementary Fig. 6A). The validation set also showed the ratio ceramides C16/C24 significantly increased (Fig. 4F) predicting a higher cardiometabolic risk ${ }^{31,32}$. The predictive powers from the ROC (Fig. 4G) remained similarly strong compared to the discovery set with AUC from 0.7 to 0.82 , suggesting very long chain ceramides as plasma biomarkers of FRDA.

## Quantification of upstream and downstream metabolites from known deficient enzymes

Because frataxin is directly involved in the regulation of citric acid enzyme aconitase, we quantified the levels of upstream and downstream metabolites of this enzyme. The upstream metabolites citric acid and aconitic acid increased in both the discovery and validation sets (raw P value $<0.05$ ), while the downstream metabolite iso-citric acid was not significantly different (Supplementary Fig. 6B,C). The alteration of citric acid intermediates indicated that enzyme activity is directly reflected in the plasma concentration.

## Unbalanced ceramide synthesis in frataxin-deficient cardiomyocytes

To investigate if the alterations of ceramides in FRDA plasma reflects the dysfunction of clinically affected tissues, we used siRNA to knockdown FXN in human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) and then examined ceramide metabolism (Fig. 5A). We used two independently derived iPSC-CM lines. Line SV20 was obtained the Penn iPSC Core Facility and line 11713 was obtained from Fujifilm Cellular Dynamics (see Materials and Methods). FXN knockdown using two different siRNA, dramatically decreased the frataxin protein levels in both cell lines (Fig. 5B,C and Supplemental Fig. 7A, using an additional cell line). Lipidomics analysis showed that both lines of frataxin-deficient cardiomyocytes had significantly decreased very long chain ceramides (Fig. 5D,E). For line 11713, higher scalability allowed us to perform lipidomics analysis with two siFRX KDs that
demonstrated the same trends versus control (Fig. 5E,G). The unbalanced alterations of ceramides increased the ratios of long chain to very long chain ceramides (Fig. 5F,G), similar to prior observations in the fibroblast cells from FRDA patients ${ }^{34}$. The de novo synthesis of long chain ceramides, and very long chain ceramides is regulated by different ceramide synthase (CerS1-6) that each have tissue and acyl-CoA chain length specificity. Ceramide synthase 2 (CerS2 or LASS2) preferentially select very long chain fatty acyl-CoA (C20-26) as the substrate ${ }^{35}$. Consistent with the lipidomics results, CerS2 protein levels decreased in iPSCCMs after FXN knockdown in comparison with control (Fig. 5H and Supplementary Fig.. 7 B,C).
To further test unbalanced ceramide regulation in frataxin-deficient cardiomyocytes, we performed ${ }^{13} \mathrm{C}_{16}$-palmitate based isotope tracing experiments using a sensitive LC-HRMS targeted method ${ }^{34}$ to quantify the mass isotopomer distribution of ceramides. Long chain ceramides (C16,C18) were not significantly changed after FXN knockdown, while very long chain ceramides (C22 and C24) had lower fractions of the labeled form in frataxin-knockdown cardiomyocytes (Fig.. 5I and Supplemental Fig. 7D,E). The isotopic labeling fractions of ceramides in FXN-KD cardiomyocytes had similar patterns in the three different cell lines: SV20 (Fig. 5J), 11713 (Fig. 5K), and an additional line from the Penn core, 233 SeV 4 (Fig. 5L) All cell lines showed around $40 \%$ incorporation from ${ }^{13} \mathrm{C}_{16}$-palmitate in the very long chain ceramides and all were significantly reduced in 12 h (Fig. 5 J -L). As the precursors in ceramides biosynthesis are palmitate and serine (Fig. 5A), we also used ${ }^{13} \mathrm{C}_{3},{ }^{15} \mathrm{~N}$-serine tracing in one of the cell lines (SV20) and similar results were observed after frataxin knockdown, with decreased labeling fractions of very long chain ceramides (Fig. 5M). All these data indicated that frataxin deficiency in cardiomyocytes led to unbalanced ceramide biosynthesis, with CerS2 being reduced at protein levels and enzymatic activity.

## Ceramides were differentially regulated in primary skeletal muscle cells

To examined if, ceramide dysfunction was a ubiquitous outcome of frataxin deficiency in another affected FRDA tissues, we chose human primary skeletal muscle cells (HSkMC). We used three different siRNA-mediated FXN knockdown (Fig. 6A) and performed the lipidomics and ${ }^{13} \mathrm{C}_{16}$-palmitate based isotope-tracing experiments. For HSkMC, FXN knockdown significantly increased the levels of ceramides, including both long chain and very long chain ceramides, with long chain ceramides increasing more significantly than very long chain ceramides (Fig. 6B). The ratios of long chain to very long chain ceramides increased in FXNknockdown HSkMC (Fig. 6C), similar to results observed in frataxin-deficient cardiomyocytes, but the increase was most likely driven by the large increase in the long chain ceramides. For isotopic labeling experiments, FXN knockdown increased the fraction of isotope labeled forms (fatty acid chain, sphingosine base, and dual) for most of ceramides based on mass isotopomer distribution data (Fig. 6D). The isotopic labeling fractions were dramatically increased in FXN-KD cells for all ceramides except $\operatorname{Cer}(\mathrm{d} 18: 1 / 24: 0)$ in HSkMCs (Fig. 6E), indicating that the FXN knockdown differentially regulated ceramides in cells originating from different affected tissues.

## Proteomics revealed decreased apolipoprotein levels.

Using a similar targeted omics workflow, we performed proteomics analysis for the plasma
discovery set. By inspecting for contamination biomarkers for coagulation, erythrocyte, and platelet ${ }^{36}$, our samples appeared to reflect high quality plasma, except for two samples contaminated by platelets (Supplementary Fig. 8). When the quantified proteins were plotted in a heatmap (Fig. 7A), the plasma proteins measured cannot distinguish FRDA patients from healthy controls in the discovery set (Fig. 7B). Statistical analysis revealed 9 proteins that were significantly altered in FRDA patients in comparison with healthy controls, with 8 decreased and 1 increased (FDR <0.05) in FRDA patients (Fig. 7C). Most of these dysregulated proteins belonged to the apolipoprotein family (Fig. 7D). However, only one apolipoprotein (APOD) could be verified in the validation set (Fig. 7E). A previous report using a stable isotope dilution quantification of APOA1 in FRDA serum samples also observed the decrease of APOA1 ${ }^{37}$. Considering the label-free quantification strategy and the smaller number of samples in the validation set a more targeted method with a larger number of samples could help the validation of additional apolipoproteins in plasma similar to the reduced levels of ApoA in FRDA serum 37.

## Machine learning identified metabolic features for FRDA prediction

To improve the predictive powers of ceramides as biomarkers for FRDA, we performed machine learning based optimization (Fig. 8A). First, we included 26 metabolites that were robustly altered in FRDA patients in both, discovery set, and validation set. Next, we chose the top 4 metabolites by linear support vector machine (SVM) based feature selection strategy, namely $\operatorname{Cer}(\mathrm{m} 19: 0 / 24: 0$ ), 3-methoxytyrosine, $\operatorname{Cer}(\mathrm{m} 18: 1 / 22: 0$ ), and putrescine (Fig. 8B). To reduce the redundancy, a k-means clustering (KM) was performed to exclude $\operatorname{Cer}(\mathrm{m} 18: 1 / 22: 0)$ that showed similar behavior with $\operatorname{Cer}(\mathrm{m} 19: 0 / 24: 0)$, creating a final model with three metabolites (Cer(m19:0/24:0), 3-methoxytyrosine, and putrescine). Using three metabolites, we optimized linear SVM models using the discovery set and verified the model in the validation set. The ROC curves showed that these three-metabolite combination improved the predictive capability, with AUC as high as 0.924 (0.850-0.998) in the discovery set (Fig. 8C) and 0.923 (0.842-1.000) in the validation set (Fig. 8D).

## DISCUSSION

FRDA is a multi-systemic mitochondrial disease caused by the frataxin deficiency. The important role of frataxin in the iron-sulfur cluster assembly results in multiple altered metabolic pathways in FRDA. However, there is no readily available metabolic biomarker adequately validated for use in human blood samples. To identify metabolic features as potential biomarkers, we performed multi-omics profiling and evaluated systematic metabolic changes in FRDA fasting plasma samples compared with healthy controls. Multiple metabolic pathways, including sphingolipid metabolism, phospholipid metabolism, citric acid cycle, and apolipoprotein metabolism were consistently affected in FRDA plasma samples (Fig. 2F).

In our lipidomics analysis, long chain ceramides were unchanged in FRDA plasma (C1620), while very long chain ceramides (C22-26) were significantly decreased (Fig. 4A,F), resulting in the increased ratio of long chain ceramide to very long chain ceramides (Fig. 4B,G). The decreased very long chain ceramides were validated in an independent cohort, indicating the robust results of our multi-omics studies. An increasing number of clinical studies are
reporting associations between ceramides and cardiovascular outcomes, to the extent that the Mayo Clinic is marketing diagnostic tests to measure ceramides ${ }^{32}$. Of note, unbalanced ceramide levels, with preferentially decreased very long chain ceramide, were first observed in human heart tissue collected post-mortem from FRDA patients, but the number of tissue samples used was very low ( $\mathrm{n}=6$ ) and this tissue is obviously not routinely accessible ${ }^{25}$.

The preferential depletion of very long chain ceramide along with enrichment of long chain ceramides were replicated in frataxin-deficient human cardiomyocytes (Fig. 5D,E) from two independent sources. Furthermore, frataxin deficient cardiomyocytes consistently showed the enrichment of long chain ceramide and depletion of very long chain ceramide. The biosynthesis enzyme CerS2 that is responsible for preferential synthesis of very long chain ceramide was decreased after FRX KD (Fig. 5H). Long-chain ceramide (C16) is usually thought to be deleterious, whereas very-long-chain ceramides (such as C24:0) are considered to be benign or protective ${ }^{38-41}$. Ceramides act as a second messenger in the apoptotic cascade, with long chain ceramides (C16 and C18) being the main ceramides activators of apoptosis. CerS5 or CerS6 (long chain ceramide synthesis) overexpression leads to more cells undergoing apoptosis whereas CerS2 overexpression protected cells from death ${ }^{42,43}$. Heart-specific Sptlc2-deficient (hSptlc2 KO) mice showed decreased C18:0 and very long chain ceramides but led to cardiac dysfunction ${ }^{44}$. Therefore, balanced ceramide metabolism is important for normal functions; thus, unbalanced ceramides in FRDA may also contribute to the pathophysiology of cardiac hypertrophy or heart failure in FRDA. Further studies testing the effects of modulating different ceramides on cardiac functions of FRDA could answer this question. Very recently, a potent N-acetylgalactosamine-conjugated antisense oligonucleotide engineered to silence CerS2 in hepatocytes in vivo, prompts the modulation of blood plasma ceramides ${ }^{45}$. This recent study points that circulating ceramides can be modulated by ceramide biosynthesis in hepatocytes.

Our studies provide very long chain ceramides as robust biomarkers for FRDA patients. Ceramide dysfunctions are involved in many neurodegenerative and cardiovascular diseases ${ }^{46-49}$. Targeting ceramide metabolism can ameliorate neurological symptoms and cardiac hypertrophy and heart failure ${ }^{50,51}$. In FRDA, ceramides accumulated in a fly model and were associated with neurodegeneration in FRDA ${ }^{24,} 25$, so we did not test the effect of frataxin knockdown in neurons due to these robust pre-existing data.

However, ceramide metabolism was differentially regulated in human primary skeletal muscle cells in response to frataxin knockdown (Fig. 6A,B), with the skeletal muscles being one of the first affected tissues in FRDA. In contrary to the finding in the cardiomyocytes, where only long chain ceramide increased after frataxin deficiency, most of ceramides were increased in the skeletal muscle cells. Noteworthy, C18 ceramide, which is mediated by CerS1an isoform highly expressed in muscles, was the most increased ceramide followed by C16 ceramides. In skeletal muscle, elevated levels of long chains ceramides (such as C16:0 or C18:0) was demonstrated to induce insulin resistance and hepatic steatosis, whereas very long chain ceramides (for instance, C24:0 or C24:1) do not ${ }^{39,40,52}$. The dramatic increase in C16 and C18 long chain ceramides in skeletal muscles cells, if replicated in the muscles, could add to the increased risk of diabetes and insulin resistance in FRDA patients, also driven by the lack of beta cells in FRDA. The tissue-specific alterations in FRDA were also revealed in a functional genomic analysis of heart and muscle tissues in FRDA mice models ${ }^{23}$. Therefore, tissue-specific intervention strategy should be considered for targeted therapy. Muscles tissues
analysis would be easier available through muscles biopsy, than heart or brain tissue.
Frataxin deficiency directly affected $\mathrm{Fe}-\mathrm{S}$ containing enzyme aconitase and respiratory chain complexes. Decreased aconitase activity was observed in FRDA heart tissues and yeast models ${ }^{18}$. However, blood cells (lymphocytes, platelets, and peripheral blood mononuclear cell) from FRDA patients failed to replicate this finding though frataxin protein levels were significantly decreased in whole blood ${ }^{53}$ or different subtypes of blood cells ${ }^{54,55}$. In our metabolomics analysis, we expectedly observed the increase of citric acid and aconitic acid, the upstream metabolites of aconitase in FRDA plasma, indicating defective activity of this enzyme. The alteration of citric acid cycle pathway activity was also demonstrated in our metabolomics analysis (Supplementary Fig. 6). These metabolic differences validate that plasma samples are relevant to the metabolic conditions of FRDA patients.

There are several limitations in this study, mostly deriving from the relatively small number of subjects in both cohorts. Although these small cohort samples showed robust metabolic and lipidomic alterations in FRDA patients, the numbers were not enough to reveal the proteomic changes. This may be due to the fact that no internal standards were used for the proteomics, workflow, but at least one internal standard per chemical class was used for the small molecule omics. Decreased levels of several apolipoproteins from our discovery cohort failed to validate in the validation cohort ( 8 out 9 could not be validated). By comparing the APOA1 levels between FRDA patients and healthy control in a larger cohort ${ }^{37}$, APOA1 levels were significantly decreased in FRDA serum samples. It appears that a larger cohort is necessary for robust proteomics biomarkers, due to the inherent challenges in measuring plasma proteins. This also seems to support the utility of small molecules biomarkers for clinical studies. We did demonstrated decreased long chain ceramides as robust biomarker for FRDA patients and replicated this finding in frataxin-deficient cardiomyocytes, consistent with of the reduced long chain ceramides in FRDA heart tissue ${ }^{25}$ but direct correlation between plasma ceramide levels and heart ceramide levels in human subjects is not readily achievable. Further studies should be done to clarify if dysregulated ceramide levels can be potential biomarkers of cardiomyopathy in FRDA patients. Hammand et al ${ }^{56}$ showed that the C24 ceramides are not affected by the fasting state, so the decreased ceramides biomarkers observed here open the possibility to utilize larger cohorts of archived non-fasting plasma samples, and evaluate their levels longitudinally. Due to their high blood concentrations (around $3 \mu \mathrm{M}$ ), excellent ionization, and specific fragmentation pattern in collision induced dissociation, very long chain ceramides are feasible for translation into a routine lab assay in clinical settings.

In summary, by performing multi-omics profiling in fasting plasma samples, we identified and validated the very long chain ceramides as robust metabolic biomarkers for FRDA patients. We also demonstrated the clear reduction in the ceramide synthase 2 in frataxin-deficient cardiomyocytes that lead to the depletion of very long chain ceramides but observed different ceramide alterations in human primary skeletal muscle cells. Tissue-specific ceramide alterations should be considered when testing therapeutic approaches. Moreover, we applied machine learning based optimization, indicating that very long chain ceramide in combination with other two metabolites can improve the prediction of FRDA.

## MATERIALS AND METHODS

## Human blood sample collection

Plasma samples were collected in two different cohorts all enrolled in parallel in an ongoing natural history study at the Children's Hospital of Philadelphia. The blood samples were collected after overnight fasting, all before 10 AM the next morning. Written informed consent was obtained from each donor participating in the study and possible consequences of the studies were explained. If subjects were under the age of 18 , written informed consent was obtained from a parent and/or legal guardian. The study was approved by the Institutional Review Board (IRB) of the Children Hospital of Philadelphia (IRB Protocol \# 01-002609). Venous blood was drawn in 8.5 mL purple cap Vacutainer EDTA tubes and gently invert to mix. Plasma was collected after centrifugation at 1000 xg for 15 min . All samples were immediately aliquoted to Eppendorf tubes and frozen at $-80^{\circ} \mathrm{C}$ until analysis. The discovery cohort was collected between 2012-2019 (Table S1). The validation cohort was collected between 2020-2022 (Table S1).

## Chemicals and reagents

Optima LC/MS-grade methanol (A456-4), water (W6500), acetonitrile (A955-4), isopropanol (A461-4), formic Acid (A117-50), and ammonium formate (A11550) were purchased from fisher scientific (Waltham, MA, USA). HPLC-grade methyl tert-butyl ether (MTBE, E127-4) and 1-Butanol (A383SK-1) were purchased from Fisher Scientific (Waltham, MA, USA). Labeled internal standards were obtained as showed in Supplementary Table 2. Bovine Serum Albumin (fatty acid free, low endotoxin, lyophilized powder) (A8806), 2-Iodoacetamide (IAA, 8047440100), urea (U0631), ammonium bicarbonate (A6141), and DL-Dithiothreitol (DTT, D0632) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Pierce ${ }^{\mathrm{TM}}$ Trypsin Protease, MS Grade (90058) was purchased from Thermo Scientific (Waltham, MA, USA).

Human induced pluripotent stem cell differentiated cardiomyocytes (iPSC-CMs). The iPSC-CMs line SV20 and 233 SeV 4 were obtained from the Penn iPSC Core Facility. The iPSC-CMs (SV20 and 233 SeV 4 ) were replated into 12 well plates ( $0.1 \%$ gelatin coated) in RPMI/ $20 \% \mathrm{FBS} / 1 \mu \mathrm{M}$ thiazovivin overnight and replaced with RPMI/B27+ for 2 days to recover. All the experiments for these two lines were conducted in RPMI/B27 medium. The iCell Cardiomyocytes 11713 (R1106) was ordered from Fujifilm Cellular Dynamics and maintained in iCell Cardiomyocyte Maintenance Medium (M1003) for all the experiments. We received the cell lines from the Penn iPSC and Fujifilm several times over 6 months period for repeated experiments, and each experiment had at least 3 technical replicates.
Human primary skeletal muscle cell culture. Human skeletal muscle cells (HSkMC, PCS-950-010) were ordered from ATCC (Manassas, VA, USA) and maintained in Mesenchymal Stem Cell Basal Medium (PCS-500-030, ATCC) supplemented with Primary Skeletal Muscle Growth Kit (PCS-950-040, ATCC).
siRNA knockdown
Silencer® Select siRNAs (s5361-siFXN-1, s530978-siFXN-2, and s5362-siFXN-3) targeting gene FXN and Silencer ${ }^{\text {TM }}$ Negative Control No. 1 (4404021-siCtrl) were purchased from Thermo Scientific (Waltham, MA, USA). FXN siRNA and negative control siRNA were transfected into targeted cells using Lipofectamine ${ }^{\mathrm{TM}}$ RNAiMAX Transfection Reagent
(13778075, Invitrogen ${ }^{\mathrm{TM}}$ ) at concentrations of $10-50 \mathrm{nM}$ according to the manufacturer's instructions. The concentrations of siRNAs were optimized to bring down the frataxin protein levels to less than $50 \%$ of negative control cells. The knockdown efficiency was verified by western blot.

## Stable isotope tracing and cell lipidomics

iPSC-CMs and HSkMCs were cultured in their respective fresh medium containing $100 \mu \mathrm{M}$ ${ }^{13} \mathrm{C}_{16}$-palmitate (conjunction with fatty acid free BSA with ratio 2:1) for 6 h or 24 h . Then cells were collected into 1 mL cold $80 \%$ methanol after washing 2 x with 5 mL PBS. 2.4 mL MTBE and 0.6 mL water were sequentially added and vortex for 1 min . The phase separation was achieved after centrifugation at 3000 xg for 10 min . The top organic phase was collected, dried under nitrogen, and reconstituted in MTBE/methanol (1:3, v/v) with 10 mM ammonium formate for LC-HRMS analysis. A parallel reactive monitoring (PRM) targeted method was used to quantify the mass isotopomer distributions of ceramides according to our previous method ${ }^{34}$.
For cell lipidomics analysis, the same protocol was used for sample preparation (iPSC-CMs and HSkMCs) after cells being spiked with the SPLASH® LIPIDOMIX® Mass Spec Standard (330707) and Cer/Sph Mixture I (LM6002). Data acquisition was performed using the sample method described in Lipidomics Section except the full scan mode was used for ceramides quantification.

## Western blot

Cells were lysed in RIPA buffer ( $150 \mathrm{mM} \mathrm{NaCl}, 1 \%$ NP-40, 20 mM Tris-HCl pH 7.5, 1 mM EGTA, $1 \%$ sodium deoxycholate, $1 \mathrm{mM} \mathrm{Na} 2_{2}$ EDTA, 2.5 mM sodium pyrophosphate, 1 mM beta-glycerophosphate, $1 \mathrm{mM} \mathrm{Na}{ }_{3} \mathrm{VO}_{4}, 1 \mu \mathrm{~g} / \mathrm{ml}$ leupeptin) containing protease inhibitors (A32963, Thermo Scientific). Total protein content was determined using the Pierce ${ }^{\mathrm{TM}} 660 \mathrm{~nm}$ protein assay reagent (22660, Thermo Scientific). $20 \mu \mathrm{~g}$ of total protein ( $3: 1$ protein/loading buffer) was boiled at $95^{\circ} \mathrm{C}$ for 5 min and then loaded onto NuPAGE $10 \%$ or $12 \%$ Bis-Tris gel. Following SDS-PAGE, proteins were transferred onto nitrocellulose membrane, blocked with $5 \%$ dry milk and incubated with primary antibodies against frataxin (1:500) and other target proteins (1:500-1:2000) overnight at $4{ }^{\circ} \mathrm{C}$. Blots were then incubated with appropriate horseradish peroxidase-conjugated secondary antibodies and developed using ultra-sensitive enhanced chemiluminescent SuperSignal West Femto (34094, Thermo Scientific). Lass2 polyclonal antibody (PA5-115496), Lass5 polyclonal antibody (PA5-95899), Lass6 polyclonal antibody (PA5-20648), beta Tubulin Monoclonal Antibody (MA5-16308), and Actin monoclonal antibody (MA1-744) were purchased from Thermo Scientific (Waltham, MA, USA). FXN Polyclonal antibody (14147-1-AP) was purchased from Proteintech (Rosemont, IL, USA). Full Wester Blots are in Supplementary Fig. 9.

## Flow cytometry

iPSC-CMs was dissociated with Trypsin-EDTA, and fixed in $4 \%$ PFA for 10 min , and permeabilized in PBS containing $0.3 \%$ Tween 20 for 1 h . Permeabilized cardiomyocytes were stained with a primary mouse anti-Troponin antibody (Abcam Ab8295) at dilution 1:200 overnight followed by goat anti mouse-Alexa Fluor 488 conjugated (Invitrogen 11001) at dilution 1:1000 for 1 h . Data were acquired on an Amnis Image Stream and analyzed using open source Flowing Software (Turku Centre for Biotechnology). We routinely used iPSC-CMs that were $80 \%$ or above c-troponin positive. Nuclei were stained with DAPI (\#P36935, Thermo

Fisher Scientific). Not stained cells were used for negative control.

## Metabolomics

$20 \mu \mathrm{~L}$ plasma, spiked with $30 \mu \mathrm{~L}$ internal standard (Supplementary Table 2), was vortex mixed with $200 \mu \mathrm{~L}$ methanol for 10 min , and incubated at $-20^{\circ} \mathrm{C}$ for 1 h . After 10 min centrifugation at 14000 g at $4^{\circ} \mathrm{C}$, the supernatant was transferred to a new tube, dried under nitrogen, and resuspended in $50 \mu \mathrm{~L}$ acetonitrile/water $(75 / 25, \mathrm{v} / \mathrm{v}) .5 \mu \mathrm{~L}$ of each sample was combined to make a quality control (QC) metabolomics sample and ran every ten samples in the sequence to monitor for retention time and signal intensity drift. The remaining samples ( $30 \mu \mathrm{~L}$ ) were transferred into injection vials for metabolomic analysis. Samples were randomized before analysis for all the LC-HRMS runs.
Metabolites were separated using an Ascentis ${ }^{\circledR}$ Express HILIC HPLC column ( $2.1 \mathrm{~mm} \times 150$ $\mathrm{mm}, 2.7 \mu \mathrm{~m}$ particle size, \#53946-U, SUPELCO Analytical) on an UltiMate 3000 quaternary UHPLC (Thermo Scientific, Waltham, MA) equipped with a refrigerated autosampler $\left(4^{\circ} \mathrm{C}\right)$ and column heater $\left(35^{\circ} \mathrm{C}\right)$. Solvent A ( $95 \%$ acetonitrile 10 mM ammonium acetate $0.1 \%$ acetic acid) and solvent $\mathrm{B}(5 \%$ acetonitrile with same modifiers as A) were used to elute the metabolites with a 26 min gradient, as follows: $10 \% \mathrm{~B}$ at $2 \mathrm{~min}, 30 \% \mathrm{~B}$ at $10 \mathrm{~min}, 100 \% \mathrm{~B}$ at $15 \mathrm{~min}, 100 \%$ B at 18 min , and back to $10 \%$ B at 19 min . The flow rate was $0.25 \mathrm{ml} / \mathrm{min}$. Samples were analyzed using a Q Exactive HF (QE-HF) (Thermo Scientific, Waltham, MA) equipped with a heated electro-spray ionization (HESI) source operated in both positive and negative ion mode. To build up metabolite spectral library for targeted analysis, we ran a plasma pooled sample extracted in 10x technical replicates in full scan/ddMS2 mode (untargeted metabolomics). The Full Scan settings were as follows: 120,000 resolution, AGC target, 1e6; Maximum IT, 200 ms ; scan range, 60 to $900 \mathrm{~m} / \mathrm{z}$. Top $20 \mathrm{MS} / \mathrm{MS}$ spectral (dd-MS2) @ 15000 were generated with AGC target $=2 \mathrm{e} 5$, Maximum IT $=25 \mathrm{~ms}$, and $(\mathrm{N}) \mathrm{CE} /$ stepped $\mathrm{NCE}=20$, $30,40 \mathrm{v}$. Metabolites detection and identification were performed using Compound Discovery 2.1 (Thermo Scientific, Waltham, MA) by searching against online database (mzCloud) and inhouse database built on Sigma metabolomics library (LSMLS, Sigma-Aldrich) (mzVault). Well annotated metabolites (by a combination of high-resolution $\mathrm{m} / \mathrm{z} \pm 5 \mathrm{ppm}$, natural isotope abundances, MS2 spectra and retention time similarity with authentic standard or a similar chemistry standard ${ }^{57}$ were used to generate an inclusion list (Supplementary Table 3) for targeted PRM analysis. Final data acquisition was performed in Full scan and PRM modes. The PRM settings were as follows: resolution $=15000$, AGC target $=2 \mathrm{e} 5$, Maximum IT=25 ms , loop count $=20$, isolation window $=2.0,(\mathrm{~N}) \mathrm{CE}$ was optimized for each metabolite.

## Lipidomics

$50 \mu \mathrm{~L}$ plasma, spiked with $20 \mu \mathrm{~L}$ internal standard (Supplementary Table 2) was extracted with $1000 \mu \mathrm{~L}$ butanol/methanol ( $1 / 1, \mathrm{v} / \mathrm{v}, 10 \mathrm{mM}$ ammonium formate) for 10 min on a shaker. Samples were pelleted by centrifugation at 4000 g for 5 min at room temperature. The supernatant was moved to a clean glass tube, dried under nitrogen, and resuspended in $100 \mu \mathrm{~L}$ MTBE/methanol ( $1 / 3, \mathrm{v} / \mathrm{v}$ ) with 10 mM ammonium formate. $5 \mu \mathrm{~L}$ of each sample was combined to make the QC-lipidomics sample that ran every ten samples in the mass spec sequence to monitor for retention time and signal intensity drift. The remaining samples were transferred into injection vials for lipidomic analysis. Lipids were analyzed exactly as we described before for plasma lipdiomics ${ }^{58}$.

## Proteomics

$5 \mu \mathrm{~L}$ plasma, was denatured in urea solution ( 8 M ), reduced with DTT ( 5 mM ) at $37^{\circ} \mathrm{C}$ for 30 min, alkylated with IAA ( 14 mM ) for 30 min (in the dark), diluted with 100 mM ABC solution, and trypsin (1:50) digested at $37^{\circ} \mathrm{C}$ overnight. The digestion was quenched by adding $10 \%$ formic acid. The digestion mixture was cleaned-up using Oasis HLB $1 \mathrm{cc}(30 \mathrm{mg})$ SPE cartridges (WAT094225, Waters). The cartridges were activated with $500 \mu \mathrm{~L}$ solvent B ( $0.1 \%$ FA in $80 \%$ acetonitrile) x 3 , equilibrated with $500 \mu \mathrm{~L}$ solvent A ( $0.1 \% \mathrm{FA}$ in water) x 3 , and after sample loading, washed with $750 \mu \mathrm{~L}$ solvent A x 4 , eluted in $500 \mu \mathrm{~L}$ B x3, dried under nitrogen, and redissolved in $60 \mu \mathrm{~L}$ water with $0.1 \% \mathrm{FA} .5 \mu \mathrm{~L}$ of each sample was combined to make a QC-proteomics sample that ran every ten samples in the mass spec sequence to monitor for retention time and signal intensity drift. The remaining samples were transferred into injection vials for proteomics analysis.
Peptides were separated using a nanoACQUIY Peptide BEH C18 (130 $\AA, 1.7 \mu \mathrm{~m}, 150 \mu \mathrm{~m} \mathrm{x}$ 100 mm ) on a nanoAcquity system (Milford, MA, USA). Solvent A ( $99.5 \%$ water $/ 0.5 \%$ acetonirtrile with $0.1 \%$ formic acid) and Solvent B (98 \% acetonitrile/ $2 \%$ water with $0.1 \%$ formic acid) were used to elute the peptides with a 30 min gradient. The initial composition of $95 \%$ A was maintained for 3 min , and ramped to $70 \% \mathrm{~A}$ in 30 min , and washed at $2 \% \mathrm{~A}$ for 10 $\min$ and equilibrated at $95 \%$ A for 10 min . The flow rate was set at $2 \mu \mathrm{~L} / \mathrm{min}$. Samples were analyzed using a Q Exactive HF (QE-HF) (Thermo Scientific, Waltham, MA) equipped with a Michrom BioResources (AUBURN, CA, USA) source operated in positive ion mode. For DDA library generation (untargeted proteomics), data acquisition was performed on the pooled QC samples in Full Scan/ddMS2 mode @ 120,000 resolutions. The Full Scan settings as follows: 120,000 reolution, AGC target $=3 \mathrm{e} 6$; Maximum $\mathrm{IT}=250 \mathrm{~ms}$; scan range $=300$ to $1650 \mathrm{~m} / \mathrm{z}$. Top $20 \mathrm{MS} / \mathrm{MS}$ spectral (dd-MS2) @ 15000 were generated with AGC target = 1e5, Maximum IT $=25 \mathrm{~ms}$, and $(\mathrm{N}) \mathrm{CE}=27 \mathrm{v}$. For untargeted proteomics analysis, ProteomeDiscover 4.2 (Thermo Scientific, Waltham, MA) was used for protein and peptide annotation. Well-annotated peptides (MS spectral match) were used to generate a inclusion list (Supplementary Table 5) for targeted proteomics analysis. Targeted proteomics were performed in full scan and PRM modes. The PRM settings were as follows: resolution $=15000$, AGC target $=2 \mathrm{e} 5$, Maximum $\mathrm{IT}=25 \mathrm{~ms}$, loop count $=32$, isolation window $=2.0,(\mathrm{~N}) \mathrm{CE}$ was set at 27 v .

## Data analysis

Peak detection and integration were performed using Skyline for metabolomics, lipidomics, and proteomics. For metabolites and lipids, the representative MS2 fragmentation was used for final quantification, and for peptides, the Top 3 MS2 fragmentations were summed to represent the final intensity. The missing values were replaced by LoDs ( $1 / 5$ of the minimum positive value of each variable. Then data was log-transformed and normalized. For each analyte and each batch, a combination of internal standards and QC-locally estimated scatterplot smoothing (LOESS) was used for signal drift correction. We applied principal component analysis (PCA) to visualize the overall distribution of all samples (mean-centered and z-score scaled data) and exclude potential outliers using package FactoMineR and factoextra in R (https://www.rproject.org/).
To identify significantly altered metabolites or proteins, we firstly performed a two-tailed $t$-test
analysis (false discovery rate, $\mathrm{FDR}<0.05$ ), volcano plots of statistical significance against $\log 2$ (fold change) were used to visualize the differences. Then a multivariate statistical analysis parameter- variable importance in projection (VIP) based on partial least square discrimination analysis (PLS-DA) were used to validate the statistically different features (metabolites, lipids, or proteins). For multiple group comparison in cell experiments, a one-way Analysis of variance (ANOVA) with Fisher's LSD post hoc test was used to compute the significance. $P<$ $0.05^{*}, P<0.01^{* *}, P<0.001^{* * *}$. The data processing and visualization were performed using R package tidyverse, pheatmap, ggplot2, Hmisc, corrplot, ggsci, RColorBrewer, and pROC, and Graphpad Prism 9.0.

## Metabolites and lipids set enrichment analysis (MSEA)

Metabolite (and we included the lipids too) set enrichment analysis (MSEA) was performed on statistically different metabolites ( $\mathrm{P}<0.05$ and FDR $<0.1$ ) using MetaboAnalyst 5.0 (https://www.metaboanalyst.ca/MetaboAnalyst/). MSEA used 84 metabolite sets based on KEGG human metabolic pathways, and LSEA used 1072 sub chemical class metabolite (lipids) sets. Enrichment Ratio was computed by Hits / Expected.
Metabolite correlation network
A debiased Sparse Partial Correlation (DSPC) algorithm was used to compute the correlation between all the quantified metabolites or significantly changed metabolites in Correlation Calculator 1.0.1. ${ }^{59}$ The MetScape 3.1.3 within Cytoscape 3.4 .0 was used for the visualization of metabolite correlation network. Each node represents a compound, and each edge represents the partial correlation coefficient between two nodes.

## Pathway activity scoring

Pathway activity was assessed by metabolic pathway based PCA scores according to previous methods ${ }^{60,}{ }^{61}$. Briefly, our quantified metabolite or lipids were mapped onto KEGG human metabolic pathways. For each pathway, intermediates were used to perform PCA, and the PC1 scores, which capture the maximum metabolite variances, were used as proxy of respective pathway activity.

## Machine Learning for FRDA prediction

26 metabolites that were altered in both the discovery set, and the validation set were used for machine learning based FRDA prediction. We applied linear support vector machine (SVM) to evaluate the feature importance by Monte-Carlo cross validation (MCCV) based sub-sampling in MetaboAnalyst 5.0. The procedure was repeated multiple times to select the important features to build SVM models and a 5 -fold cross validation was performed to optimize the best model using Caret package in R. We also applied k-means clustering (KM) to detect features with similar behavior to reduce the redundancy. The final fitted model was applied to the validation set for prediction and verification.

## List of Supplementary Materials

Supplementary Fig. 1. The extracted ion chromatogram (XIC) of lipids in positive ion mode (a) and in negative ion mode (b).

Supplementary Fig. 2. The extracted ion chromatogram (XIC) of metabolites in positive ion mode (a) and in negative ion mode (b).
Supplementary Fig. 3. The extracted ion chromatogram (XIC) of protein (peptides) in positive
ion mode.
Supplementary Fig. 4. Coefficient of variances (CVs) of quantified metabolites (a) and lipids (b) in each of their quality control (QC) samples.

Supplementary Fig. 5. Metabolite correlation network based on all of metabolites and lipids.
Each node represented one metabolite (lipid), and nodes were colored according to metabolite (lipid) class. The edge colored with red indicated positive correlation, while the edge with blue indicated negative correlation. The edge width represented the strength of partial correlation coefficient.
Supplementary Fig. 6. The relative abundance of long chain ceramides in validation set (a).
Relative abundance of citric acid cycle intermediates between healthy controls and FRDA patients in discovery set (b) and validation set (c).
Supplementary Fig. 7. Unbalanced ceramide synthesis in frataxin-deficient cardiomyocytes.
a Western blots showing the frataxin levels in FXN-knockdown cardiomyocyte 233-SeV4
b,c Western blots showing the protein levels of ceramide synthase (CerS2) in cardiomyocyte 11713 (b) and 233-SeV4 (c) after siRNA-mediated FXN knockdown
doe The mass isotopomer distribution of ceramides from FXN-knockdown cardiomyocyte 11713 (d) and 233-SeV4 (e).
Supplementary Fig. 8. Quality assessment of each sample according to main contamination sources of coagulation (a), erythrocyte (b), and platelet (c).
Supplementary Fig. 9. Full Western blots used in the cellular work.
Supplementary Table 1. Demographic data for each cohort.
Supplementary Table 2. Internal Standards (ISTD) used for metabolomics and lipidomics analysis.
Supplementary Table 3. Inclusion list for targeted metabolomics (PRM).
Supplementary Table 4. Inclusion list for targeted lipidomics (PRM).
Supplementary Tables 5. Inclusion list for targeted proteomics (PRM)


Fig. 1. A multi-omics workflow to identify potential plasma biomarkers of FRDA.
A. Multi-omics analysis workflow. Plasma samples from healthy controls and FRDA patients were pooled and processed in three different ways for metabolomics, lipidomics, or proteomics. Libraries were built by running the pooled plasma samples and authentic standards in a datadependent acquisition (DDA) mode. Narrow scheduled chromatographic windows (1-2 min) were set based on DDA libraries to acquire MS2 data in a parrel reaction monitoring (PRM) mode, and full scan (MS1) data was also acquired simultaneously to have a better annotation. Univariate and multivariate statistical analysis were performed to identify potential biomarkers of FRDA.B. The overlapped total ion counts (TICs) from 10 technical workflow replicates for lipidomics in positive mode. C. Same as B but in negative mode. Those showed excellent chromatographic reproducibly. D. Color-coded $\mathrm{R}^{2}$ values for the Pearson correlation comparison of 10 technical workflow replicates for metabolomics. E. lipidomics $\mathbf{F}$. proteomics. $\mathrm{R}^{2}$ values indicated high reproducibility. G. Intra-assay variability was evaluated by calculating the coefficient of variation (CV) for 10 technical workflow replicates for all quantified metabolites. H. lipids I. peptides; CV $<20 \%$ colored with blue, $20 \%<\mathrm{CV}<30 \%$ colored with yellow, and CV $>30 \%$ colored with grey.


Fig. 2. Metabolomics and lipidomics analysis revealed dysregulated metabolism in FRDA plasma. A. PCA score plot shows the plasma clustering according to disease conditions. Quality controls (QCs) were run every ten samples. The internal standard and QC-LOESS were combined to be used for signal drift correction. The closed clustering of the QC samples shows the robust methodology. B. Volcano plot of Carrier samples versus Control samples showed no statistical significance ( $-\log _{10} \mathrm{P}$, two-sided $t$-test) against $\log 2$-fold change between the means. C. Volcano plot of statistical significance $\left(-\log _{10} \mathrm{P}\right.$, two-sided $t$-test) against $\log 2$ fold change between the means of FRDA patients versus Controls. Upregulated metabolites (lipids) were colored with red, and downregulated ones with blue. D. Volcano plot of statistical significance (VIP, PLS-DA) against $\log 2$-fold change between the means of FRDA patients versus Controls. Metabolites (lipids) were colored according to VIPs from blue (low) to red (high). E. Heatmap showing relative abundances of top 50 metabolites or lipids ( $\mathrm{P}<0.05$ and FDR $<0.1$ ) in Control, Carrier, and FRDA groups. The abundances of metabolites (lipids) were mean-centered and unit-scaled. F. Metabolite correlation network using MetScape and Cytoscape. Each node represented one metabolite (lipid), and nodes were colored according to metabolite (lipid) pathways. The edge colored with red indicated positive correlation, while the edge with blue indicated negative correlation. The edge width represented the strength of partial correlation coefficient.


Fig. 3. Pathway analysis indicated abnormal sphingolipid metabolism in FRDA. A. Lipid set enrichment analysis of significantly changed lipids (FDR adjusted $P$ value less than 0.1). Enrichment Ratio is computed by Hits / Expected. B. Metabolite set enrichment analysis of significantly changed metabolites (FDR adjusted P value less than 0.1 ). Enrichment Ratio is computed by Hits / Expected. C. Metabolic pathway activity inferred by pathway score (PC1 scores) between healthy controls and FRDA patients. Hierarchical clustering of pathway scores were colored with pathway names labeled. D. Significant pathway scores changes of several metabolic pathways between FRDA patients and Controls. * $\mathrm{p}<0.05$, ${ }^{* *} \mathrm{p}<0.005$.

Discovery set


Fig. 4. Decreased very long chain ceramides distinguished FRDA patients from healthy controls in two independent cohorts. A. Relative abundances of ceramides including long chain ceramides and very long chain ceramides between Controls and FRDA patients in the discovery set. B. The ratio of long chain ceramide ( $\operatorname{Cer}(\mathrm{d} 18: 1 / 16: 0)$ ) to very long chain ceramide $(\operatorname{Cer}(\mathrm{d} 18: 1 / 24: 0))$ and $(\operatorname{Cer}(\mathrm{d} 18: 1 / 26: 0))$ between Controls and FRDA patients in the discovery set. C. The receiver operating characteristic (ROC) curves for prediction of FRDA versus healthy controls using different ceramides, showed AUC values higher than 0.75. D. Independently obtained plasma samples have been include in the Validation set to verify the outcomes from the discovery set. E. Relative abundances of very long chain ceramides between heathy controls and FRDA patients in the validation set. F. The ratio of long chain ceramide $(\operatorname{Cer}(\mathrm{d} 18: 1 / 16: 0))$ to very long chain ceramide $(\operatorname{Cer}(\mathrm{d} 18: 1 / 24: 0))$ between heathy controls and FRDA patients in the validation set. G. The receiver operating characteristic (ROC) curves for prediction of FRDA versus healthy controls using different ceramides in the validation set, and AUC values were calculated and stated in plot. * $\mathrm{p}<0.05$, ${ }^{* *} \mathrm{p}<0.005,{ }^{* * *}$ $\mathrm{p}<0.005$.


Fig. 5. Unbalanced ceramide synthesis in several lines of frataxin-deficient cardiomyocytes. A. Schematic depiction of de nova ceramide synthesis B. Western blots showing the frataxin levels in FXN-knockdown cardiomyocyte SV20 C. same as B but for a different cell line, 11713. D. The relative abundances of ceramides in cardiomyocyte SV20 and E. 11713 (after siRNA-mediated FXN knockdown. F. The ratios of long chain ceramide (C16) to very long chain ceramide (C24 and C26) in cardiomyocyte SV20 and G. in cardiomyocytes 11713, both after FXN-knockdown. H. Western blots showing the protein levels of ceramide synthase (CerS2, CerS5, and CerS6) in cardiomyocyte SV20 after siRNAmediated FXN knockdown I. The mass isotopomer distribution of ceramides from FXNknockdown cardiomyocyte SV20 $\mathbf{J}$. The isotopic labeling fractions of ceramides in FXN-KD cardiomyocytes SV20 K. in cardiomyocytes 11713 and $\mathbf{L}$. cardiomyocytes 233-SeV4, all after ${ }^{13} \mathrm{C}_{16}$-palmitate labeling. K. The isotopic labeling fractions of ceramides in FXN-KD cardiomyocytes SV20 after ${ }^{13} \mathrm{C}_{3},{ }^{15} \mathrm{~N}$-serine labeling. * $\mathrm{p}<0.05$, ${ }^{* *} \mathrm{p}<0.005$, ${ }^{* * *} \mathrm{p}<0.005$.


Fig. 6. Frataxin deficiency had different effect on the ceramide metabolism in primary skeletal muscle cells A. Western blots showing the frataxin levels in human primary skeletal muscle cells (HSkMC) after siRNA-mediated FXN knockdown B. The relative abundances of ceramides in FXN-knockdown HSkMC. C. The ratios of long chain ceramide (C16) to very long chain ceramide (C24 and C26) in FXN-knockdown HSkMC D. The mass isotopomer distribution of ceramides from control (siCtrl) and FXN-Knockdown HSkMCs. E. The isotopic labeling fractions of ceramides in FXN-knockdown HSkMC. * $\mathrm{p}<0.05$, ${ }^{* *} \mathrm{p}<0.005, * * * \mathrm{p}<0.005$.


Fig. 7. Proteomics analysis showed decreased apolipoprotein levels in FRDA plasma.
A. Heatmap showing hierarchical clustering of peptides (proteins) in Control, Carrier, and FRDA groups. B. PCA score plot showing the plasma clustering according to disease conditions, and quality controls (QCs) were run every ten samples. The QC-LOESS were used for signal drift correction. C. Volcano plot of statistical significance (-Log 10P, two-sided t-test) against $\log 2$-fold change between the means of FRDA patients versus healthy controls. Upregulated proteins were colored with red, and downregulated ones with blue. D. ProteinProtein Interaction Networks of significantly changed proteins (FDR corrected P value less than 0.05 ) using String. E. APOD was the only significantly decreased protein in FRDA patients versus healthy controls in the validation set. * $p<0.05$.


Fig. 8. Machine learning improves the prediction of FRDA. A. Machine learning workflow for prediction of FRDA using metabolic features. B. Top 15 selected metabolites from Linear support vector machine (SVM) model. C. K-Means Clustering revealed different 4 clusters for these metabolites. D. The receiver operating characteristic (ROC) curves using three metabolites [Cer(m19:0/24:0), 3-methoxytyrosine, and putrescine] based SVM model in the discovery set $\mathbf{E}$. same as D but in the validation set.

## References

1. Parkinson, M. H.; Boesch, S.; Nachbauer, W.; Mariotti, C.; Giunti, P., Clinical features of Friedreich's ataxia: classical and atypical phenotypes. Journal of neurochemistry 2013, 126 Suppl 1, 103-17.
2. Hamedani, A. G.; Hauser, L. A.; Perlman, S.; Mathews, K.; Wilmot, G. R.; Zesiewicz, T.; Subramony, S. H.; Ashizawa, T.; Delatycki, M. B.; Brocht, A.; Lynch, D. R., Longitudinal analysis of contrast acuity in Friedreich ataxia. Neurology. Genetics 2018, 4 (4), e250.
3. Rance, G.; Corben, L.; Delatycki, M., Auditory processing deficits in children with Friedreich ataxia. Journal of child neurology 2012, 27 (9), 1197-203.
4. Garg, M.; Kulkarni, S. D.; Shah, K. N.; Hegde, A. U., Diabetes Mellitus as the Presenting Feature of Friedreich's Ataxia. Journal of neurosciences in rural practice 2017, 8 (Suppl 1), S117-s119.
5. McCormick, A.; Farmer, J.; Perlman, S.; Delatycki, M.; Wilmot, G.; Matthews, K.; Yoon, G.; Hoyle, C.; Subramony, S. H.; Zesiewicz, T.; Lynch, D. R.; McCormack, S. E., Impact of diabetes in the Friedreich ataxia clinical outcome measures study. Annals of clinical and translational neurology 2017, 4 (9), 622-631.
6. Rummey, C.; Flynn, J. M.; Corben, L. A.; Delatycki, M. B.; Wilmot, G.; Subramony, S. H.; Bushara, K.; Duquette, A.; Gomez, C. M.; Hoyle, J. C.; Roxburgh, R.; Seeberger, L.; Yoon, G.; Mathews, K. D.; Zesiewicz, T.; Perlman, S.; Lynch, D. R., Scoliosis in Friedreich's ataxia: longitudinal characterization in a large heterogeneous cohort. Annals of clinical and translational neurology 2021, 8 (6), 1239-1250.
7. Lynch, D. R.; Schadt, K.; Kichula, E.; McCormack, S.; Lin, K. Y., Friedreich Ataxia: Multidisciplinary Clinical Care. Journal of multidisciplinary healthcare 2021, 14, 1645-1658. 8. Legrand, L.; Weinsaft, J. W.; Pousset, F.; Ewenczyk, C.; Charles, P.; Hatem, S.; Heinzmann, A.; Biet, M.; Durr, A.; Redheuil, A., Characterizing cardiac phenotype in Friedreich's ataxia: The CARFA study. Arch Cardiovasc Dis 2022, 115 (1), 17-28.
8. Koeppen, A. H., Friedreich's ataxia: pathology, pathogenesis, and molecular genetics. Journal of the neurological sciences 2011, 303 (1-2), 1-12.
9. Li, Y.; Polak, U.; Bhalla, A. D.; Rozwadowska, N.; Butler, J. S.; Lynch, D. R.; Dent, S. Y. R.; Napierala, M., Excision of Expanded GAA Repeats Alleviates the Molecular Phenotype of Friedreich's Ataxia. Molecular therapy : the journal of the American Society of Gene Therapy 2015, 23 (6), 1055-1065.
10. Cai, K.; Frederick, R. O.; Tonelli, M.; Markley, J. L., Interactions of iron-bound frataxin with ISCU and ferredoxin on the cysteine desulfurase complex leading to $\mathrm{Fe}-\mathrm{S}$ cluster assembly. Journal of inorganic biochemistry 2018, 183, 107-116.
11. Cotticelli, M. G.; Crabbe, A. M.; Wilson, R. B.; Shchepinov, M. S., Insights into the role of oxidative stress in the pathology of Friedreich ataxia using peroxidation resistant polyunsaturated fatty acids. Redox biology 2013, $l$ (1), 398-404.
12. Schmucker, S.; Martelli, A.; Colin, F.; Page, A.; Wattenhofer-Donzé, M.; Reutenauer, L.; Puccio, H., Mammalian frataxin: an essential function for cellular viability through an interaction with a preformed ISCU/NFS1/ISD11 iron-sulfur assembly complex. PloS one 2011, 6 (1), e16199.
13. Clark, E.; Johnson, J.; Dong, Y. N.; Mercado-Ayon, E.; Warren, N.; Zhai, M.;

McMillan, E.; Salovin, A.; Lin, H.; Lynch, D. R., Role of frataxin protein deficiency and metabolic dysfunction in Friedreich ataxia, an autosomal recessive mitochondrial disease. Neuronal signaling 2018, 2 (4).
15. Britti, E.; Delaspre, F.; Sanz-Alcázar, A.; Medina-Carbonero, M.; Llovera, M.; Purroy, R.; Mincheva-Tasheva, S.; Tamarit, J.; Ros, J., Calcitriol increases frataxin levels and restores mitochondrial function in cell models of Friedreich Ataxia. The Biochemical journal 2021, 478 (1), 1-20.
16. Chiang, S.; Braidy, N.; Maleki, S.; Lal, S.; Richardson, D. R.; Huang, M. L., Mechanisms of impaired mitochondrial homeostasis and $\mathrm{NAD}(+)$ metabolism in a model of mitochondrial heart disease exhibiting redox active iron accumulation. Redox biology 2021, 46, 102038.
17. Stepanova, A.; Magrané, J., Mitochondrial dysfunction in neurons in Friedreich's ataxia. Molecular and cellular neurosciences 2020, 102, 103419.
18. Rötig, A.; de Lonlay, P.; Chretien, D.; Foury, F.; Koenig, M.; Sidi, D.; Munnich, A.; Rustin, P., Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nature genetics 1997, 17 (2), 215-217.
19. DeBrosse, C.; Nanga, R. P. R.; Wilson, N.; D'Aquilla, K.; Elliott, M.; Hariharan, H.; Yan, F.; Wade, K.; Nguyen, S.; Worsley, D., Muscle oxidative phosphorylation quantitation using creatine chemical exchange saturation transfer (CrCEST) MRI in mitochondrial disorders. JCI insight 2016, $l$ (18).
20. Lodi, R.; Cooper, J. M.; Bradley, J. L.; Manners, D.; Styles, P.; Taylor, D. J.; Schapira, A. H., Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia. Proceedings of the National Academy of Sciences 1999, 96 (20), 11492-11495.
21. Purroy, R.; Medina-Carbonero, M.; Ros, J.; Tamarit, J., Frataxin-deficient cardiomyocytes present an altered thiol-redox state which targets actin and pyruvate dehydrogenase. Redox biology 2020, 32, 101520.
22. Worth, A. J.; Basu, S. S.; Deutsch, E. C.; Hwang, W.-T.; Snyder, N. W.; Lynch, D. R.; Blair, I. A., Stable isotopes and LC-MS for monitoring metabolic disturbances in Friedreich's ataxia platelets. Bioanalysis 2015, 7 (15), 1843-1855.
23. Coppola, G.; Marmolino, D.; Lu, D.; Wang, Q.; Cnop, M.; Rai, M.; Acquaviva, F.; Cocozza, S.; Pandolfo, M.; Geschwind, D. H., Functional genomic analysis of frataxin deficiency reveals tissue-specific alterations and identifies the PPAR $\gamma$ pathway as a therapeutic target in Friedreich's ataxia. Human molecular genetics 2009, 18 (13), 2452-2461.
24. Chen, K.; Lin, G.; Haelterman, N. A.; Ho, T. S.-Y.; Li, T.; Li, Z.; Duraine, L.; Graham, B. H.; Jaiswal, M.; Yamamoto, S., Loss of Frataxin induces iron toxicity, sphingolipid synthesis, and Pdk1/Mef2 activation, leading to neurodegeneration. Elife 2016, 5, e16043.
25. Chen, K.; Ho, T. S.-Y.; Lin, G.; Tan, K. L.; Rasband, M. N.; Bellen, H. J., Loss of Frataxin activates the iron/sphingolipid/PDK1/Mef2 pathway in mammals. Elife 2016, 5, e20732.
26. Blair, I. A.; Farmer, J.; Hersch, S.; Larkindale, J.; Lynch, D. R.; Napierala, J.; Napierala, M.; Payne, R. M.; Subramony, S. H., The current state of biomarker research for Friedreich's ataxia: a report from the 2018 FARA biomarker meeting. Future Sci OA 2019, 5 (6), Fso398.
27. O'Connell, T. M.; Logsdon, D. L.; Payne, R. M., Metabolomics analysis reveals
dysregulation in one carbon metabolism in Friedreich Ataxia. Mol Genet Metab 2022, 136 (4), 306-314.
28. Schult, T. A.; Lauer, M. J.; Berker, Y.; Cardoso, M. R.; Vandergrift, L. A.; Habbel, P.; Nowak, J.; Taupitz, M.; Aryee, M.; Mino-Kenudson, M. A., Screening human lung cancer with predictive models of serum magnetic resonance spectroscopy metabolomics. Proceedings of the National Academy of Sciences 2021, 118 (51).
29. Shu, T.; Ning, W.; Wu, D.; Xu, J.; Han, Q.; Huang, M.; Zou, X.; Yang, Q.; Yuan, Y.; Bie, Y., Plasma proteomics identify biomarkers and pathogenesis of COVID-19. Immunity 2020, 53 (5), 1108-1122. e5.
30. Liang, L.; Rasmussen, M.-L. H.; Piening, B.; Shen, X.; Chen, S.; Röst, H.; Snyder, J. K.; Tibshirani, R.; Skotte, L.; Lee, N. C., Metabolic dynamics and prediction of gestational age and time to delivery in pregnant women. Cell 2020, 181 (7), 1680-1692. e15.
31. Choi, R. H.; Tatum, S. M.; Symons, J. D.; Summers, S. A.; Holland, W. L., Ceramides and other sphingolipids as drivers of cardiovascular disease. Nat Rev Cardiol 2021, 18 (10), 701-711.
32. Tippetts, T. S.; Holland, W. L.; Summers, S. A., The ceramide ratio: a predictor of cardiometabolic risk. Journal of lipid research 2018, 59 (9), 1549-1550.
33. Anroedh, S.; Hilvo, M.; Akkerhuis, K. M.; Kauhanen, D.; Koistinen, K.; Oemrawsingh, R.; Serruys, P.; van Geuns, R.-J.; Boersma, E.; Laaksonen, R., Plasma concentrations of molecular lipid species predict long-term clinical outcome in coronary artery disease patients. Journal of lipid research 2018, 59 (9), 1729-1737.
34. Wang, D.; Ho, E. S.; Cotticelli, M. G.; Xu, P.; Napierala, J. S.; Hauser, L. A.; Napierala, M.; Himes, B. E.; Wilson, R. B.; Lynch, D. R., Skin fibroblast metabolomic profiling reveals that lipid dysfunction predicts the severity of Friedreich's ataxia. Journal of lipid research 2022, 100255.
35. Levy, M.; Futerman, A. H., Mammalian ceramide synthases. IUBMB life 2010, 62 (5), 347-56.
36. Geyer, P. E.; Voytik, E.; Treit, P. V.; Doll, S.; Kleinhempel, A.; Niu, L.; Müller, J. B.; Buchholtz, M. L.; Bader, J. M.; Teupser, D.; Holdt, L. M.; Mann, M., Plasma Proteome Profiling to detect and avoid sample-related biases in biomarker studies. EMBO Mol Med 2019, 11 (11), e10427.
37. Wang, Q.; Guo, L.; Strawser, C. J.; Hauser, L. A.; Hwang, W. T.; Snyder, N. W.; Lynch, D. R.; Mesaros, C.; Blair, I. A., Low apolipoprotein A-I levels in Friedreich's ataxia and in frataxin-deficient cells: Implications for therapy. PloS one 2018, 13 (2), e0192779.
38. Hammerschmidt, P.; Ostkotte, D.; Nolte, H.; Gerl, M. J.; Jais, A.; Brunner, H. L.; Sprenger, H.-G.; Awazawa, M.; Nicholls, H. T.; Turpin-Nolan, S. M., CerS6-derived sphingolipids interact with Mff and promote mitochondrial fragmentation in obesity. Cell 2019, 177 (6), 1536-1552. e23.
39. Turpin, S. M.; Nicholls, H. T.; Willmes, D. M.; Mourier, A.; Brodesser, S.; Wunderlich, C. M.; Mauer, J.; Xu, E.; Hammerschmidt, P.; Brönneke, H. S., Obesity-induced CerS6-dependent C16: 0 ceramide production promotes weight gain and glucose intolerance. Cell metabolism 2014, 20 (4), 678-686.
40. Raichur, S.; Wang, S. T.; Chan, P. W.; Li, Y.; Ching, J.; Chaurasia, B.; Dogra, S.; Öhman, M. K.; Takeda, K.; Sugii, S., CerS2 haploinsufficiency inhibits $\beta$-oxidation and
confers susceptibility to diet-induced steatohepatitis and insulin resistance. Cell metabolism 2014, 20 (4), 687-695.
41. Turpin-Nolan, S. M.; Brüning, J. C., The role of ceramides in metabolic disorders: when size and localization matters. Nature Reviews Endocrinology 2020, 16 (4), 224-233.
42. Mesicek, J.; Lee, H.; Feldman, T.; Jiang, X.; Skobeleva, A.; Berdyshev, E. V.; Haimovitz-Friedman, A.; Fuks, Z.; Kolesnick, R., Ceramide synthases 2, 5, and 6 confer distinct roles in radiation-induced apoptosis in HeLa cells. Cellular signalling 2010, 22 (9), 1300-1307.
43. Hartmann, D.; Lucks, J.; Fuchs, S.; Schiffmann, S.; Schreiber, Y.; Ferreirós, N.; Merkens, J.; Marschalek, R.; Geisslinger, G.; Grösch, S., Long chain ceramides and very long chain ceramides have opposite effects on human breast and colon cancer cell growth. The international journal of biochemistry \& cell biology 2012, 44 (4), 620-628.
44. Lee, S.-Y.; Kim, J. R.; Hu, Y.; Khan, R.; Kim, S.-J.; Bharadwaj, K. G.; Davidson, M. M.; Choi, C.-S.; Shin, K.-O.; Lee, Y.-M., Cardiomyocyte specific deficiency of serine palmitoyltransferase subunit 2 reduces ceramide but leads to cardiac dysfunction. Journal of Biological Chemistry 2012, 287 (22), 18429-18439.
45. Schmidt, S.; Gallego, S. F.; Zelnik, I. D.; Kovalchuk, S.; Albæk, N.; Sprenger, R. R.; Øverup, C.; Pewzner-Jung, Y.; Futerman, A. H.; Lindholm, M. W.; Jensen, O. N.; Ejsing, C. S., Silencing of ceramide synthase 2 in hepatocytes modulates plasma ceramide biomarkers predictive of cardiovascular death. Molecular therapy : the journal of the American Society of Gene Therapy 2022, 30 (4), 1661-1674.
46. Choi, R. H.; Tatum, S. M.; Symons, J. D.; Summers, S. A.; Holland, W. L., Ceramides and other sphingolipids as drivers of cardiovascular disease. Nature Reviews Cardiology 2021, 1-11.
47. Vasile, V. C.; Meeusen, J. W.; Medina Inojosa, J. R.; Donato, L. J.; Scott, C. G.; Hyun, M. S.; Vinciguerra, M.; Rodeheffer, R. R.; Lopez-Jimenez, F.; Jaffe, A. S., Ceramide Scores Predict Cardiovascular Risk in the Community. Arteriosclerosis, thrombosis, and vascular biology 2021, 41 (4), 1558-1569.
48. Tong, M.; de la Monte, S. M., Mechanisms of ceramide-mediated neurodegeneration. Journal of Alzheimer's Disease 2009, 16 (4), 705-714.
49. Laaksonen, R.; Ekroos, K.; Sysi-Aho, M.; Hilvo, M.; Vihervaara, T.; Kauhanen, D.; Suoniemi, M.; Hurme, R.; März, W.; Scharnagl, H., Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol. European heart journal 2016, 37 (25), 1967-1976.
50. Ji, R.; Akashi, H.; Drosatos, K.; Liao, X.; Jiang, H.; Kennel, P. J.; Brunjes, D. L.; Castillero, E.; Zhang, X.; Deng, L. Y., Increased de novo ceramide synthesis and accumulation in failing myocardium. JCI insight 2017, 2 (9).
51. Russo, S. B.; Baicu, C. F.; Van Laer, A.; Geng, T.; Kasiganesan, H.; Zile, M. R.; Cowart, L. A., Ceramide synthase 5 mediates lipid-induced autophagy and hypertrophy in cardiomyocytes. The Journal of clinical investigation 2012, 122 (11), 3919-3930.
52. Hla, T.; Kolesnick, R., C16: 0-ceramide signals insulin resistance. Cell metabolism 2014, 20 (5), 703-705.
53. Wang, Q.; Laboureur, L.; Weng, L.; Eskenazi, N. M.; Hauser, L. A.; Mesaros, C.; Lynch, D. R.; Blair, I. A., Simultaneous Quantification of Mitochondrial Mature Frataxin and

Extra-Mitochondrial Frataxin Isoform E in Friedreich's Ataxia Blood. Front Neurosci 2022, 16, 874768.
54. Selak, M. A.; Lyver, E.; Micklow, E.; Deutsch, E. C.; Önder, Ö.; Selamoglu, N.; Yager, C.; Knight, S.; Carroll, M.; Daldal, F., Blood cells from Friedreich ataxia patients harbor frataxin deficiency without a loss of mitochondrial function. Mitochondrion 2011, 11 (2), 342-350.
55. Télot, L.; Rousseau, E.; Lesuisse, E.; Garcia, C.; Morlet, B.; Léger, T.; Camadro, J.-M.; Serre, V., Quantitative proteomics in Friedreich's ataxia B-lymphocytes: A valuable approach to decipher the biochemical events responsible for pathogenesis. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 2018, 1864 (4), 997-1009.
56. Hammad, S. M.; Pierce, J. S.; Soodavar, F.; Smith, K. J.; Al Gadban, M. M.; Rembiesa, B.; Klein, R. L.; Hannun, Y. A.; Bielawski, J.; Bielawska, A., Blood sphingolipidomics in healthy humans: impact of sample collection methodology. Journal of lipid research 2010, 51 (10), 3074-87.
57. Chen, L.; Lu, W.; Wang, L.; Xing, X.; Chen, Z.; Teng, X.; Zeng, X.; Muscarella, A. D.; Shen, Y.; Cowan, A.; McReynolds, M. R.; Kennedy, B. J.; Lato, A. M.; Campagna, S. R.; Singh, M.; Rabinowitz, J. D., Metabolite discovery through global annotation of untargeted metabolomics data. Nat Methods 2021, 18 (11), 1377-1385.
58. Wang, D.; Xu, P.; Mesaros, C., Analytical considerations for reducing the matrix effect for the sphingolipidome quantification in whole blood. Bioanalysis 2021, 13 (13), 1037-1049.
59. Basu, S.; Duren, W.; Evans, C. R.; Burant, C. F.; Michailidis, G.; Karnovsky, A., Sparse network modeling and metscape-based visualization methods for the analysis of largescale metabolomics data. Bioinformatics 2017, 33 (10), 1545-1553.
60. Cherkaoui, S.; Durot, S.; Bradley, J.; Critchlow, S.; Dubuis, S.; Masiero, M. M.; Wegmann, R.; Snijder, B.; Othman, A.; Bendtsen, C., Epithelial-mesenchymal transition is the main driver of intrinsic metabolism in cancer cell lines. bioRxiv 2021.
61. Segura-Lepe, M. P.; Keun, H. C.; Ebbels, T. M. D., Predictive modelling using pathway scores: robustness and significance of pathway collections. BMC Bioinformatics 2019, 20 (1), 543.

## Acknowledgements

We thank Prof. Ian Blair for providing unlimited access to the use of LC-HRMS, Rachel Truitt for assistance with the iPSC-CMs, and Dr. Nathaniel Snyder for discussions and editing of the manuscript. We are very grateful to all FRDA patients for agreeing to give blood for research purposes and to the healthy volunteers that agreed to serve as controls. We recognize the positive support of the Hamilton and Finneran families and the Penn Medicine/CHOP Friedreich's Ataxia Center of Excellence.

## Funding:

National Institutes of Health grant R21NS116315 (CM)
National Institutes of Health grant P30ES013508 (CM)
Friedreich's Ataxia Research Alliance (FARA) Postdoctoral Research Award (DW)

## Author contributions:

Conceptualization: CM, DW, MGC
Methodology: DW, MGC, BEH, DRL
Investigation: DW, MGC, CM
Visualization: DW, BEH
Funding acquisition: CM, DW
Project administration: CM, DRL
Supervision: CM
Writing original draft: DW, CM, DRL
Writing review \& editing: DW, MGC, CM, BEH, DRL
Competing interests: Authors declare that they have no competing interests.
Data and materials availability: All data are available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website (supported by NIH grant U2C-DK119886), the Metabolomics Workbench, https://www.metabolomicsworkbench.org where it has been assigned Project ID PR001432. The data can be accessed directly via it's Project DOI:10.21228/M8MQ5M. Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Clementina Mesaros, mesaros@upenn.edu.

# Supplementary material: Plasma multi-omics analysis reveals very long chain ceramides as validated biomarkers of Friedreich's ataxia 

Authors: Dezhen Wang, ${ }^{1}$ M. Grazia Cotticelli, ${ }^{2}$ Blanca E. Himes, ${ }^{3}$ David R. Lynch, ${ }^{4}$ Clementina Mesaros ${ }^{1 *}$
${ }^{1}$ Department of Systems Pharmacology and Translational Therapeutics and Center for Excellence in Environmental Toxicology, University of Pennsylvania; Philadelphia, PA, 19104, USA.
${ }^{2}$ Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia; Philadelphia, PA, 19104, USA.
${ }^{3}$ Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania; Philadelphia, PA, 19104, USA.
${ }^{4}$ Departments of Neurology and Pediatrics, Children's Hospital of Philadelphia; Philadelphia, PA, 19104, USA.

* Corresponding author. Email: mesaros@upenn.edu.


## a Lipidomics



Supplementary Fig. 1. The extracted ion chromatogram (XIC) of lipids in positive ion mode (a) and in negative ion mode (b).

## Metabolomics

## a


b


Supplementary Fig. 2. The extracted ion chromatogram (XIC) of metabolites in positive ion mode (a) and in negative ion mode (b).

## Proteomics



Supplementary Fig. 3. The extracted ion chromatogram (XIC) of protein (peptides) in positive ion mode.


Supplementary Fig. 4. Coefficient of variances (CVs) of quantified metabolites (a) and lipids (b) in each of their quality control (QC) samples.


Supplementary Fig. 5. Metabolite correlation network based on all of metabolites and lipids. Each node represented one metabolite (lipid), and nodes were colored according to metabolite (lipid) class. The edge colored with red indicated positive correlation, while the edge with blue indicated negative correlation. The edge width represented the strength of partial correlation coefficient.
a

b
Discovery set

| Citric acid | Isocitric acid | Aconitic acid |
| :---: | :---: | :---: |
|  |  |  |
| $0^{0} 0^{x^{0}}<Q^{0+}$ | $0^{0+0^{0}}<8^{8}$ |  |
| C | Validation set |  |

Citric acid


Isocitric acid



Supplementary Fig. 6. The relative abundance of long chain ceramides in validation set (a). Relative abundance of citric acid cycle intermediates between healthy controls and FRDA patients in discovery set (b) and validation set (c).


Supplementary Fig. 7. Unbalanced ceramide synthesis in frataxin-deficient cardiomyocytes. a Western blots showing the frataxin levels in FXN-knockdown cardiomyocyte 233-SeV4 $\mathrm{b}, \mathrm{c}$ Western blots showing the protein levels of ceramide synthase (CerS2) in cardiomyocyte 11713 (b) and 233-SeV4 (c) after siRNA-mediated FXN knockdown doe The mass isotopomer distribution of ceramides from FXN-knockdown cardiomyocyte 11713 (d) and 233-SeV4 (e)



Supplementary Fig. 8. Quality assessment of each sample according to main contamination sources of coagulation (a), erythrocyte (b), and platelet (c).

Western blot



Fig. 5h


Fig. 6 a


Supplementary Fig. 9. Full Western blots used in the cellular work.


Supplementary Fig. 10. Machine learning improves the prediction of FRDA. A. Machine learning workflow for prediction of FRDA using metabolic features. B. Top 15 selected metabolites from Linear support vector machine (SVM) model. C. K-Means Clustering revealed different 4 clusters for these metabolites. D. The receiver operating characteristic (ROC) curves using three metabolites [ $\operatorname{Cer}(\mathrm{m19:0/24:0)}, \mathrm{3-methoxytyrosine} ,\mathrm{and} \mathrm{putrescine]}$ based SVM model in the discovery set $\mathbf{E}$. same as D but in the validation set.

Supplementary Table 1. Demographic data for each cohort.

| Discovery set (59) |  |  |  | Validation set (38) |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  | Control | FRDA | Carrier | Control | FRDA |
| Gender | $\mathrm{M}(8) / \mathrm{F}(7)$ | $\mathrm{M}(10) / \mathrm{F}(19)$ <br> 4 Unknown | $\mathrm{M}(4) \mathrm{F} /(7)$ | $\mathrm{M}(7) / \mathrm{F}(5)$ | $\mathrm{M}(17) / \mathrm{F}(9)$ |
| Age $($ mean $\pm$ sd) | $32.7 \pm 11.0$ | $25.6 \pm 8.1$ | $54.2 \pm 9.3$ | $29.4 \pm 7.6$ | $21.2 \pm 7.7$ |
| GAA1 $($ mean $\pm$ sd) | - | $634.9 \pm 184.2$ | - | - | $693.3 \pm 198.2$ |
| Age of onset <br> (mean $\pm$ sd) | - | $11.8 \pm 5.4$ | - | - | $11.6 \pm 4.2$ |

Supplementary Table 2. Internal Standards (ISTD) used for metabolomics and lipidomics analysis.

| Internal Standard (ISTD) | Concentration in $\operatorname{Mix}\left(\mathrm{ng} \mu^{-1}\right)$ | Supplier |
| :---: | :---: | :---: |
| Metabolomics ISTD Mix |  |  |
| Glycine (13C2, 99\%; 15N, 99\%) | 11 | CIL |
| Serine (13C3, 98\%; 15N, 98\%) | 60 | CIL |
| Isoleucine (13C6, $99 \% ; 15 \mathrm{~N}$, $99 \%)$ | 10.5 | CIL |
| Threonine-13C4,15N | 11 | SA |
| Sodium Pyruvate (13C3, 99\%) | 10 | CIL |
| Arginine (13C6, 99\%) | 9.5 | CIL |
| Valine (13C5, 99\%; 15N, 99\%) | 110 | CIL |
| Tryptophan (13C11, 99\%) | 11.5 | CIL |
| Lysine (13C6, 99\%) | 10 | CIL |
| Aspartic Acid (13C4, $99 \% ; 15 \mathrm{~N}$, $99 \%)$ | 10.5 | CIL |
| Glutamic Acid-13C5,15N | 10 | SA |
| Glutamine-13C5,15N2 | 10 | SA |
| $\begin{gathered} \text { D-3-Hydroxybutyrate (13C4, } \\ 99 \%) \\ \hline \end{gathered}$ | 10.5 | CIL |
| Adenosine (Ribose-13c5, 98\%+) | 50 | CIL |
| Alpha-Ketoglutaric Acid (13C5, $99 \%$ ) | 2.5 | CIL |
| A-Hydroxyglutaric Acid-13C5 | 2.5 | SA |
| Fumaric Acid - [13]C4 | N/A | CIL |
| Succinic Acid-2,2,3,3-d4 | 11 | SA |
| Citric Acid-13C6 | 9 | SA |
| ${ }^{1}$ Carnitine - D9 | 2.16 | CIL |
| ${ }^{1}$ Acetylcarnitine - D3 | 0.77 | CIL |
| ${ }^{1}$ Propionylcarnitine - D3 | 0.16 | CIL |
| ${ }^{1}$ Butyrylcarnitine - D3 | 0.17 | CIL |
| ${ }^{1}$ Isovalerylcarnitine - D9 | 0.18 | CIL |


| ${ }^{1}$ Octanoylcarnitine - D3 | 0.21 | CIL |
| :---: | :---: | :---: |
| ${ }^{1}$ Myristoylcarnitine - D9 | 0.26 | CIL |
| ${ }^{1}$ Palmitoylcarnitine - D3 | 0.56 | CIL |
| Lipidomics ISTD Mix |  |  |
| ${ }^{2} 15: 0-18: 1$ PC - D7 | 80 | APL |
| ${ }^{2} 15: 0-18: 1 \mathrm{PE}$ - D7 | 2.5 | APL |
| ${ }^{2} 15: 0-18: 1$ PS - D7 | 2.5 | APL |
| ${ }^{2} 15: 0-18: 1$ PG - D7 | 15 | APL |
| ${ }^{2} 15: 0-18: 1$ PI - D7 | 5 | APL |
| ${ }^{2} 15: 0-18: 1$ PA - D7 | 3.5 | APL |
| ${ }^{2} 18: 1$ LPC - D7 | 12.5 | APL |
| ${ }^{2} 18: 1$ LPE - D7 | 2.5 | APL |
| ${ }^{2} 18: 1$ Cholesterol Ester - D7 | 175 | APL |
| ${ }^{2} 18: 1 \mathrm{MG}$ - D7 | 1 | APL |
| ${ }^{2} 15: 0-18: 1 \mathrm{DG}$ - D7 | 5 | APL |
| ${ }^{2} 15: 0-18: 1-15: 0$ TG - D7 | 27.5 | APL |
| ${ }^{2} 18: 1 \mathrm{SM}$ - D9 | 15 | APL |
| ${ }^{2}$ Cholesterol - D7 | 50 | APL |
| Sphingosine (C17 base) | 3.6 | APL |
| Sphinganine (C17 base) | 3.6 | APL |
| Sphingosine-1-P (C17 base) | 4.6 | APL |
| Sphinganine-1-P (C17 base) | 4.6 | APL |
| Lactosyl(ß) C12 Ceramide | 8.1 | APL |
| 12:0 Sphingomyelin | 6 | APL |
| Glucosyl( $\beta$ ) C12 Ceramide | 8 | APL |
| 12:0 Ceramide | 10.1 | APL |
| 12:0 Ceramide-1-P | 7 | APL |
| 25:0 Ceramide | 8.3 | APL |
| Palmitoyl-1,2,3,4-13C4-Lcarnitine hydrochloride | 2.2 | SA |

CIL $=$ Cambridge Isotope Laboratories, Inc. (Tewksbury, MA, USA).
SA = Sigma-Aldrich (St. Louis, MO, USA)
TRC = Toronto Research Chemicals, Inc.,
APL = Avanti Polar Lipids (Birmingham, AL, USA). CC = Cayman Chemicals
${ }^{1}$ Labeled carnitine standards set B from CIL
${ }^{2}$ Splash Lipidomix Mass Spec Standards from APL

Supplementary Table 3. Inclusion list for targeted metabolomics (PRM).

| $\begin{aligned} & \text { Mass } \\ & {[\mathrm{m} / \mathrm{z}]} \end{aligned}$ | $\begin{gathered} \text { For } \\ \text { mula } \\ {[\mathbf{M}]} \end{gathered}$ | $\begin{gathered} \text { For } \\ \text { mula } \\ \text { type } \end{gathered}$ | $\begin{aligned} & \hline \text { Spe } \\ & \text { cies } \end{aligned}$ | $\begin{aligned} & \hline \mathbf{C} \\ & \mathbf{S} \\ & {[\mathbf{z}} \end{aligned}$ | Pola rity | $\begin{gathered} \hline \text { Sta } \\ \text { rt } \\ {[\mathbf{m i}} \\ \mathbf{n}] \\ \hline \end{gathered}$ | $\begin{gathered} \text { En } \\ \text { d } \\ {[\mathbf{m i}} \\ \mathbf{n}] \\ \hline \end{gathered}$ | $\begin{aligned} & (\mathbf{N}) \\ & \mathbf{C E} \end{aligned}$ | $\begin{aligned} & \hline(N) \\ & \text { CE } \\ & \text { typ } \end{aligned}$ | $\begin{gathered} \hline \mathbf{M} \\ \mathbf{S X} \\ \text { ID } \end{gathered}$ | Comment |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{aligned} & 61.04 \\ & 02 \end{aligned}$ |  |  |  | 1 | Positi ve | 1.3 | 3.3 | 10 | $\begin{aligned} & \hline \mathrm{NC} \\ & \mathrm{E} \end{aligned}$ |  | Urea |
| $\begin{aligned} & 62.06 \\ & 004 \\ & \hline \end{aligned}$ |  |  |  | 1 | Positi ve | 7.7 | 9.7 | 10 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \end{aligned}$ |  | Ethanolamine |
| $\begin{aligned} & 76.03 \\ & 931 \end{aligned}$ |  |  |  | 1 | Positi <br> ve | 8 | 10 | 20 | $\begin{array}{\|l\|} \hline \mathrm{NC} \\ \mathrm{E} \\ \hline \end{array}$ |  | Glycine |
| $\begin{aligned} & 81.04 \\ & 473 \end{aligned}$ |  |  |  | 1 | Positi <br> ve | 10 | 12 | 20 | $\begin{aligned} & \hline \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ |  | Pyrimidine |
| $\begin{aligned} & 89.10 \\ & 733 \\ & \hline \end{aligned}$ |  |  |  | 1 | Positi ve | $\begin{array}{\|l\|} \hline 14 . \\ 9 \\ \hline \end{array}$ | 18 | 10 | $\begin{array}{\|l\|} \hline \mathrm{NC} \\ \mathrm{E} \\ \hline \end{array}$ |  | Putrescine |
| $\begin{aligned} & 90.05 \\ & 496 \end{aligned}$ |  |  |  | 1 | Positi <br> ve | 7.5 | 9.5 | 20 | $\begin{array}{\|l\|} \hline \mathrm{NC} \\ \mathrm{E} \\ \hline \end{array}$ |  | Alanine |
| $\begin{aligned} & 90.05 \\ & 496 \\ & \hline \end{aligned}$ |  |  |  | 1 | Positi ve | 8.5 | $\begin{array}{\|l\|} \hline 10 . \\ 5 \\ \hline \end{array}$ | 20 | $\begin{array}{\|l\|} \hline \mathrm{NC} \\ \mathrm{E} \\ \hline \end{array}$ |  | Sarcosine |
| $\begin{aligned} & 90.05 \\ & 496 \end{aligned}$ |  |  |  | 1 | Positi ve | 9.4 | $\begin{aligned} & 11 . \\ & 4 \\ & \hline \end{aligned}$ | 20 | $\begin{aligned} & \hline \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ |  | $\beta$-Alanine |
| $\begin{aligned} & 102.0 \\ & 55 \end{aligned}$ |  |  |  | 1 | Positi ve | 7 | 9 | 10 | $\begin{aligned} & \hline \mathrm{NC} \\ & \mathrm{E} \end{aligned}$ |  | 1Aminocyclopropan ecarboxylic acid |
| $\begin{aligned} & 103.0 \\ & 395 \end{aligned}$ |  |  |  | 1 | Positi <br> ve | 12 | 14 | 20 | $\begin{aligned} & \hline \mathrm{NC} \\ & \mathrm{E} \end{aligned}$ |  | Acetoacetate |
| $\begin{aligned} & 104.0 \\ & 706 \end{aligned}$ |  |  |  | 1 | Positi ve | 6.8 | 8.8 | 20 | $\begin{array}{\|l\|} \hline \mathrm{NC} \\ \mathrm{E} \\ \hline \end{array}$ |  | 2-Aminoisobutyric acid |
| $\begin{aligned} & 104.0 \\ & 706 \end{aligned}$ |  |  |  | 1 | Positi ve | 8.5 | $\begin{array}{\|l\|} \hline 10 . \\ 5 \\ \hline \end{array}$ | 20 | $\begin{array}{\|l\|} \hline \mathrm{NC} \\ \mathrm{E} \\ \hline \end{array}$ |  | Dimethylglycine |
| $\begin{aligned} & 104.1 \\ & 075 \end{aligned}$ |  |  |  | 1 | Positi <br> ve | $\begin{aligned} & \hline 10 . \\ & 6 \\ & \hline \end{aligned}$ | $\begin{array}{\|l\|} \hline 12 . \\ 6 \\ \hline \end{array}$ | 10 | $\begin{array}{\|l\|} \hline \mathrm{NC} \\ \mathrm{E} \\ \hline \end{array}$ |  | Choline |
| $\begin{aligned} & 106.0 \\ & 499 \end{aligned}$ |  |  |  | 1 | Positi ve | 7.5 | 9.5 | 20 | $\begin{array}{\|l\|} \hline \mathrm{NC} \\ \mathrm{E} \\ \hline \end{array}$ |  | Serine |
| $\begin{aligned} & 112.0 \\ & 506 \end{aligned}$ |  |  |  | 1 | Positi <br> ve | 2.4 | 4.4 | 10 | $\begin{array}{\|l\|} \hline \mathrm{NC} \\ \mathrm{E} \\ \hline \end{array}$ |  | Cytosine |
| $\begin{aligned} & 112.0 \\ & 869 \\ & \hline \end{aligned}$ |  |  |  | 1 | Positi ve | 10 | 12 | 20 | $\begin{array}{\|l\|} \hline \mathrm{NC} \\ \mathrm{E} \\ \hline \end{array}$ |  | Histamine |
| $\begin{aligned} & 113.0 \\ & 346 \end{aligned}$ |  |  |  | 1 | Positi ve | 1.1 | 3.1 | 10 | $\begin{array}{\|l\|} \hline \mathrm{NC} \\ \mathrm{E} \\ \hline \end{array}$ |  | Uracil |
| $\begin{aligned} & 114.0 \\ & 662 \end{aligned}$ |  |  |  | 1 | Positi ve | 2.9 | 4.9 | 20 | $\begin{aligned} & \hline \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ |  | Creatinine |
| $\begin{aligned} & 116.0 \\ & 706 \\ & \hline \end{aligned}$ |  |  |  | 1 | Positi ve | 7.9 | 9.9 | 20 | $\begin{array}{\|l\|} \hline \mathrm{NC} \\ \mathrm{E} \\ \hline \end{array}$ |  | Proline |
| $\begin{aligned} & 118.0 \\ & 611 \end{aligned}$ |  |  |  | 1 | Positi <br> ve | 7.8 | 9.8 | 40 | $\begin{array}{\|l\|} \hline \mathrm{NC} \\ \mathrm{E} \\ \hline \end{array}$ |  | Guanidineacetic acid |
| 118.0 |  |  |  | 1 | Positi | 3.6 | 7 | 50 | NC |  | Indole |


| 656 |  |  |  |  | ve |  |  |  | E |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{aligned} & 118.0 \\ & 863 \\ & \hline \end{aligned}$ |  |  |  | 1 | Positi ve | 6.4 | 8.4 | 20 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ | Valine |
| $\begin{aligned} & 118.0 \\ & 863 \end{aligned}$ |  |  |  | 1 | Positi ve | 9 | 11 | 50 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ | Betaine |
| $\begin{aligned} & 120.0 \\ & 655 \end{aligned}$ |  |  |  | 1 | Positi ve | 7 | 9 | 20 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ | Threonine |
| $\begin{aligned} & 123.0 \\ & 439 \end{aligned}$ |  |  |  | 1 | Positi ve | 5 | 7 | 20 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ | Benzoic acid |
| $\begin{aligned} & 123.0 \\ & 553 \end{aligned}$ |  |  |  | 1 | Positi ve | 1 | 3 | 50 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ | Nicotinamide |
| $\begin{aligned} & 126.0 \\ & 22 \end{aligned}$ |  |  |  | 1 | Positi ve | 4.3 | 6.3 | 10 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ | Taurine |
| $\begin{aligned} & 127.0 \\ & 501 \\ & \hline \end{aligned}$ |  |  |  | 1 | Positi <br> ve | 1 | 3 | 20 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ | Thymine |
| $\begin{aligned} & 130.0 \\ & 499 \\ & \hline \end{aligned}$ |  |  |  | 1 | Positi ve | 5.9 | 8 | 20 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ | Pyroglutamic acid |
| $\begin{aligned} & 130.0 \\ & 863 \end{aligned}$ |  |  |  | 1 | Positi ve | 6.7 | 8.7 | 30 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \end{aligned}$ | Pipecolic acid |
| $\begin{aligned} & 130.0 \\ & 863 \\ & \hline \end{aligned}$ |  |  |  | 1 | Positi ve | 5.6 | 7.6 | 30 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ | L-betaHomoproline |
| $\begin{aligned} & 131.1 \\ & 179 \\ & \hline \end{aligned}$ |  |  |  | 1 | Positi ve | 9.2 | $\begin{aligned} & 11 . \\ & 2 \end{aligned}$ | 20 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \end{aligned}$ | N-Acetylputrescine |
| $\begin{aligned} & \hline 132.0 \\ & 655 \\ & \hline \end{aligned}$ |  |  |  | 1 | $\begin{aligned} & \hline \text { Positi } \\ & \text { ve } \\ & \hline \end{aligned}$ | 7.5 | 9.5 | 40 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \end{aligned}$ | trans-4-Hydroxy-L-proline |
| $\begin{aligned} & 132.0 \\ & 768 \\ & \hline \end{aligned}$ |  |  |  | 1 | Positi ve | 8.7 | $\begin{aligned} & 10 . \\ & 7 \\ & \hline \end{aligned}$ | 30 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \end{aligned}$ | Creatine |
| $\begin{aligned} & 132.1 \\ & 019 \end{aligned}$ |  |  |  | 1 | Positi ve | 5.2 | 7.2 | 20 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ | Leucine |
| $\begin{aligned} & 132.1 \\ & 019 \end{aligned}$ |  |  |  | 1 | Positi ve | 5.5 | 7.5 | 20 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ | Isoleucine |
| $\begin{aligned} & \hline 132.1 \\ & 019 \end{aligned}$ |  |  |  | 1 | Positi <br> ve | 7.6 | 9.6 | 50 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ | Alanine betaine |
| $\begin{aligned} & \hline 133.0 \\ & 972 \end{aligned}$ |  |  |  | 1 | Positi ve | $\begin{aligned} & 12 . \\ & \hline \end{aligned}$ | 15 | 10 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ | Ornithine |
| $\begin{aligned} & 136.0 \\ & 618 \\ & \hline \end{aligned}$ |  |  |  | 1 | Positi ve | 1.9 | 3.9 | 50 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ | Adenine |
| $\begin{aligned} & 137.0 \\ & 458 \end{aligned}$ |  |  |  | 1 | Positi ve | 1.9 | 3.9 | 50 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \end{aligned}$ | Hypoxanthine |
| $\begin{aligned} & 137.0 \\ & 715 \end{aligned}$ |  |  |  | 1 | Positi ve | $\begin{aligned} & 10 . \\ & 3 \end{aligned}$ | $\begin{aligned} & 12 . \\ & 3 \end{aligned}$ | 50 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \end{aligned}$ | 1- <br> Methylnicotinamid <br> e |
| $\begin{aligned} & 138.0 \\ & 55 \end{aligned}$ |  |  |  | 1 | Positi <br> ve | 8.9 | $\begin{array}{\|l\|} \hline 10 . \\ 9 \end{array}$ | 50 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \end{aligned}$ | Trigonelline |
| $\begin{aligned} & 139.0 \\ & 502 \end{aligned}$ |  |  |  | 1 | Positi ve | 4.5 | 6.5 | 10 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ | Urocanic acid |



| $\begin{aligned} & 189.1 \\ & 234 \end{aligned}$ |  |  |  | 1 | Positi ve | $\begin{aligned} & 10 . \\ & 3 \end{aligned}$ | $\begin{aligned} & 12 . \\ & 3 \end{aligned}$ | 40 | $\begin{array}{\|l\|} \hline \mathrm{NC} \\ \mathrm{E} \\ \hline \end{array}$ |  | N $\alpha$-Acetyl-L-lysine |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{aligned} & 189.1 \\ & 234 \\ & \hline \end{aligned}$ |  |  |  | 1 | Positi ve | $\begin{array}{\|l\|} \hline 8.4 \\ 7 \\ \hline \end{array}$ | $\begin{aligned} & 10 . \\ & 47 \\ & \hline \end{aligned}$ | 40 | $\begin{array}{\|l} \hline \mathrm{NC} \\ \mathrm{E} \\ \hline \end{array}$ |  | N-epsilonAcetyllysine |
| $\begin{aligned} & 189.1 \\ & 344 \\ & \hline \end{aligned}$ |  |  |  | 1 | Positi ve | $\begin{aligned} & 14 . \\ & 06 \end{aligned}$ | $\begin{aligned} & 16 . \\ & 06 \\ & \hline \end{aligned}$ | 40 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ |  | Targinine |
| $\begin{aligned} & 189.1 \\ & 344 \\ & \hline \end{aligned}$ |  |  |  | 1 | Positi ve | 12 | 14 | 30 | $\begin{array}{\|l} \hline \mathrm{NC} \\ \mathrm{E} \\ \hline \end{array}$ |  | $\begin{aligned} & \text { Asparagine butyl } \\ & \text { ester } \end{aligned}$ |
| $\begin{aligned} & 189.1 \\ & 598 \\ & \hline \end{aligned}$ |  |  |  | 1 | Positi ve | $\begin{aligned} & \hline 14 . \\ & 3 \\ & \hline \end{aligned}$ | 17 | 30 | $\begin{array}{\|l\|} \hline \mathrm{NC} \\ \mathrm{E} \\ \hline \end{array}$ |  | $\mathrm{N} \varepsilon, \mathrm{N} \varepsilon, \mathrm{N} \varepsilon-$ Trimethyllysine |
| $\begin{aligned} & 190.0 \\ & 499 \end{aligned}$ |  |  |  | 1 | Positi ve | 1.5 | 3.5 | 50 | $\begin{array}{\|l\|} \hline \mathrm{NC} \\ \mathrm{E} \\ \hline \end{array}$ |  | Kynurenic acid |
| $\begin{aligned} & 195.0 \\ & 875 \\ & \hline \end{aligned}$ |  |  |  | 1 | Positi ve | 0.8 | 2.8 | 50 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ |  | Caffeine |
| $\begin{aligned} & 204.1 \\ & 231 \end{aligned}$ |  |  |  | 1 | Positi ve | $\begin{aligned} & \hline 11 . \\ & 9 \\ & \hline \end{aligned}$ | $\begin{aligned} & 13 . \\ & 9 \\ & \hline \end{aligned}$ | 40 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ |  | Acetyl-L-Carnitine |
| $\begin{aligned} & 218.1 \\ & 537 \end{aligned}$ |  |  |  | 1 | Positi ve | $\begin{aligned} & 11 . \\ & 2 \\ & \hline \end{aligned}$ | $\begin{aligned} & 13 . \\ & 2 \\ & \hline \end{aligned}$ | 40 | $\begin{array}{\|l\|} \hline \mathrm{NC} \\ \mathrm{E} \\ \hline \end{array}$ |  | Propionyl-LCarnitine |
| $\begin{aligned} & 232.1 \\ & 783 \end{aligned}$ |  |  |  | 1 | Positi ve | $\begin{aligned} & 10 . \\ & 2 \end{aligned}$ | $\begin{aligned} & 12 . \\ & 2 . \end{aligned}$ | 40 | $\begin{array}{\|l\|} \hline \mathrm{NC} \\ \mathrm{E} \\ \hline \end{array}$ |  | Butyryl-LCarnitine |
| $\begin{aligned} & 232.1 \\ & 783 \end{aligned}$ |  |  |  | 1 | Positi ve | $\begin{aligned} & 10 . \\ & 4 \end{aligned}$ | $\begin{aligned} & 12 . \\ & 4 \end{aligned}$ | 40 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \end{aligned}$ |  | Isobutyryl-LCarnitine |
| $\begin{aligned} & 246.2 \\ & 04 \end{aligned}$ |  |  |  | 1 | Positi ve | 9.3 | $\begin{aligned} & 11 . \\ & 3 \\ & \hline \end{aligned}$ | 40 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ |  | Isovaleryl-LCarnitine |
| $\begin{aligned} & 246.2 \\ & 04 \end{aligned}$ |  |  |  | 1 | Positi <br> ve | 9.5 | $\begin{aligned} & 11 . \\ & 5 \\ & \hline \end{aligned}$ | 40 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ |  | 2-Methylbutyryl-LCarnitine |
| $\begin{aligned} & 260.1 \\ & 855 \\ & \hline \end{aligned}$ |  |  |  | 1 | Positi <br> ve | 8.3 | $\begin{aligned} & 10 . \\ & 3 \\ & \hline \end{aligned}$ | 40 | $\begin{array}{\|l} \hline \mathrm{NC} \\ \mathrm{E} \\ \hline \end{array}$ |  | Hexanoyl-LCarnitine |
| $\begin{aligned} & \hline 282.1 \\ & 201 \end{aligned}$ |  |  |  | 1 | Positi <br> ve | 8.2 | $\begin{aligned} & 10 . \\ & 2 \end{aligned}$ | 30 | $\begin{array}{\|l\|} \hline \mathrm{NC} \\ \mathrm{E} \\ \hline \end{array}$ |  | 1-Methyladenosine |
| $\begin{aligned} & 288.2 \\ & 172 \end{aligned}$ |  |  |  | 1 | Positi ve | 7.2 | 9.2 | 40 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ |  | Octanoyl-LCarnitine |
| $\begin{aligned} & 316.2 \\ & 481 \\ & \hline \end{aligned}$ |  |  |  | 1 | Positi ve | 6.9 | 8.9 | 40 | $\begin{array}{\|l\|} \hline \mathrm{NC} \\ \mathrm{E} \\ \hline \end{array}$ |  | Decanoyl-LCarnitine |
| $\begin{aligned} & 344.2 \\ & 796 \end{aligned}$ |  |  |  | 1 | Positi <br> ve | 6.5 | 8.5 | 40 | $\begin{array}{\|l\|} \hline \mathrm{NC} \\ \mathrm{E} \\ \hline \end{array}$ |  | Lauroyl-L- <br> Carnitine |
| $\begin{aligned} & 372.3 \\ & 11 \end{aligned}$ |  |  |  | 1 | $\begin{aligned} & \text { Positi } \\ & \text { ve } \end{aligned}$ | 5.9 | 7.9 | 40 | $\begin{array}{\|l\|} \hline \mathrm{NC} \\ \mathrm{E} \\ \hline \end{array}$ |  | Myristoyl-LCarnitine |
| $\begin{aligned} & 400.3 \\ & 422 \end{aligned}$ |  |  |  | 1 | Positi ve | 5.5 | 7.5 | 40 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ |  | Palmitoyl-LCarnitine |
| $\begin{aligned} & 403.2 \\ & 326 \\ & \hline \end{aligned}$ |  |  |  | 1 | $\begin{array}{\|l\|} \hline \begin{array}{l} \text { Positi } \\ \text { ve } \end{array} \\ \hline \end{array}$ | $\begin{array}{\|l\|} \hline 0.3 \\ 1 \\ \hline \end{array}$ | $\begin{aligned} & 2.3 \\ & 1 \\ & \hline \end{aligned}$ | 30 | $\begin{array}{\|l\|l} \hline \mathrm{NC} \\ \mathrm{E} \\ \hline \end{array}$ |  | Acetyl tributyl citrate |
| $\begin{aligned} & 466.3 \\ & 163 \end{aligned}$ |  |  |  | 1 | $\begin{aligned} & \text { Positi } \\ & \text { ve } \end{aligned}$ | $\begin{aligned} & \hline 4.4 \\ & 6 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 6.4 \\ & 6 \\ & \hline \end{aligned}$ | 20 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ |  | Glycocholic acid |
| $\begin{aligned} & 489.1 \\ & 146 \end{aligned}$ |  |  |  | 1 | $\begin{array}{\|l\|} \hline \begin{array}{l} \text { Positi } \\ \text { ve } \end{array} \\ \hline \end{array}$ | $\begin{aligned} & 12 . \\ & 3 \end{aligned}$ | $14 .$ $3$ | 30 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ |  | CDP-Choline |


| $\begin{aligned} & 583.2 \\ & 551 \end{aligned}$ |  |  |  | 1 | Positi ve | 2.3 | 4.3 | 30 | NC <br> E |  | Biliverdin |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{aligned} & 585.2 \\ & 708 \end{aligned}$ |  |  |  | 1 | Positi <br> ve | 0.5 | 2.5 | 30 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ |  | Bilirubin |
| $\begin{aligned} & 79.04 \\ & 3 \end{aligned}$ |  |  |  | 1 | Positi <br> ve | 8 | 10 | 20 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \end{aligned}$ |  | Glycine_IS |
| $\begin{aligned} & 110.0 \\ & 568 \end{aligned}$ |  |  |  | 1 | Positi <br> ve | 7.5 | 9.5 | 20 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \end{aligned}$ |  | Serine_IS |
| $\begin{aligned} & 139.1 \\ & 189 \end{aligned}$ |  |  |  | 1 | Positi <br> ve | 5.5 | 7.5 | 20 | $\begin{aligned} & \hline \mathrm{NC} \\ & \mathrm{E} \end{aligned}$ |  | Isoleucine_IS |
| $\begin{aligned} & 125.0 \\ & 759 \\ & \hline \end{aligned}$ |  |  |  | 1 | Positi <br> ve | 7 | 9 | 20 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \end{aligned}$ |  | Threonine_IS |
| $\begin{aligned} & 181.1 \\ & 388 \end{aligned}$ |  |  |  | 1 | Positi ve | $12 .$ $1$ | $14 .$ $1$ | 40 | $\begin{aligned} & \hline \mathrm{NC} \\ & \mathrm{E} \end{aligned}$ |  | Arginine_IS |
| $\begin{aligned} & 124.0 \\ & 999 \end{aligned}$ |  |  |  | 1 | Positi <br> ve | 6.4 | 8.4 | 20 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ |  | Valine_IS |
| $\begin{aligned} & 153.1 \\ & 328 \end{aligned}$ |  |  |  | 1 | Positi ve | 12 | 17 | 10 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \end{aligned}$ |  | Lysine_IS |
| $\begin{aligned} & 171.1 \\ & 689 \\ & \hline \end{aligned}$ |  |  |  | 1 | Positi ve | 12 | 14 | 40 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \end{aligned}$ |  | Carnitine-D9 |
| $\begin{aligned} & 207.1 \\ & 489 \end{aligned}$ |  |  |  | 1 | Positi ve | $\begin{array}{\|l\|} \hline 11 . \\ 9 \\ \hline \end{array}$ | $\begin{array}{\|l} \hline 13 . \\ 9 \\ \hline \end{array}$ | 40 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ |  | Acetyl-L- <br> Carnitine-D3 |
| $\begin{aligned} & 221.1 \\ & 726 \end{aligned}$ |  |  |  | 1 | Positi ve | $\begin{aligned} & 11 . \\ & 2 \\ & \hline \end{aligned}$ | $\begin{aligned} & 13 . \\ & 2 . \\ & \hline \end{aligned}$ | 40 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ |  | Propionyl-L-Carnitine-D3 |
| $\begin{aligned} & 235.1 \\ & 974 \end{aligned}$ |  |  |  | 1 | Positi <br> ve | $\begin{aligned} & 10 . \\ & 2 \\ & \hline \end{aligned}$ | $\begin{aligned} & 12 . \\ & 2 \end{aligned}$ | 40 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \end{aligned}$ |  | Butyryl-L- <br> Carnitine-D3 |
| $\begin{aligned} & 255.2 \\ & 616 \\ & \hline \end{aligned}$ |  |  |  | 1 | Positi <br> ve | 9.2 | $\begin{array}{\|l} \hline 11 . \\ 2 \\ \hline \end{array}$ | 40 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ |  | Isobutyryl-L- <br> Carnitine-D9 |
| $\begin{aligned} & 403.3 \\ & 605 \\ & \hline \end{aligned}$ |  |  |  | 1 | Positi ve | 5.4 | 7.4 | 30 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ |  | Palmitoyl-L- <br> Carnitine-D3 |
| $\begin{aligned} & 154.0 \\ & 741 \end{aligned}$ |  |  |  | 1 | $\begin{aligned} & \text { Positi } \\ & \text { ve } \\ & \hline \end{aligned}$ | 9.2 | $\begin{aligned} & 11 . \\ & 2 \\ & \hline \end{aligned}$ | 30 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ |  | Glutamic Acid_IS |
| $\begin{aligned} & 153.0 \\ & 901 \end{aligned}$ |  |  |  | 1 | Positi <br> ve | 8.2 | $10 .$ | 30 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ |  | Glutamine_IS |
| $\begin{aligned} & 147.0 \\ & 764 \end{aligned}$ |  |  |  | 1 | Positi <br> ve | 8.2 | $\begin{aligned} & 10 . \\ & 2 \end{aligned}$ | 30 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \end{aligned}$ |  | Glutamine |
| $\begin{aligned} & 148.0 \\ & 605 \end{aligned}$ |  |  |  | 1 | Positi <br> ve | 9.2 | $\begin{aligned} & 11 . \\ & 2 \\ & \hline \end{aligned}$ | 30 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \end{aligned}$ |  | Glutamic acid |
| $\begin{aligned} & \text { Mass } \\ & {[\mathrm{m} / \mathrm{z}]} \end{aligned}$ |  |  | Spec ies | $\begin{array}{\|l} \hline \mathrm{C} \\ \mathrm{~S} \\ {[\mathrm{z}} \\ ] \\ \hline \end{array}$ | Polar ity | $\begin{array}{\|l\|} \hline \mathrm{Sta} \\ \mathrm{rt} \\ {[\mathrm{mi}} \\ \hline \mathrm{n}] \\ \hline \end{array}$ | $\begin{array}{\|l\|} \hline \mathrm{En} \\ \mathrm{~d} \\ {[\mathrm{mi}} \\ \mathrm{n}] \\ \hline \end{array}$ | $\begin{aligned} & \mathrm{CN}) \\ & \mathrm{CE} \end{aligned}$ | $\begin{aligned} & \hline \mathrm{N}) \\ & \mathrm{CE} \\ & \text { type } \end{aligned}$ | $\begin{array}{\|l\|} \hline \mathrm{M} \\ \mathrm{SX} \\ \mathrm{ID} \\ \hline \end{array}$ | Comment |
| $\begin{aligned} & 73.02 \\ & 95 \end{aligned}$ |  |  |  | 1 | Nega tive | 2.8 | 4.8 | 40 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ |  | Propionate |
| $\begin{aligned} & 87.00 \\ & 876 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | 1.5 | 3.5 | 50 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ |  | Pyruvic acid |


| $\begin{aligned} & \hline 89.02 \\ & 441 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | 3.1 | 5.1 | 40 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \end{aligned}$ | Lactic acid |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{aligned} & 102.0 \\ & 196 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | 5 | 7 | 20 | $\begin{array}{\|l\|} \hline \mathrm{NC} \\ \mathrm{E} \\ \hline \end{array}$ | N-Formylglycine |
| $\begin{aligned} & 103.0 \\ & 4 \end{aligned}$ |  |  |  | 1 | Nega tive | 2.4 | 4.4 | 30 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ | 2-Hydroxybutyric acid |
| $\begin{aligned} & 103.0 \\ & 4 \end{aligned}$ |  |  |  | 1 | Nega tive | 2.8 | 4.8 | 30 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \end{aligned}$ | 3- <br> Hydroxyisobutyric acid |
| $\begin{aligned} & 103.0 \\ & 4 \end{aligned}$ |  |  |  | 1 | Nega tive | 3.3 | 6 | 30 | $\begin{array}{\|l} \hline \mathrm{NC} \\ \mathrm{E} \\ \hline \end{array}$ | 3-Hydroxybutyric acid |
| $\begin{aligned} & 105.0 \\ & 193 \end{aligned}$ |  |  |  | 1 | Nega tive | 4.4 | 6.4 | 20 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ | Glyceric acid |
| $\begin{aligned} & 115.0 \\ & 037 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | 7.1 | 9.1 | 10 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ | Fumaric acid |
| $\begin{aligned} & 116.0 \\ & 353 \end{aligned}$ |  |  |  | 1 | Nega tive | 5.7 | 7.7 | 30 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ | N-Acetylglycine |
| $\begin{aligned} & 117.0 \\ & 193 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | 6.4 | 8.4 | 10 | $\begin{array}{\|l} \hline \mathrm{NC} \\ \mathrm{E} \\ \hline \end{array}$ | Succinic acid |
| $\begin{aligned} & 128.0 \\ & 353 \end{aligned}$ |  |  |  | 1 | Nega tive | 5.9 | 7.9 | 30 | $\begin{array}{\|l\|} \hline \mathrm{NC} \\ \mathrm{E} \\ \hline \end{array}$ | Pyroglutamic acid |
| $\begin{aligned} & 129.0 \\ & 193 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{aligned} & 1.9 \\ & 5 \\ & \hline \end{aligned}$ | $\begin{aligned} & 3.9 \\ & 5 \\ & \hline \end{aligned}$ | 40 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \end{aligned}$ | Citraconic acid |
| $\begin{aligned} & 129.0 \\ & 193 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | 6 | 8 | 40 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ | Itaconic acid |
| $\begin{aligned} & 130.0 \\ & 509 \end{aligned}$ |  |  |  | 1 | Nega tive | 5.1 | 7.1 | 20 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ | N-Acetyl-L-alanine |
| $\begin{aligned} & 130.0 \\ & 619 \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{aligned} & \hline 8.6 \\ & 6 \end{aligned}$ | $\begin{aligned} & 10 . \\ & 66 \end{aligned}$ | 30 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \end{aligned}$ | 3- <br> Guanidinopropioni c acid |
| $\begin{aligned} & 131.0 \\ & 462 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | 8 | 10 | 20 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ | Asparagine |
| $\begin{aligned} & 132.0 \\ & 302 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | 8.6 | 12 | 30 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \end{aligned}$ | Aspartic acid |
| $\begin{aligned} & 133.0 \\ & 142 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | 7 | $\begin{aligned} & 10 . \\ & 6 \\ & \hline \end{aligned}$ | 20 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ | Malic acid |
| $\begin{aligned} & \hline 137.0 \\ & 244 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | 0.5 | 2.5 | 50 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ | Salicylic acid |
| $\begin{aligned} & 144.0 \\ & 666 \end{aligned}$ |  |  |  | 1 | Nega tive | 5.4 | 7.4 | 20 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \end{aligned}$ | 4- <br> Acetamidobutyric acid |
| $\begin{aligned} & \hline 145.0 \\ & 142 \end{aligned}$ |  |  |  | 1 | Nega tive | 6.7 | 8.7 | 20 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \end{aligned}$ | $\alpha$-Ketoglutaric acid |
| $\begin{aligned} & 145.0 \\ & 506 \end{aligned}$ |  |  |  | 1 | Nega tive | 7 | 9 | 10 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \end{aligned}$ | 3-Methylglutaric acid |
| 145.0 |  |  |  | 1 | Nega | 8.2 | 10. | 20 | NC | Glutamine |


| 618 |  |  |  |  | tive |  | 2 |  | E |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{aligned} & 146.0 \\ & 459 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | 5.4 | 7.4 | 30 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ |  | N-Acetyl-serine |
| $\begin{aligned} & 146.0 \\ & 459 \end{aligned}$ |  |  |  | 1 | Nega tive | 9.2 | $\begin{aligned} & 11 . \\ & 2 . \\ & \hline \end{aligned}$ | 30 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \end{aligned}$ |  | Glutamic acid |
| $\begin{aligned} & 147.0 \\ & 294 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | 7.1 | 9.1 | 10 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ |  | 2-Hydroxyglutarate |
| $151.0$ |  |  |  | 1 | Nega tive | $\begin{aligned} & 0.5 \\ & 5 \end{aligned}$ | $\begin{aligned} & 2.5 \\ & 5 \end{aligned}$ | 10 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ |  | Mandelic acid |
| $\begin{aligned} & 153.0 \\ & 193 \end{aligned}$ |  |  |  | 1 | Nega tive | 0.3 | 2.3 | 50 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \end{aligned}$ |  | 2,3- <br> Dihydroxybenzoic acid |
| $\begin{aligned} & 153.0 \\ & 193 \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{aligned} & 0.5 \\ & 1 \end{aligned}$ | $\begin{aligned} & 2.5 \\ & 1 \end{aligned}$ | 50 | $\begin{aligned} & \hline \mathrm{NC} \\ & \mathrm{E} \end{aligned}$ |  | 3,4- <br> Dihydroxybenzoic acid |
| $\begin{aligned} & 160.0 \\ & 615 \end{aligned}$ |  |  |  | 1 | Nega tive | 5.5 | 7.5 | 10 | $\begin{aligned} & \hline \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ |  | N-Methyl-Lglutamic acid |
| $\begin{aligned} & 160.0 \\ & 615 \end{aligned}$ |  |  |  | 1 | Nega tive | 9.8 | $\begin{aligned} & 11 . \\ & 8 \\ & \hline \end{aligned}$ | 20 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ |  | 2-Aminoadipic acid |
| $\begin{aligned} & 161.0 \\ & 455 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | 6.6 | 8.6 | 20 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ |  | 3-Hydroxy-3methylglutaric acid |
| $\begin{aligned} & 167.0 \\ & 21 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | 2.6 | 4.6 | 50 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ |  | Uric acid |
| $\begin{aligned} & 173.0 \\ & 091 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | 6.1 | 8.1 | 20 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \end{aligned}$ |  | trans-Aconitic acid |
| $\begin{aligned} & 174.0 \\ & 408 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | 8.9 | $\begin{aligned} & 10 . \\ & 9 \\ & \hline \end{aligned}$ | 10 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ |  | N-Acetyl-Laspartic acid |
| $\begin{aligned} & 175.0 \\ & 248 \end{aligned}$ |  |  |  | 1 | Nega tive | 2.6 | 4.6 | 10 | $\mathrm{NC}$ <br> E |  | Ascorbic acid |
| $\begin{aligned} & 176.0 \\ & 387 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | 2.3 | 4.3 | 30 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ |  | N-Formyl-Lmethionine |
| $\begin{aligned} & 179.0 \\ & 556 \end{aligned}$ |  |  |  | 1 | Nega tive | 5.1 | 7.1 | 30 | $\mathrm{NC}$ <br> E |  | Myoinositol/Fructose |
| $\begin{aligned} & 181.0 \\ & 717 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | 3 | 5 | 40 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ |  | Dulcitol/MANNIT OL |
| $\begin{aligned} & 182.0 \\ & 459 \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{aligned} & 0.5 \\ & 5 \end{aligned}$ | $\begin{aligned} & \hline 2.5 \\ & 5 \end{aligned}$ | 40 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ |  | 4-Pyridoxic acid |
| $\begin{aligned} & 187.0 \\ & 976 \end{aligned}$ |  |  |  | 1 | Nega tive | 3.2 | 5.2 | 30 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ |  | Azelaic acid |
| $\begin{aligned} & 188.0 \\ & 715 \end{aligned}$ |  |  |  | 1 | Nega tive | 0.6 | 2.6 | 30 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ |  | 3-Indolepropionic acid |
| $\begin{aligned} & 190.0 \\ & 543 \end{aligned}$ |  |  |  | 1 | Nega tive | 2.9 | 4.9 | 20 | $\mathrm{NC}$ <br> E |  | N-Acetylmethionine |
| $\begin{aligned} & 190.0 \\ & 505 \end{aligned}$ |  |  |  | 1 | Nega tive | 4.1 | 6.1 | 20 | $\begin{aligned} & \hline \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ |  | 5-Hydroxyindole-3-acetic acid |
| 191.0 |  |  |  | 1 | Nega | 8.9 | 15 | 30 | NC |  | Citric acid |


| 197 |  |  |  |  | tive |  |  |  | E |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{aligned} & 191.0 \\ & 197 \end{aligned}$ |  |  |  | 1 | Nega tive | 8.9 | 15 | 30 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ | Isocitric acid |
| $\begin{aligned} & 191.0 \\ & 561 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | 5.5 | 7.8 | 50 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ | Quinic acid |
| $\begin{aligned} & 193.0 \\ & 354 \end{aligned}$ |  |  |  | 1 | Nega tive | 6.1 | 8.1 | 10 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ | Glucuronic acid |
| $\begin{aligned} & 195.0 \\ & 51 \end{aligned}$ |  |  |  | 1 | Nega tive | 6.1 | 8.1 | 30 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ | Gluconate |
| $\begin{aligned} & 203.0 \\ & 826 \end{aligned}$ |  |  |  | 1 | Nega tive | 3.9 | 5.9 | 30 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \end{aligned}$ | Tryptophan |
| $\begin{aligned} & 207.0 \\ & 775 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | 4.1 | 6.1 | 20 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ | Kynurenine |
| $\begin{aligned} & 210.0 \\ & 772 \end{aligned}$ |  |  |  | 1 | Nega tive | 5.2 | 7.2 | 50 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ | 3-Methoxy-L- tyrosine |
| $\begin{aligned} & 212.0 \\ & 018 \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{array}{\|l\|} \hline 0.2 \\ 7 \end{array}$ | $\begin{array}{\|l\|} \hline 2.2 \\ 7 \end{array}$ | 50 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ | 3-Indoxyl sulfate |
| $\begin{aligned} & 218.1 \\ & 034 \end{aligned}$ |  |  |  | 1 | Nega tive | 4.5 | 6.5 | 40 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ | Pantothenic acid |
| $\begin{aligned} & 239.0 \\ & 165 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{aligned} & 10 \\ & 6 \end{aligned}$ | $\begin{array}{\|l\|} \hline 12 . \\ 6 \end{array}$ | 30 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ | Cystine |
| $\begin{aligned} & 308.0 \\ & 987 \end{aligned}$ |  |  |  | 1 | Nega tive | 6.8 | 8.8 | 20 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \end{aligned}$ | $\begin{aligned} & \mathrm{N}- \\ & \text { Acetylneuraminic } \\ & \text { acid } \end{aligned}$ |
| $\begin{aligned} & 327.2 \\ & 322 \\ & \hline \end{aligned}$ |  |  |  | 1 | $\begin{aligned} & \text { Nega } \\ & \text { tive } \end{aligned}$ | $\begin{array}{\|l\|} \hline 0.3 \\ 6 \\ \hline \end{array}$ | $\begin{aligned} & \hline 2.3 \\ & 6 \\ & \hline \end{aligned}$ | 30 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ | Docosahexaenoic $\operatorname{acid}(\mathrm{DHA})$ |
| $\begin{aligned} & 395.1 \\ & 897 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{array}{\|l\|} \hline 0.2 \\ 6 \\ \hline \end{array}$ | $\begin{aligned} & 2.2 \\ & 6 \end{aligned}$ | 50 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ | Pregnenolone sulfate |
| $\begin{aligned} & 448.3 \\ & 069 \end{aligned}$ |  |  |  | 1 | Nega tive | 2.6 | 4.6 | 50 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ | Glycoursodeoxych olic acid |
| $\begin{aligned} & 152.0 \\ & 595 \end{aligned}$ |  |  |  | 1 | Nega tive | 9.2 | $\begin{aligned} & 11 . \\ & 2 \\ & \hline \end{aligned}$ | 30 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ | Glutamic Acid_IS |
| $\begin{aligned} & 152.0 \\ & 725 \end{aligned}$ |  |  |  | 1 | Nega tive | 8.2 | $\begin{aligned} & 10 . \\ & 2 \\ & \hline \end{aligned}$ | 20 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ | Glutamine_IS |
| $\begin{aligned} & 214.1 \\ & 193 \end{aligned}$ |  |  |  | 1 | Nega tive | 3.9 | 5.9 | 30 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ | Tryptophan_IS |
| $\begin{aligned} & 90.01 \\ & 87 \end{aligned}$ |  |  |  | 1 | Nega tive | 1.5 | 3.5 | 50 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ | Pyruvate_IS |
| $\begin{aligned} & 107.0 \\ & 534 \end{aligned}$ |  |  |  | 1 | Nega tive | 3.3 | 6 | 30 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \end{aligned}$ | $\begin{array}{\|l\|} \hline 3 \\ \text { Hydroxybutyrate_I } \\ \text { S } \end{array}$ |
| $\begin{aligned} & 150.0 \\ & 309 \end{aligned}$ |  |  |  | 1 | Nega tive | 6.7 | 8.7 | 20 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ | KG_IS |
| $\begin{aligned} & 152.0 \\ & 465 \end{aligned}$ |  |  |  | 1 | Nega tive | 7.1 | 9.1 | 10 | $\begin{aligned} & \mathrm{NC} \\ & \mathrm{E} \\ & \hline \end{aligned}$ | HG_IS |
| 119.0 |  |  |  | 1 | Nega | 7.1 | 9.1 | 10 | NC | Fumaric Acid_IS |


| 169 |  |  |  |  | tive |  |  |  | E |  |  |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| 121.0 <br> 327 |  |  | 1 | Nega <br> tive | 6.4 | 8.4 | 10 | NC <br> E |  | Succinic Acid_IS |  |
| 197.0 <br> 396 |  |  |  | 1 | Nega <br> tive | 8.9 | 15 | 30 | NC <br> E |  | Citric Acid_IS |
| 137.0 <br> 405 |  |  |  | 1 | Nega <br> tive | 8.9 | 12 | 30 | NC <br> E |  | Aspartic Acid_IS |

Supplementary Table 4. Inclusion list for targeted lipidomics (PRM).

| $\begin{aligned} & \hline \text { Mass } \\ & {[\mathrm{m} / \mathrm{z}]} \end{aligned}$ | $\begin{gathered} \text { Form } \\ \text { ula } \\ {[\mathrm{M}]} \end{gathered}$ | Formu la type | Spe cies | $\begin{aligned} & \mathrm{CS} \\ & {[\mathrm{z}]} \end{aligned}$ | Polar ity | Start [min ] | End [min ] | $\begin{aligned} & (\mathrm{N}) \\ & \mathrm{CE} \end{aligned}$ | $\begin{gathered} (\mathrm{N}) \mathrm{C} \\ \mathrm{E} \\ \text { type } \end{gathered}$ | $\begin{gathered} \mathrm{MS} \\ \mathrm{X} \\ \text { ID } \\ \hline \end{gathered}$ | Comment |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{aligned} & 344.2 \\ & 795 \end{aligned}$ |  |  |  | 1 | Posit ive | 1 | 2 | 30 | NCE |  | AcCa 12:0 |
| $\begin{array}{\|l\|} \hline 372.3 \\ 108 \\ \hline \end{array}$ |  |  |  | 1 | Posit ive | 2.5 | 3.5 | 30 | NCE |  | AcCa 14:0 |
| $\begin{array}{\|l} \hline 370.2 \\ 952 \\ \hline \end{array}$ |  |  |  | 1 | Posit ive | 1.4 | 2.4 | 30 | NCE |  | AcCa 14:1 |
| $\begin{array}{\|l\|} \hline 368.2 \\ 795 \end{array}$ |  |  |  | 1 | Posit ive | 1 | 2 | 30 | NCE |  | AcCa 14:2 |
| $\begin{array}{\|l} \hline 400.3 \\ 421 \\ \hline \end{array}$ |  |  |  | 1 | Posit ive | 4.1 | 6 | 30 | NCE |  | AcCa 16:0 |
| $\begin{array}{\|l\|} \hline 404.3 \\ 552 \\ \hline \end{array}$ |  |  |  | 1 | Posit ive | 4.1 | 6 | 30 | NCE |  | $\begin{aligned} & \text { AcCa 16:0- } \\ & \text { 13C4 } \end{aligned}$ |
| $\begin{array}{\|l\|} \hline 403.3 \\ 606 \\ \hline \end{array}$ |  |  |  | 1 | Posit ive | 4.1 | 6 | 30 | NCE |  | $\begin{aligned} & \text { AcCa 16:0- } \\ & \text { D3 } \end{aligned}$ |
| $\begin{aligned} & \hline 398.3 \\ & 265 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 2.9 | 4.5 | 30 | NCE |  | AcCa 16:1 |
| $\begin{aligned} & 428.3 \\ & 734 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 5.4 | 7.5 | 30 | NCE |  | AcCa 18:0 |
| $\begin{array}{\|l\|} \hline 426.3 \\ 578 \\ \hline \end{array}$ |  |  |  | 1 | Posit ive | 4.3 | 6 | 30 | NCE |  | AcCa 18:1 |
| $\begin{array}{\|l\|} \hline 424.3 \\ 421 \\ \hline \end{array}$ |  |  |  | 1 | Posit ive | 3.4 | 5 | 30 | NCE |  | AcCa 18:2 |
| $\begin{array}{\|l\|} \hline 456.4 \\ 047 \\ \hline \end{array}$ |  |  |  | 1 | Posit ive | 6.9 | 7.9 | 30 | NCE |  | AcCa 20:0 |
| $\begin{array}{\|l} \hline 454.3 \\ 891 \\ \hline \end{array}$ |  |  |  | 1 | Posit ive | 5.5 | 6.5 | 30 | NCE |  | AcCa 20:1 |
| $\begin{array}{\|l\|} \hline 452.3 \\ 734 \\ \hline \end{array}$ |  |  |  | 1 | Posit ive | 4.6 | 5.6 | 30 | NCE |  | AcCa 20:2 |
| $\begin{aligned} & 450.3 \\ & 578 \end{aligned}$ |  |  |  | 1 | Posit ive | 3.9 | 4.9 | 30 | NCE |  | AcCa 20:3 |
| $\begin{array}{\|l\|} \hline 448.3 \\ 421 \\ \hline \end{array}$ |  |  |  | 1 | Posit ive | 3 | 4.3 | 30 | NCE |  | AcCa 20:4 |
| 484.4 |  |  |  | 1 | Posit | 8.3 | 9.3 | 30 | NCE |  | AcCa 22:0 |


| 36 |  |  |  |  | ive |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{aligned} & 476.3 \\ & 734 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 4.3 | 5.3 | 30 | NCE |  | AcCa 22:4 |
| $\begin{aligned} & 474.3 \\ & 578 \end{aligned}$ |  |  |  | 1 | Posit ive | 3.5 | 4.5 | 30 | NCE |  | AcCa 22:5 |
| $\begin{aligned} & 472.3 \\ & 421 \end{aligned}$ |  |  |  | 1 | Posit ive | 3.1 | 4.1 | 30 | NCE |  | AcCa 22:6 |
| $\begin{aligned} & 512.4 \\ & 673 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 9.5 | 10.5 | 30 | NCE |  | AcCa 24:0 |
| $\begin{aligned} & 300.2 \\ & 897 \end{aligned}$ |  |  |  | 1 | Posit ive | 5.3 | 6.3 | 30 | NCE |  | AEA 16:0 |
| $\begin{aligned} & 328.3 \\ & 21 \end{aligned}$ |  |  |  | 1 | Posit ive | 6.9 | 7.9 | 30 | NCE |  | AEA 18:0 |
| $\begin{aligned} & 326.3 \\ & 054 \end{aligned}$ |  |  |  | 1 | Posit ive | 5.4 | 6.4 | 30 | NCE |  | AEA 18:1 |
| $\begin{aligned} & 324.2 \\ & 897 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 4.5 | 5.5 | 30 | NCE |  | AEA 18:2 |
| $\begin{aligned} & 540.5 \\ & 35 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 12.6 | 13.6 | 25 | NCE |  | $\begin{array}{\|l\|} \hline \text { Cer } \\ \text { 18:0;2/16:0 } \\ \hline \end{array}$ |
| $\begin{aligned} & 624.6 \\ & 289 \end{aligned}$ |  |  |  | 1 | Posit ive | 15.1 | 16.1 | 25 | NCE |  | $\begin{aligned} & \text { Cer } \\ & \text { 18:0;2/22:0 } \end{aligned}$ |
| $\begin{aligned} & 638.6 \\ & 446 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 15.5 | 16.5 | 25 | NCE |  | $\begin{aligned} & \text { Cer } \\ & 18: 0 ; 2 / 23: 0 \\ & \hline \end{aligned}$ |
| $\begin{aligned} & \hline 652.6 \\ & 602 \end{aligned}$ |  |  |  | 1 | Posit ive | 15.9 | 16.9 | 25 | NCE |  | $\begin{aligned} & \text { Cer } \\ & 18: 0 ; 2 / 24: 0 \end{aligned}$ |
| $\begin{aligned} & 650.6 \\ & 446 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 14.9 | 15.9 | 25 | NCE |  | $\begin{aligned} & \text { Cer } \\ & 18: 0 ; 2 / 24: 1 \end{aligned}$ |
| $\begin{aligned} & \hline 666.6 \\ & 759 \end{aligned}$ |  |  |  | 1 | Posit ive | 16.2 | 17.2 | 25 | NCE |  | $\begin{aligned} & \text { Cer } \\ & 18: 0 ; 2 / 25: 0 \end{aligned}$ |
| $\begin{aligned} & 482.4 \\ & 568 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 10.2 | 11.2 | 25 | NCE |  | $\begin{aligned} & \text { Cer } \\ & 18: 1 ; 2 / 12: 0 \end{aligned}$ |
| $\begin{aligned} & 538.5 \\ & 194 \end{aligned}$ |  |  |  | 1 | Posit ive | 12.2 | 13.2 | 25 | NCE |  | $\begin{aligned} & \text { Cer } \\ & 18: 1 ; 2 / 16: 0 \end{aligned}$ |
| $\begin{aligned} & \hline 566.5 \\ & 507 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 13.1 | 14.1 | 25 | NCE |  | $\begin{aligned} & \text { Cer } \\ & 18: 1 ; 2 / 18: 0 \end{aligned}$ |
| $\begin{aligned} & 594.5 \\ & 82 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 14 | 15 | 25 | NCE |  | $\begin{aligned} & \text { Cer } \\ & 18: 1 ; 2 / 20: 0 \end{aligned}$ |
| $\begin{aligned} & 622.6 \\ & 133 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 14.8 | 15.8 | 25 | NCE |  | $\begin{array}{\|l\|} \hline \text { Cer } \\ \text { 18:1;2/22:0 } \\ \hline \end{array}$ |
| $\begin{aligned} & 636.6 \\ & 289 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 15.2 | 16.2 | 25 | NCE |  | $\begin{array}{\|l\|} \hline \text { Cer } \\ 18: 1 ; 2 / 23: 0 \\ \hline \end{array}$ |
| $\begin{aligned} & 650.6 \\ & 446 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 15.6 | 16.6 | 25 | NCE |  | $\begin{array}{\|l\|} \hline \text { Cer } \\ 18: 1 ; 2 / 24: 0 \\ \hline \end{array}$ |
| $\begin{aligned} & 648.6 \\ & 289 \end{aligned}$ |  |  |  | 1 | Posit ive | 14.6 | 15.6 | 25 | NCE |  | $\begin{aligned} & \text { Cer } \\ & 18: 1 ; 2 / 24: 1 \end{aligned}$ |
| 646.6 |  |  |  | 1 | Posit | 13.9 | 14.9 | 25 | NCE |  | Cer |



| $\begin{aligned} & \hline 640.6 \\ & 027 \end{aligned}$ |  |  |  | 1 | Posit ive | 18.4 | 19.4 | 10 | NCE | ChE 16:1 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{aligned} & 670.6 \\ & 497 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 19.9 | 20.9 | 10 | NCE | ChE 18:0 |
| $\begin{aligned} & 668.6 \\ & 34 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 19.1 | 20.5 | 10 | NCE | ChE 18:1 |
| $\begin{aligned} & 675.6 \\ & 779 \end{aligned}$ |  |  |  | 1 | Posit ive | 19.1 | 20.5 | 10 | NCE | $\begin{aligned} & \text { ChE } \\ & \text { 18:1D7 } \end{aligned}$ |
| $\begin{aligned} & 666.6 \\ & 184 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 18.6 | 19.6 | 10 | NCE | ChE 18:2 |
| $\begin{aligned} & \hline 664.6 \\ & 027 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 18 | 19 | 10 | NCE | ChE 18:3 |
| $\begin{aligned} & \hline 696.6 \\ & 653 \end{aligned}$ |  |  |  | 1 | Posit ive | 19.7 | 20.7 | 10 | NCE | ChE 20:1 |
| $\begin{aligned} & \hline 694.6 \\ & 497 \\ & \hline \end{aligned}$ |  |  |  | 1 | $\begin{array}{\|l\|} \hline \text { Posit } \\ \text { ive } \\ \hline \end{array}$ | 19.3 | 20.3 | 10 | NCE | ChE 20:2 |
| $\begin{aligned} & 692.6 \\ & 34 \end{aligned}$ |  |  |  | 1 | Posit ive | 18.6 | 19.6 | 10 | NCE | ChE 20:3 |
| $\begin{aligned} & \hline 690.6 \\ & 184 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 18.2 | 19.5 | 10 | NCE | ChE 20:4 |
| $\begin{aligned} & 688.6 \\ & 027 \end{aligned}$ |  |  |  | 1 | $\begin{aligned} & \text { Posit } \\ & \text { ive } \\ & \hline \end{aligned}$ | 17.6 | 18.6 | 10 | NCE | ChE 20:5 |
| $\begin{aligned} & 718.6 \\ & 497 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 18.7 | 19.7 | 10 | NCE | ChE 22:4 |
| $\begin{aligned} & 716.6 \\ & 34 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 18.1 | 19.5 | 10 | NCE | ChE 22:5 |
| $\begin{aligned} & 714.6 \\ & 184 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 18 | 19 | 10 | NCE | ChE 22:6 |
| $\begin{aligned} & 863.6 \\ & 912 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 16.3 | 17.3 | 30 | NCE | CoQ10 |
| $\begin{aligned} & 584.5 \\ & 249 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 12.8 | 13.8 | 20 | NCE | $\begin{aligned} & \text { DAG 14:0- } \\ & 18: 1 \end{aligned}$ |
| $\begin{aligned} & \hline 605.5 \\ & 844 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 13.2 | 14.2 | 20 | NCE | $\begin{array}{\|l} \hline \text { DAG 15:0- } \\ \text { 18:1D7 } \\ \hline \end{array}$ |
| $\begin{aligned} & 586.5 \\ & 405 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 13.7 | 14.7 | 20 | NCE | $\begin{aligned} & \text { DAG 16:0- } \\ & \text { 16:0 } \end{aligned}$ |
| $\begin{aligned} & \hline 584.5 \\ & 249 \end{aligned}$ |  |  |  | 1 | Posit ive | 12.8 | 13.8 | 20 | NCE | $\begin{aligned} & \text { DAG 16:0- } \\ & 16: 1 \end{aligned}$ |
| $\begin{aligned} & 614.5 \\ & 718 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 14.5 | 15.5 | 20 | NCE | $\begin{aligned} & \text { DAG 16:0- } \\ & \text { 18:0 } \end{aligned}$ |
| $\begin{aligned} & 612.5 \\ & 562 \\ & \hline \end{aligned}$ |  |  |  | 1 | $\begin{array}{\|l\|} \hline \text { Posit } \\ \text { ive } \\ \hline \end{array}$ | 13.6 | 14.6 | 20 | NCE | $\begin{aligned} & \text { DAG 16:0- } \\ & 18: 1 \end{aligned}$ |
| $\begin{aligned} & 610.5 \\ & 405 \end{aligned}$ |  |  |  | 1 | Posit ive | 12.9 | 13.9 | 20 | NCE | $\begin{aligned} & \text { DAG 16:0- } \\ & 18: 2 \end{aligned}$ |
| $\begin{aligned} & 610.5 \\ & 405 \end{aligned}$ |  |  |  | 1 | Posit ive | 12.8 | 13.8 | 20 | NCE | $\begin{aligned} & \text { DAG 16:1- } \\ & 18: 1 \end{aligned}$ |


| $\begin{aligned} & 608.5 \\ & 249 \end{aligned}$ |  |  |  | 1 | Posit ive | 12.2 | 13.2 | 20 | NCE | $\begin{aligned} & \text { DAG 16:1- } \\ & \text { 18:2 } \end{aligned}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{aligned} & 642.6 \\ & 031 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 15.5 | 16.5 | 20 | NCE | $\begin{aligned} & \text { DAG 18:0- } \\ & \text { 18:0 } \end{aligned}$ |
| $\begin{aligned} & 640.5 \\ & 875 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 14.5 | 15.5 | 20 | NCE | $\begin{aligned} & \text { DAG 18:0- } \\ & 18: 1 \end{aligned}$ |
| $\begin{aligned} & 638.5 \\ & 718 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 13.7 | 14.7 | 20 | NCE | $\begin{aligned} & \text { DAG 18:0- } \\ & \text { 18:2 } \\ & \hline \end{aligned}$ |
| $\begin{aligned} & 638.5 \\ & 718 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 13.6 | 14.6 | 20 | NCE | $\begin{aligned} & \hline \text { DAG 18:1- } \\ & 18: 1 \\ & \hline \end{aligned}$ |
| $\begin{aligned} & 636.5 \\ & 562 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 12.9 | 13.9 | 20 | NCE | $\begin{aligned} & \text { DAG 18:1- } \\ & 18: 2 \end{aligned}$ |
| $\begin{aligned} & 634.5 \\ & 405 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 12.4 | 13.4 | 20 | NCE | $\begin{aligned} & \hline \text { DAG 18:1- } \\ & 18: 3 \end{aligned}$ |
| $\begin{aligned} & 668.6 \\ & 188 \end{aligned}$ |  |  |  | 1 | Posit ive | 14.3 | 15.3 | 20 | NCE | $\begin{aligned} & \text { DAG 18:1- } \\ & 20: 0 \end{aligned}$ |
| $\begin{aligned} & 662.5 \\ & 718 \end{aligned}$ |  |  |  | 1 | Posit ive | 13.1 | 14.1 | 20 | NCE | $\begin{aligned} & \text { DAG 18:1- } \\ & 20: 3 \end{aligned}$ |
| $\begin{aligned} & 660.5 \\ & 562 \end{aligned}$ |  |  |  | 1 | Posit ive | 12.7 | 13.7 | 20 | NCE | $\begin{aligned} & \text { DAG 18:1- } \\ & 20: 4 \end{aligned}$ |
| $\begin{aligned} & 634.5 \\ & 405 \end{aligned}$ |  |  |  | 1 | Posit ive | 12.4 | 13.4 | 20 | NCE | $\begin{aligned} & \text { DAG 18:2- } \\ & 18: 2 \end{aligned}$ |
| $\begin{aligned} & 632.5 \\ & 249 \end{aligned}$ |  |  |  | 1 | Posit ive | 11.6 | 12.6 | 20 | NCE | $\begin{aligned} & \text { DAG 18:2- } \\ & 18: 3 \end{aligned}$ |
| $\begin{aligned} & 806.5 \\ & 624 \end{aligned}$ |  |  |  | 1 | Posit ive | 8.9 | 9.9 | 25 | NCE | $\begin{aligned} & \text { Hex2Cer } \\ & \text { 18:1;2/12:0 } \end{aligned}$ |
| $\begin{aligned} & 834.5 \\ & 937 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 10.1 | 11.1 | 25 | NCE | $\begin{aligned} & \text { Hex2Cer } \\ & 18: 1 ; 2 / 14: 0 \\ & \hline \end{aligned}$ |
| $\begin{aligned} & 862.6 \\ & 25 \end{aligned}$ |  |  |  | 1 | Posit ive | 11.1 | 12.1 | 25 | NCE | $\begin{aligned} & \text { Hex2Cer } \\ & 18: 1 ; 2 / 16: 0 \end{aligned}$ |
| $\begin{aligned} & 890.6 \\ & 563 \end{aligned}$ |  |  |  | 1 | Posit ive | 12.1 | 13.1 | 25 | NCE | $\begin{aligned} & \text { Hex2Cer } \\ & 18: 1 ; 2 / 18: 0 \end{aligned}$ |
| $\begin{aligned} & 918.6 \\ & 876 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 12.9 | 13.9 | 25 | NCE | $\begin{aligned} & \text { Hex2Cer } \\ & 18: 1 ; 2 / 20: 0 \\ & \hline \end{aligned}$ |
| $\begin{aligned} & 946.7 \\ & 189 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 13.7 | 14.7 | 25 | NCE | $\begin{aligned} & \text { Hex2Cer } \\ & 18: 1 ; 2 / 22: 0 \end{aligned}$ |
| $\begin{aligned} & 974.7 \\ & 502 \end{aligned}$ |  |  |  | 1 | Posit ive | 14.4 | 15.4 | 25 | NCE | $\begin{aligned} & \text { Hex2Cer } \\ & 18: 1 ; 2 / 24: 0 \end{aligned}$ |
| $\begin{aligned} & 972.7 \\ & 346 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 13.5 | 14.5 | 25 | NCE | $\begin{aligned} & \text { Hex2Cer } \\ & 18: 1 ; 2 / 24: 1 \end{aligned}$ |
| $\begin{aligned} & 970.7 \\ & 189 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 12.8 | 13.8 | 25 | NCE | $\begin{aligned} & \text { Hex2Cer } \\ & 18: 1 ; 2 / 24: 2 \end{aligned}$ |
| $\begin{aligned} & 860.6 \\ & 094 \end{aligned}$ |  |  |  | 1 | Posit ive | 10.2 | 11.2 | 25 | NCE | $\begin{aligned} & \text { Hex2Cer } \\ & 18: 2 ; 2 / 16: 0 \end{aligned}$ |
| $\begin{aligned} & 1024 . \\ & 678 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 10.8 | 11.8 | 25 | NCE | $\begin{aligned} & \text { Hex3Cer } \\ & 18: 1 ; 2 / 16: 0 \end{aligned}$ |


| $\begin{aligned} & 1052 . \\ & 709 \end{aligned}$ |  |  |  | 1 | Posit ive | 11.8 | 12.8 | 25 | NCE | $\begin{aligned} & \hline \text { Hex3Cer } \\ & \text { 18:1;2/18:0 } \end{aligned}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{aligned} & 1080 . \\ & 74 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 12.7 | 13.7 | 25 | NCE | $\begin{aligned} & \text { Hex3Cer } \\ & 18: 1 ; 2 / 20: 0 \\ & \hline \end{aligned}$ |
| $\begin{aligned} & 1108 . \\ & 772 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 13.4 | 14.4 | 25 | NCE | $\begin{aligned} & \text { Hex3Cer } \\ & 18: 1 ; 2 / 22: 0 \end{aligned}$ |
| $\begin{aligned} & 1136 . \\ & 803 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 14.2 | 15.2 | 25 | NCE | $\begin{array}{\|l\|} \hline \text { Hex3Cer } \\ \text { 18:1;2/24:0 } \\ \hline \end{array}$ |
| $\begin{aligned} & 1134 . \\ & 787 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 13.2 | 14.2 | 25 | NCE | $\begin{aligned} & \text { Hex3Cer } \\ & 18: 1 ; 2 / 24: 1 \\ & \hline \end{aligned}$ |
| $\begin{aligned} & \hline 644.5 \\ & 096 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 9.3 | 10.3 | 25 | NCE | $\begin{aligned} & \text { HexCer } \\ & 18: 1 ; 2 / 12: 0 \\ & \hline \end{aligned}$ |
| $\begin{aligned} & 700.5 \\ & 722 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 11.5 | 12.5 | 25 | NCE | $\begin{aligned} & \hline \text { HexCer } \\ & 18: 1 ; 2 / 16: 0 \\ & \hline \end{aligned}$ |
| $\begin{aligned} & 728.6 \\ & 035 \end{aligned}$ |  |  |  | 1 | Posit ive | 12.4 | 13.4 | 25 | NCE | $\begin{aligned} & \text { HexCer } \\ & \text { 18:1;2/18:0 } \end{aligned}$ |
| $\begin{aligned} & 756.6 \\ & 348 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 13.2 | 14.2 | 25 | NCE | $\begin{aligned} & \text { HexCer } \\ & 18: 1 ; 2 / 20: 0 \\ & \hline \end{aligned}$ |
| $\begin{aligned} & 784.6 \\ & 661 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 14 | 15 | 25 | NCE | $\begin{aligned} & \text { HexCer } \\ & 18: 1 ; 2 / 22: 0 \end{aligned}$ |
| $\begin{aligned} & 798.6 \\ & 818 \end{aligned}$ |  |  |  | 1 | Posit ive | 14.4 | 15.4 | 25 | NCE | $\begin{aligned} & \text { HexCer } \\ & 18: 1 ; 2 / 23: 0 \end{aligned}$ |
| $\begin{aligned} & 812.6 \\ & 974 \end{aligned}$ |  |  |  | 1 | Posit ive | 14.8 | 15.8 | 25 | NCE | $\begin{aligned} & \text { HexCer } \\ & 18: 1 ; 2 / 24: 0 \end{aligned}$ |
| $\begin{aligned} & 810.6 \\ & 818 \end{aligned}$ |  |  |  | 1 | Posit ive | 13.8 | 14.8 | 25 | NCE | $\begin{aligned} & \text { HexCer } \\ & 18: 1 ; 2 / 24: 1 \end{aligned}$ |
| $\begin{aligned} & 808.6 \\ & 661 \end{aligned}$ |  |  |  | 1 | Posit ive | 13.1 | 14.1 | 25 | NCE | $\begin{aligned} & \text { HexCer } \\ & 18: 1 ; 2 / 24: 2 \end{aligned}$ |
| $\begin{aligned} & 782.6 \\ & 505 \end{aligned}$ |  |  |  | 1 | Posit ive | 13.3 | 14.3 | 25 | NCE | $\begin{aligned} & \text { HexCer } \\ & 18: 2 ; 2 / 22: 0 \end{aligned}$ |
| $\begin{aligned} & 810.6 \\ & 818 \end{aligned}$ |  |  |  | 1 | Posit ive | 14.1 | 15.1 | 25 | NCE | $\begin{aligned} & \text { HexCer } \\ & 18: 2 ; 2 / 24: 0 \\ & \hline \end{aligned}$ |
| $\begin{aligned} & 808.6 \\ & 661 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 13.1 | 14.1 | 25 | NCE | $\begin{aligned} & \hline \text { HexCer } \\ & 18: 2 ; 2 / 24: 1 \\ & \hline \end{aligned}$ |
| $\begin{aligned} & 468.3 \\ & 085 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 1.5 | 3 | 30 | NCE | LPC 14:0 |
| $\begin{aligned} & 454.3 \\ & 292 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 2.4 | 3.4 | 30 | NCE | LPC 14:0e |
| $\begin{aligned} & 482.3 \\ & 241 \end{aligned}$ |  |  |  | 1 | Posit ive | 2.4 | 4 | 30 | NCE | LPC 15:0 |
| $\begin{aligned} & 496.3 \\ & 398 \end{aligned}$ |  |  |  | 1 | Posit ive | 3.5 | 5.5 | 30 | NCE | LPC 16:0 |
| $\begin{aligned} & 482.3 \\ & 605 \end{aligned}$ |  |  |  | 1 | Posit ive | 4.5 | 6 | 30 | NCE | LPC 16:0e |
| $\begin{aligned} & 494.3 \\ & 241 \end{aligned}$ |  |  |  | 1 | Posit ive | 1.9 | 3.9 | 30 | NCE | LPC 16:1 |


| $\begin{aligned} & 480.3 \\ & 449 \end{aligned}$ |  |  |  | 1 | Posit ive | 4.5 | 5.5 | 30 | NCE | LPC 16:1e |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{aligned} & 478.3 \\ & 292 \end{aligned}$ |  |  |  | 1 | Posit ive | 3.9 | 4.9 | 30 | NCE | LPC 16:2e |
| $\begin{aligned} & 510.3 \\ & 554 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 4.2 | 6.2 | 30 | NCE | LPC 17:0 |
| $\begin{aligned} & 508.3 \\ & 398 \end{aligned}$ |  |  |  | 1 | Posit ive | 2.9 | 4.9 | 30 | NCE | LPC 17:1 |
| $\begin{aligned} & 524.3 \\ & 711 \end{aligned}$ |  |  |  | 1 | Posit ive | 5.2 | 7.2 | 30 | NCE | LPC 18:0 |
| $\begin{aligned} & 510.3 \\ & 918 \end{aligned}$ |  |  |  | 1 | Posit ive | 6.4 | 7.4 | 30 | NCE | LPC 18:0e |
| $\begin{aligned} & 522.3 \\ & 554 \end{aligned}$ |  |  |  | 1 | Posit ive | 3.9 | 5.9 | 30 | NCE | LPC 18:1 |
| $\begin{aligned} & 529.3 \\ & 994 \end{aligned}$ |  |  |  | 1 | Posit ive | 3.9 | 5.9 | 30 | NCE | $\begin{aligned} & \hline \text { LPC } \\ & \text { 18:1D7 } \end{aligned}$ |
| $\begin{aligned} & 508.3 \\ & 762 \end{aligned}$ |  |  |  | 1 | Posit ive | 4.7 | 6 | 30 | NCE | LPC 18:1e |
| $\begin{aligned} & 520.3 \\ & 398 \end{aligned}$ |  |  |  | 1 | Posit ive | 2.6 | 4.6 | 30 | NCE | LPC 18:2 |
| $\begin{aligned} & 518.3 \\ & 241 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 1.8 | 3 | 30 | NCE | LPC 18:3 |
| $\begin{aligned} & 538.3 \\ & 867 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 6 | 7.5 | 30 | NCE | LPC 19:0 |
| $\begin{aligned} & 536.3 \\ & 711 \end{aligned}$ |  |  |  | 1 | Posit ive | 4.9 | 6.5 | 30 | NCE | LPC 19:1 |
| $\begin{aligned} & 552.4 \\ & 024 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 7 | 8.5 | 30 | NCE | LPC 20:0 |
| $\begin{aligned} & 538.4 \\ & 231 \end{aligned}$ |  |  |  | 1 | Posit ive | 7.9 | 8.9 | 30 | NCE | LPC 20:0e |
| $\begin{aligned} & 550.3 \\ & 867 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 5.3 | 7 | 30 | NCE | LPC 20:1 |
| $\begin{aligned} & 548.3 \\ & 711 \end{aligned}$ |  |  |  | 1 | Posit ive | 4.3 | 5.6 | 30 | NCE | LPC 20:2 |
| $\begin{aligned} & 546.3 \\ & 554 \end{aligned}$ |  |  |  | 1 | Posit ive | 3.5 | 5 | 30 | NCE | LPC 20:3 |
| $\begin{aligned} & 544.3 \\ & 398 \end{aligned}$ |  |  |  | 1 | Posit ive | 2.6 | 4 | 30 | NCE | LPC 20:4 |
| $\begin{aligned} & 542.3 \\ & 241 \end{aligned}$ |  |  |  | 1 | Posit ive | 1.8 | 3 | 30 | NCE | LPC 20:5 |
| $\begin{aligned} & 580.4 \\ & 337 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 8.4 | 9.7 | 30 | NCE | LPC 22:0 |
| $\begin{aligned} & 578.4 \\ & 18 \end{aligned}$ |  |  |  | 1 | Posit ive | 7.1 | 8.1 | 30 | NCE | LPC 22:1 |
| $\begin{aligned} & 574.3 \\ & 867 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 4.9 | 5.9 | 30 | NCE | LPC 22:3 |


| $\begin{aligned} & \hline 572.3 \\ & 711 \end{aligned}$ |  |  |  | 1 | Posit ive | 4.2 | 5.2 | 30 | NCE | LPC 22:4 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{aligned} & 570.3 \\ & 554 \end{aligned}$ |  |  |  | 1 | Posit ive | 3.2 | 4.7 | 30 | NCE | LPC 22:5 |
| $\begin{aligned} & 568.3 \\ & 398 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 2.4 | 4 | 30 | NCE | LPC 22:6 |
| $\begin{aligned} & 608.4 \\ & 65 \end{aligned}$ |  |  |  | 1 | Posit ive | 9.7 | 11 | 30 | NCE | LPC 24:0 |
| $\begin{aligned} & 606.4 \\ & 493 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 8.5 | 9.5 | 30 | NCE | LPC 24:1 |
| $\begin{aligned} & 604.4 \\ & 337 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 7.3 | 8.3 | 30 | NCE | LPC 24:2 |
| $\begin{aligned} & \hline 426.2 \\ & 615 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 1.8 | 2.8 | 30 | NCE | LPE 14:0 |
| $\begin{aligned} & 454.2 \\ & 928 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 3.7 | 5 | 30 | NCE | LPE 16:0 |
| $\begin{aligned} & 482.3 \\ & 241 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 5.4 | 6.7 | 30 | NCE | LPE 18:0 |
| $\begin{aligned} & 480.3 \\ & 085 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 4 | 5.3 | 30 | NCE | LPE 18:1 |
| $\begin{aligned} & 487.3 \\ & 524 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 4 | 5.3 | 30 | NCE | $\begin{aligned} & \text { LPE } \\ & \text { 18:1D7 } \end{aligned}$ |
| $\begin{aligned} & 478.2 \\ & 928 \end{aligned}$ |  |  |  | 1 | Posit ive | 2.6 | 4 | 30 | NCE | LPE 18:2 |
| $\begin{aligned} & 504.3 \\ & 085 \end{aligned}$ |  |  |  | 1 | Posit ive | 3.4 | 4.7 | 30 | NCE | LPE 20:3 |
| $\begin{aligned} & 502.2 \\ & 928 \end{aligned}$ |  |  |  | 1 | Posit ive | 2.6 | 3.9 | 30 | NCE | LPE 20:4 |
| $\begin{aligned} & 526.2 \\ & 928 \end{aligned}$ |  |  |  | 1 | Posit ive | 2.5 | 3.8 | 30 | NCE | LPE 22:6 |
| $\begin{aligned} & 647.5 \\ & 123 \end{aligned}$ |  |  |  | 1 | Posit ive | 8.8 | 10.8 | 30 | NCE | SM(d30:1) |
| $\begin{aligned} & \hline 645.4 \\ & 966 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 7.6 | 8.6 | 30 | NCE | SM(d30:2) |
| $\begin{aligned} & 677.5 \\ & 592 \end{aligned}$ |  |  |  | 1 | Posit ive | 10.5 | 11.5 | 30 | NCE | SM(d32:0) |
| $\begin{aligned} & \hline 675.5 \\ & 436 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 10 | 12 | 30 | NCE | SM(d32:1) |
| $\begin{aligned} & 673.5 \\ & 279 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 8.9 | 10.5 | 30 | NCE | SM(d32:2) |
| $\begin{aligned} & 705.5 \\ & 905 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 11.5 | 12.5 | 30 | NCE | SM(d34:0) |
| $\begin{aligned} & 703.5 \\ & 749 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 11.1 | 12.5 | 30 | NCE | SM(d34:1) |
| $\begin{aligned} & 701.5 \\ & 592 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 10.1 | 12 | 30 | NCE | SM(d34:2) |


| $\begin{array}{\|l\|} \hline 699.5 \\ 436 \\ \hline \end{array}$ |  |  |  | 1 | Posit ive | 9.3 | 11 | 30 | NCE | SM(d34:3) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{array}{\|l\|} \hline 733.6 \\ 218 \\ \hline \end{array}$ |  |  |  | 1 | Posit ive | 12.2 | 13.6 | 30 | NCE | SM(d36:0) |
| $\begin{array}{\|l\|} \hline 731.6 \\ 062 \end{array}$ |  |  |  | 1 | Posit ive | 12.1 | 13.5 | 30 | NCE | SM(d36:1) |
| $\begin{aligned} & \hline 729.5 \\ & 905 \end{aligned}$ |  |  |  | 1 | Posit ive | 11 | 13 | 30 | NCE | SM(d36:2) |
| $\begin{array}{\|l\|} \hline 738.6 \\ 47 \\ \hline \end{array}$ |  |  |  | 1 | Posit ive | 11 | 13 | 30 | NCE | $\begin{aligned} & \text { SM(d36:2 } \\ & \text { D9) } \\ & \hline \end{aligned}$ |
| $\begin{array}{\|l\|} \hline 727.5 \\ 749 \\ \hline \end{array}$ |  |  |  | 1 | Posit ive | 10.4 | 12.4 | 30 | NCE | SM(d36:3) |
| $\begin{array}{\|l\|} \hline 759.6 \\ 375 \\ \hline \end{array}$ |  |  |  | 1 | Posit ive | 13 | 14.5 | 30 | NCE | SM(d38:1) |
| $\begin{array}{\|l\|} \hline 757.6 \\ 218 \\ \hline \end{array}$ |  |  |  | 1 | Posit ive | 12.2 | 13.5 | 30 | NCE | SM(d38:2) |
| $\begin{array}{\|l} \hline 755.6 \\ 062 \\ \hline \end{array}$ |  |  |  | 1 | Posit ive | 11.5 | 13 | 30 | NCE | SM(d38:3) |
| $\begin{array}{\|l\|} \hline 787.6 \\ 688 \\ \hline \end{array}$ |  |  |  | 1 | Posit ive | 13.8 | 16 | 30 | NCE | SM(d40:1) |
| $\begin{array}{\|l\|} \hline 785.6 \\ 531 \\ \hline \end{array}$ |  |  |  | 1 | Posit ive | 13 | 14.5 | 30 | NCE | SM(d40:2) |
| $\begin{array}{\|l\|} \hline 783.6 \\ 375 \\ \hline \end{array}$ |  |  |  | 1 | Posit ive | 12 | 13.5 | 30 | NCE | SM(d40:3) |
| $\begin{aligned} & 815.7 \\ & 001 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 14.6 | 16.6 | 30 | NCE | SM(d42:1) |
| $\begin{array}{\|l} \hline 813.6 \\ 844 \\ \hline \end{array}$ |  |  |  | 1 | Posit ive | 13.5 | 15.5 | 30 | NCE | SM(d42:2) |
| $\begin{aligned} & 811.6 \\ & 688 \end{aligned}$ |  |  |  | 1 | Posit ive | 12.8 | 14.5 | 30 | NCE | SM(d42:3) |
| $\begin{array}{\|l} \hline 845.7 \\ 47 \\ \hline \end{array}$ |  |  |  | 1 | Posit ive | 16.2 | 17.2 | 30 | NCE | SM(d44:0) |
| $\begin{aligned} & 843.7 \\ & 314 \end{aligned}$ |  |  |  | 1 | Posit ive | 15.3 | 17 | 30 | NCE | SM(d44:1) |
| $\begin{array}{\|l\|} \hline 841.7 \\ 157 \end{array}$ |  |  |  | 1 | Posit ive | 14.4 | 16 | 30 | NCE | SM(d44:2) |
| $\begin{array}{\|l\|} \hline 839.7 \\ 001 \\ \hline \end{array}$ |  |  |  | 1 | Posit ive | 13.6 | 15 | 30 | NCE | SM(d44:3) |
| $\begin{array}{\|l\|} \hline 288.2 \\ 897 \\ \hline \end{array}$ |  |  |  | 1 | Posit ive | 2 | 4 | 20 | NCE | SPH d17:0 |
| $\begin{array}{\|l\|} \hline 286.2 \\ 741 \\ \hline \end{array}$ |  |  |  | 1 | Posit ive | 2 | 3.5 | 20 | NCE | SPH d17:1 |
| $\begin{array}{\|l\|} \hline 302.3 \\ 054 \\ \hline \end{array}$ |  |  |  | 1 | Posit ive | 3 | 5 | 20 | NCE | SPH d18:0 |
| $\begin{aligned} & 300.2 \\ & 897 \end{aligned}$ |  |  |  | 1 | Posit ive | 3 | 4.5 | 20 | NCE | SPH d18:1 |


| $\begin{array}{\|l\|} \hline 352.2 \\ 247 \\ \hline \end{array}$ |  |  |  | 1 | Posit ive | 1 | 3 | 20 | NCE | $\begin{aligned} & \hline \text { SPHP } \\ & \text { d16:1 } \end{aligned}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{aligned} & 368.2 \\ & 56 \end{aligned}$ |  |  |  | 1 | Posit ive | 1 | 5 | 20 | NCE | $\begin{aligned} & \text { SPHP } \\ & \text { d17:0 } \end{aligned}$ |
| $\begin{aligned} & \hline 366.2 \\ & 404 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 1 | 5 | 20 | NCE | $\begin{aligned} & \text { SPHP } \\ & \text { d17:1 } \end{aligned}$ |
| $\begin{aligned} & 382.2 \\ & 717 \end{aligned}$ |  |  |  | 1 | Posit ive | 2 | 6 | 20 | NCE | $\begin{aligned} & \text { SPHP } \\ & \text { d18:0 } \end{aligned}$ |
| $\begin{aligned} & 380.2 \\ & 56 \end{aligned}$ |  |  |  | 1 | Posit ive | 2 | 5 | 20 | NCE | $\begin{aligned} & \text { SPHP } \\ & \text { d18:1 } \end{aligned}$ |
| $\begin{aligned} & \hline 378.2 \\ & 404 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 1 | 4 | 20 | NCE | $\begin{aligned} & \text { SPHP } \\ & \text { d18:2 } \end{aligned}$ |
| $\begin{aligned} & \hline 766.6 \\ & 919 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 16.8 | 17.8 | 20 | NCE | $\begin{aligned} & \text { TAG 12:0- } \\ & \text { 14:0-18:1 } \end{aligned}$ |
| $\begin{aligned} & \hline 780.7 \\ & 076 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 17.1 | 18.1 | 20 | NCE | $\begin{aligned} & \text { TAG 12:0- } \\ & \text { 15:0-18:1 } \end{aligned}$ |
| $\begin{aligned} & 768.7 \\ & 076 \end{aligned}$ |  |  |  | 1 | Posit ive | 17.6 | 18.6 | 20 | NCE | $\begin{aligned} & \text { TAG 12:0- } \\ & \text { 16:0-16:0 } \end{aligned}$ |
| $\begin{aligned} & 796.7 \\ & 389 \end{aligned}$ |  |  |  | 1 | Posit ive | 18.1 | 19.1 | 20 | NCE | $\begin{aligned} & \text { TAG 12:0- } \\ & \text { 16:0-18:0 } \end{aligned}$ |
| $\begin{aligned} & 794.7 \\ & 232 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 17.4 | 18.4 | 20 | NCE | $\begin{aligned} & \text { TAG 12:0- } \\ & \text { 16:0-18:1 } \end{aligned}$ |
| $\begin{array}{\|l\|} \hline 792.7 \\ 076 \\ \hline \end{array}$ |  |  |  | 1 | Posit ive | 16.9 | 17.9 | 20 | NCE | $\begin{aligned} & \text { TAG 12:0- } \\ & \text { 16:0-18:2 } \end{aligned}$ |
| $\begin{aligned} & 818.7 \\ & 232 \end{aligned}$ |  |  |  | 1 | Posit ive | 17 | 18 | 20 | NCE | $\begin{aligned} & \text { TAG 12:0- } \\ & 18: 1-18: 2 \end{aligned}$ |
| $\begin{array}{\|l\|} \hline 816.7 \\ 076 \\ \hline \end{array}$ |  |  |  | 1 | Posit ive | 16.4 | 17.4 | 20 | NCE | $\begin{aligned} & \text { TAG 12:0- } \\ & \text { 18:1-18:3 } \end{aligned}$ |
| $\begin{aligned} & \hline 808.7 \\ & 389 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 17.7 | 18.7 | 20 | NCE | $\begin{aligned} & \text { TAG 14:0- } \\ & \text { 15:0-18:1 } \end{aligned}$ |
| $\begin{array}{\|l} \hline 806.7 \\ 232 \\ \hline \end{array}$ |  |  |  | 1 | Posit ive | 17.2 | 18.2 | 20 | NCE | $\begin{aligned} & \text { TAG 14:0- } \\ & 15: 0-18: 2 \end{aligned}$ |
| $\begin{aligned} & \hline 796.7 \\ & 389 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 18.2 | 19.2 | 20 | NCE | $\begin{aligned} & \text { TAG 14:0- } \\ & \text { 16:0-16:0 } \end{aligned}$ |
| $\begin{array}{\|l\|} \hline 810.7 \\ 545 \\ \hline \end{array}$ |  |  |  | 1 | Posit ive | 18.4 | 19.4 | 20 | NCE | $\begin{aligned} & \hline \text { TAG 14:0- } \\ & \text { 16:0-17:0 } \\ & \hline \end{aligned}$ |
| $\begin{aligned} & 824.7 \\ & 702 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 18.9 | 19.9 | 20 | NCE | $\begin{aligned} & \text { TAG 14:0- } \\ & \text { 16:0-18:0 } \end{aligned}$ |
| $\begin{aligned} & 822.7 \\ & 545 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 18.2 | 19.2 | 20 | NCE | $\begin{aligned} & \text { TAG 14:0- } \\ & \text { 16:0-18:1 } \end{aligned}$ |
| $\begin{aligned} & 820.7 \\ & 389 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 17.5 | 18.5 | 20 | NCE | $\begin{aligned} & \text { TAG 14:0- } \\ & 16: 0-18: 2 \end{aligned}$ |
| $\begin{aligned} & 868.7 \\ & 389 \end{aligned}$ |  |  |  | 1 | Posit ive | 17 | 18 | 20 | NCE | $\begin{aligned} & \text { TAG 14:0- } \\ & 16: 0-22: 6 \end{aligned}$ |
| $\begin{array}{\|l\|} \hline 834.7 \\ 545 \\ \hline \end{array}$ |  |  |  | 1 | Posit ive | 17.7 | 18.7 | 20 | NCE | $\begin{aligned} & \text { TAG 14:0- } \\ & 17: 1-18: 1 \end{aligned}$ |


| $\begin{aligned} & 848.7 \\ & 702 \end{aligned}$ |  |  |  | 1 | Posit ive | 18 | 19 | 20 | NCE | $\begin{aligned} & \hline \text { TAG 14:0- } \\ & \text { 18:1-18:1 } \end{aligned}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{aligned} & 844.7 \\ & 389 \end{aligned}$ |  |  |  | 1 | Posit ive | 16.9 | 17.9 | 20 | NCE | TAG 14:0-18:2-18:2 |
| $\begin{aligned} & 842.7 \\ & 232 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 16.5 | 17.5 | 20 | NCE | $\begin{aligned} & \text { TAG 14:0- } \\ & \text { 18:2-18:3 } \end{aligned}$ |
| $\begin{aligned} & 820.7 \\ & 389 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 17.5 | 18.5 | 20 | NCE | $\begin{aligned} & \hline \text { TAG 14:1- } \\ & \text { 16:0-18:1 } \\ & \hline \end{aligned}$ |
| $\begin{aligned} & 840.7 \\ & 076 \end{aligned}$ |  |  |  | 1 | Posit ive | 15.9 | 16.9 | 20 | NCE | $\begin{aligned} & \text { TAG 14:1- } \\ & \text { 18:2-18:3 } \end{aligned}$ |
| $\begin{aligned} & \hline 932.8 \\ & 641 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 19.8 | 20.8 | 20 | NCE | $\begin{array}{\|l\|} \hline \text { TAG 14:2- } \\ \text { 20:0-22:0 } \\ \hline \end{array}$ |
| $\begin{aligned} & 838.7 \\ & 858 \end{aligned}$ |  |  |  | 1 | Posit ive | 19 | 20 | 20 | NCE | $\begin{aligned} & \text { TAG 15:0- } \\ & \text { 16:0-18:0 } \\ & \hline \end{aligned}$ |
| $\begin{aligned} & 836.7 \\ & 702 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 18.4 | 19.4 | 20 | NCE | $\begin{aligned} & \text { TAG 15:0- } \\ & \text { 16:0-18:1 } \\ & \hline \end{aligned}$ |
| $\begin{aligned} & 834.7 \\ & 545 \end{aligned}$ |  |  |  | 1 | Posit ive | 17.7 | 18.7 | 20 | NCE | $\begin{aligned} & \text { TAG 15:0- } \\ & \text { 16:0-18:2 } \end{aligned}$ |
| $\begin{aligned} & 832.7 \\ & 389 \end{aligned}$ |  |  |  | 1 | Posit ive | 17.2 | 18.2 | 20 | NCE | $\begin{aligned} & \text { TAG 15:0- } \\ & \text { 16:0-18:3 } \end{aligned}$ |
| $\begin{aligned} & 806.7 \\ & 232 \end{aligned}$ |  |  |  | 1 | Posit ive | 17.2 | 18.2 | 20 | NCE | $\begin{aligned} & \text { TAG 15:0- } \\ & \text { 16:1-16:1 } \end{aligned}$ |
| $\begin{aligned} & 832.7 \\ & 389 \end{aligned}$ |  |  |  | 1 | Posit ive | 17.2 | 18.2 | 20 | NCE | $\begin{aligned} & \text { TAG 15:0- } \\ & \text { 16:1-18:2 } \end{aligned}$ |
| $\begin{aligned} & 862.7 \\ & 858 \end{aligned}$ |  |  |  | 1 | Posit ive | 18.3 | 19.3 | 20 | NCE | $\begin{aligned} & \text { TAG 15:0- } \\ & \text { 18:1-18:1 } \end{aligned}$ |
| $\begin{aligned} & 860.7 \\ & 702 \end{aligned}$ |  |  |  | 1 | Posit ive | 17.8 | 18.8 | 20 | NCE | $\begin{aligned} & \text { TAG 15:0- } \\ & \text { 18:1-18:2 } \end{aligned}$ |
| $\begin{aligned} & 858.7 \\ & 545 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 17.3 | 18.3 | 20 | NCE | $\begin{array}{\|l} \hline \text { TAG 15:0- } \\ \text { 18:2-18:2 } \\ \hline \end{array}$ |
| $\begin{aligned} & 856.7 \\ & 389 \end{aligned}$ |  |  |  | 1 | Posit ive | 16.8 | 17.8 | 20 | NCE | $\begin{aligned} & \text { TAG 15:0- } \\ & \text { 18:2-18:3 } \end{aligned}$ |
| $\begin{aligned} & 836.7 \\ & 702 \end{aligned}$ |  |  |  | 1 | Posit ive | 18.4 | 19.4 | 20 | NCE | $\begin{aligned} & \text { TAG 16:0- } \\ & \text { 16:0-17:1 } \\ & \hline \end{aligned}$ |
| $\begin{aligned} & 852.8 \\ & 015 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 19.5 | 20.5 | 20 | NCE | $\begin{aligned} & \text { TAG 16:0- } \\ & \text { 16:0-18:0 } \end{aligned}$ |
| $\begin{aligned} & 850.7 \\ & 858 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 18.7 | 19.7 | 20 | NCE | $\begin{aligned} & \text { TAG 16:0- } \\ & 16: 0-18: 1 \end{aligned}$ |
| $\begin{aligned} & 848.7 \\ & 702 \end{aligned}$ |  |  |  | 1 | Posit ive | 18.2 | 19.2 | 20 | NCE | $\begin{aligned} & \text { TAG 16:0- } \\ & \text { 16:0-18:2 } \end{aligned}$ |
| $\begin{aligned} & 846.7 \\ & 545 \end{aligned}$ |  |  |  | 1 | Posit ive | 18 | 19 | 20 | NCE | $\begin{aligned} & \text { TAG 16:0- } \\ & \text { 16:0-18:3 } \end{aligned}$ |
| $\begin{aligned} & 844.7 \\ & 389 \end{aligned}$ |  |  |  | 1 | Posit ive | 16.9 | 17.9 | 20 | NCE | $\begin{aligned} & \text { TAG 16:0- } \\ & \text { 16:1-18:3 } \end{aligned}$ |
| $\begin{aligned} & 866.8 \\ & 171 \end{aligned}$ |  |  |  | 1 | Posit ive | 19.6 | 20.6 | 20 | NCE | $\begin{aligned} & \text { TAG 16:0- } \\ & \text { 17:0-18:0 } \end{aligned}$ |


| $\begin{aligned} & \hline 864.8 \\ & 015 \end{aligned}$ |  |  |  | 1 | Posit ive | 18.9 | 19.9 | 20 | NCE | $\begin{aligned} & \text { TAG 16:0- } \\ & \text { 17:0-18:1 } \end{aligned}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{aligned} & 862.7 \\ & 858 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 18.3 | 19.3 | 20 | NCE | $\begin{aligned} & \text { TAG 16:0- } \\ & \text { 17:1-18:1 } \end{aligned}$ |
| $\begin{aligned} & \hline 860.7 \\ & 702 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 17.8 | 18.8 | 20 | NCE | $\begin{aligned} & \text { TAG 16:0- } \\ & 17: 1-18: 2 \end{aligned}$ |
| $\begin{aligned} & 880.8 \\ & 328 \end{aligned}$ |  |  |  | 1 | Posit ive | 19.8 | 20.8 | 20 | NCE | $\begin{aligned} & \text { TAG 16:0- } \\ & \text { 18:0-18:0 } \end{aligned}$ |
| $\begin{aligned} & 878.8 \\ & 171 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 19.3 | 20.3 | 20 | NCE | $\begin{aligned} & \text { TAG 16:0- } \\ & \text { 18:0-18:1 } \end{aligned}$ |
| $\begin{aligned} & \hline 908.8 \\ & 641 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 20.4 | 21.4 | 20 | NCE | $\begin{aligned} & \text { TAG 16:0- } \\ & 18: 0-20: 0 \end{aligned}$ |
| $\begin{aligned} & 936.8 \\ & 954 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 20.7 | 21.7 | 20 | NCE | $\begin{aligned} & \text { TAG 16:0- } \\ & \text { 18:0-22:0 } \end{aligned}$ |
| $\begin{aligned} & 876.8 \\ & 015 \end{aligned}$ |  |  |  | 1 | Posit ive | 18.6 | 19.6 | 20 | NCE | $\begin{aligned} & \text { TAG 16:0- } \\ & \text { 18:1-18:1 } \end{aligned}$ |
| $\begin{aligned} & \hline 874.7 \\ & 858 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 18.1 | 19.1 | 20 | NCE | $\begin{aligned} & \text { TAG 16:0- } \\ & \text { 18:1-18:2 } \end{aligned}$ |
| $\begin{aligned} & 872.7 \\ & 702 \end{aligned}$ |  |  |  | 1 | Posit ive | 17.5 | 18.5 | 20 | NCE | $\begin{aligned} & \text { TAG 16:0- } \\ & \text { 18:1-18:3 } \end{aligned}$ |
| $\begin{aligned} & 898.7 \\ & 858 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 17.9 | 18.9 | 20 | NCE | TAG 16:0- $18: 1-20: 4$ |
| $\begin{aligned} & 924.8 \\ & 015 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 17.8 | 18.8 | 20 | NCE | $\begin{aligned} & \text { TAG 16:0- } \\ & \text { 18:1-22:5 } \end{aligned}$ |
| $\begin{aligned} & \hline 922.7 \\ & 858 \end{aligned}$ |  |  |  | 1 | Posit ive | 17.7 | 18.7 | 20 | NCE | $\begin{aligned} & \text { TAG 16:0- } \\ & \text { 18:1-22:6 } \end{aligned}$ |
| $\begin{aligned} & 872.7 \\ & 702 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 17.5 | 18.5 | 20 | NCE | $\begin{aligned} & \text { TAG 16:0- } \\ & 18: 2-18: 2 \end{aligned}$ |
| $\begin{aligned} & 870.7 \\ & 545 \end{aligned}$ |  |  |  | 1 | Posit ive | 17.1 | 18.1 | 20 | NCE | $\begin{aligned} & \text { TAG 16:0- } \\ & \text { 18:2-18:3 } \end{aligned}$ |
| $\begin{aligned} & 868.7 \\ & 389 \end{aligned}$ |  |  |  | 1 | Posit ive | 16.6 | 17.6 | 20 | NCE | $\begin{aligned} & \text { TAG 16:0- } \\ & \text { 18:3-18:3 } \end{aligned}$ |
| $\begin{aligned} & \hline 944.7 \\ & 702 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 16.5 | 17.5 | 20 | NCE | $\begin{aligned} & \text { TAG 16:0- } \\ & 20: 4-22: 6 \\ & \hline \end{aligned}$ |
| $\begin{aligned} & \hline 892.8 \\ & 328 \end{aligned}$ |  |  |  | 1 | Posit ive | 19.4 | 20.4 | 20 | NCE | $\begin{aligned} & \text { TAG 17:0- } \\ & \text { 18:0-18:1 } \end{aligned}$ |
| $\begin{aligned} & 890.8 \\ & 171 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 18.9 | 19.9 | 20 | NCE | $\begin{aligned} & \text { TAG 17:0- } \\ & \text { 18:1-18:1 } \end{aligned}$ |
| $\begin{aligned} & 888.8 \\ & 015 \end{aligned}$ |  |  |  | 1 | Posit ive | 18.4 | 19.4 | 20 | NCE | $\begin{aligned} & \text { TAG 17:0- } \\ & \text { 18:1-18:2 } \end{aligned}$ |
| $\begin{aligned} & 886.7 \\ & 858 \end{aligned}$ |  |  |  | 1 | Posit ive | 17.8 | 18.8 | 20 | NCE | $\begin{aligned} & \text { TAG 17:0- } \\ & \text { 18:1-18:3 } \end{aligned}$ |
| $\begin{aligned} & \hline 884.7 \\ & 702 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 17.2 | 18.2 | 20 | NCE | $\begin{aligned} & \text { TAG 17:0- } \\ & \text { 18:2-18:3 } \end{aligned}$ |
| $\begin{aligned} & 910.7 \\ & 858 \end{aligned}$ |  |  |  | 1 | Posit ive | 17.7 | 18.7 | 20 | NCE | $\begin{aligned} & \text { TAG 17:0- } \\ & 18: 2-20: 4 \end{aligned}$ |


| $\begin{aligned} & \hline 890.8 \\ & 171 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 18.9 | 19.9 | 20 | NCE | $\begin{aligned} & \text { TAG 17:1- } \\ & \text { 18:0-18:1 } \end{aligned}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{aligned} & 888.8 \\ & 015 \end{aligned}$ |  |  |  | 1 | Posit ive | 18.4 | 19.4 | 20 | NCE | $\begin{aligned} & \text { TAG 17:1- } \\ & \text { 18:1-18:1 } \end{aligned}$ |
| $\begin{aligned} & \hline 886.7 \\ & 858 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 17.8 | 18.8 | 20 | NCE | $\begin{aligned} & \text { TAG 17:1- } \\ & \text { 18:1-18:2 } \end{aligned}$ |
| $\begin{aligned} & \hline 910.7 \\ & 858 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 17.7 | 18.7 | 20 | NCE | $\begin{aligned} & \text { TAG 17:1- } \\ & \text { 18:1-20:4 } \end{aligned}$ |
| $\begin{aligned} & \hline 884.7 \\ & 702 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 17.2 | 18.2 | 20 | NCE | $\begin{aligned} & \text { TAG 17:1- } \\ & \text { 18:2-18:2 } \end{aligned}$ |
| $\begin{aligned} & \hline 908.8 \\ & 641 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 20.3 | 21.3 | 20 | NCE | $\begin{aligned} & \text { TAG 18:0- } \\ & \text { 18:0-18:0 } \\ & \hline \end{aligned}$ |
| $\begin{aligned} & \hline 906.8 \\ & 484 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 19.7 | 20.7 | 20 | NCE | $\begin{aligned} & \text { TAG 18:0- } \\ & \text { 18:0-18:1 } \end{aligned}$ |
| $\begin{aligned} & \hline 936.8 \\ & 954 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 20.7 | 21.7 | 20 | NCE | $\begin{aligned} & \text { TAG 18:0- } \\ & \text { 18:0-20:0 } \end{aligned}$ |
| $\begin{aligned} & 928.8 \\ & 328 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 18.6 | 19.6 | 20 | NCE | $\begin{aligned} & \text { TAG 18:0- } \\ & \text { 18:0-20:4 } \end{aligned}$ |
| $\begin{aligned} & 904.8 \\ & 328 \end{aligned}$ |  |  |  | 1 | Posit ive | 19.3 | 20.3 | 20 | NCE | $\begin{array}{\|l\|} \hline \text { TAG 18:0- } \\ \text { 18:1-18:1 } \\ \hline \end{array}$ |
| $\begin{aligned} & 902.8 \\ & 171 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 18.7 | 19.7 | 20 | NCE | $\begin{aligned} & \text { TAG 18:0- } \\ & \text { 18:1-18:2 } \end{aligned}$ |
| $\begin{aligned} & 920.8 \\ & 641 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 19.9 | 20.9 | 20 | NCE | $\begin{aligned} & \text { TAG 18:0- } \\ & \text { 18:1-19:0 } \end{aligned}$ |
| $\begin{aligned} & 918.8 \\ & 484 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 19.4 | 20.4 | 20 | NCE | $\begin{aligned} & \text { TAG 18:0- } \\ & \text { 18:1-19:1 } \end{aligned}$ |
| $\begin{aligned} & 934.8 \\ & 797 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 20.1 | 21.1 | 20 | NCE | $\begin{aligned} & \text { TAG 18:0- } \\ & \text { 18:1-20:0 } \\ & \hline \end{aligned}$ |
| $\begin{aligned} & 928.8 \\ & 328 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 18.6 | 19.6 | 20 | NCE | $\begin{aligned} & \text { TAG 18:0- } \\ & \text { 18:1-20:3 } \end{aligned}$ |
| $\begin{aligned} & \hline 962.9 \\ & 11 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 20.6 | 21.6 | 20 | NCE | $\begin{aligned} & \text { TAG 18:0- } \\ & 18: 1-22: 0 \end{aligned}$ |
| $\begin{aligned} & \hline 954.8 \\ & 484 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 18.9 | 19.9 | 20 | NCE | $\begin{aligned} & \text { TAG 18:0- } \\ & \text { 18:1-22:4 } \\ & \hline \end{aligned}$ |
| $\begin{aligned} & \hline 952.8 \\ & 328 \end{aligned}$ |  |  |  | 1 | Posit ive | 18.3 | 19.3 | 20 | NCE | $\begin{aligned} & \text { TAG 18:0- } \\ & \text { 18:1-22:5 } \end{aligned}$ |
| $\begin{aligned} & 900.8 \\ & 015 \end{aligned}$ |  |  |  | 1 | Posit ive | 18.2 | 19.2 | 20 | NCE | $\begin{aligned} & \text { TAG 18:0- } \\ & 18: 2-18: 2 \end{aligned}$ |
| $\begin{aligned} & 916.8 \\ & 328 \end{aligned}$ |  |  |  | 1 | Posit ive | 18.9 | 19.9 | 20 | NCE | $\begin{aligned} & \text { TAG 18:0- } \\ & \text { 18:2-19:1 } \end{aligned}$ |
| $\begin{aligned} & 948.8 \\ & 015 \end{aligned}$ |  |  |  | 1 | Posit ive | 17.6 | 18.6 | 20 | NCE | $\begin{aligned} & \text { TAG 18:0- } \\ & 18: 2-22: 6 \end{aligned}$ |
| $\begin{aligned} & 902.8 \\ & 171 \end{aligned}$ |  |  |  | 1 | Posit ive | 18.7 | 19.7 | 20 | NCE | $\begin{aligned} & \text { TAG 18:1- } \\ & \text { 18:1-18:1 } \end{aligned}$ |
| $\begin{array}{\|l} 900.8 \\ 015 \\ \hline \end{array}$ |  |  |  | 1 | Posit ive | 18 | 19 | 20 | NCE | $\begin{aligned} & \text { TAG 18:1- } \\ & \text { 18:1-18:2 } \end{aligned}$ |


| $\begin{aligned} & 898.7 \\ & 858 \end{aligned}$ |  |  |  | 1 | Posit ive | 17.5 | 18.5 | 20 | NCE | $\begin{aligned} & \text { TAG 18:1- } \\ & \text { 18:1-18:3 } \end{aligned}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{aligned} & 932.8 \\ & 641 \end{aligned}$ |  |  |  | 1 | Posit ive | 19.8 | 20.8 | 20 | NCE | $\begin{aligned} & \text { TAG 18:1- } \\ & \text { 18:1-20:0 } \end{aligned}$ |
| $\begin{aligned} & 930.8 \\ & 484 \end{aligned}$ |  |  |  | 1 | Posit ive | 19 | 20 | 20 | NCE | $\begin{aligned} & \text { TAG 18:1- } \\ & 18: 1-20: 1 \end{aligned}$ |
| $\begin{aligned} & 926.8 \\ & 171 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 18.3 | 19.3 | 20 | NCE | $\begin{aligned} & \text { TAG 18:1- } \\ & \text { 18:1-20:3 } \end{aligned}$ |
| $\begin{aligned} & 960.8 \\ & 954 \end{aligned}$ |  |  |  | 1 | Posit ive | 20.3 | 21.3 | 20 | NCE | $\begin{aligned} & \text { TAG 18:1- } \\ & \text { 18:1-22:0 } \end{aligned}$ |
| $\begin{aligned} & 958.8 \\ & 797 \\ & \hline \end{aligned}$ |  |  |  | 1 | $\begin{array}{\|l} \hline \text { Posit } \\ \text { ive } \\ \hline \end{array}$ | 19.7 | 20.7 | 20 | NCE | $\begin{aligned} & \text { TAG 18:1- } \\ & \text { 18:1-22:1 } \\ & \hline \end{aligned}$ |
| $\begin{aligned} & 952.8 \\ & 328 \\ & \hline \end{aligned}$ |  |  |  | 1 | $\begin{aligned} & \text { Posit } \\ & \text { ive } \end{aligned}$ | 18.3 | 19.3 | 20 | NCE | $\begin{aligned} & \text { TAG 18:1- } \\ & \text { 18:1-22:4 } \end{aligned}$ |
| $\begin{aligned} & 950.8 \\ & 171 \end{aligned}$ |  |  |  | 1 | $\begin{aligned} & \hline \text { Posit } \\ & \text { ive } \\ & \hline \end{aligned}$ | 17.8 | 18.8 | 20 | NCE | $\begin{aligned} & \text { TAG 18:1- } \\ & \text { 18:1-22:5 } \end{aligned}$ |
| $\begin{aligned} & 974.9 \\ & 11 \\ & \hline \end{aligned}$ |  |  |  | 1 | $\begin{array}{\|l} \hline \text { Posit } \\ \text { ive } \\ \hline \end{array}$ | 20.3 | 21.3 | 20 | NCE | $\begin{aligned} & \text { TAG 18:1- } \\ & \text { 18:1-23:0 } \\ & \hline \end{aligned}$ |
| $\begin{aligned} & 986.9 \\ & 11 \\ & \hline \end{aligned}$ |  |  |  | 1 | $\begin{aligned} & \text { Posit } \\ & \text { ive } \end{aligned}$ | 20.1 | 21.1 | 20 | NCE | $\begin{aligned} & \text { TAG } 18: 1- \\ & 18: 1-24: 1 \end{aligned}$ |
| $\begin{aligned} & 1016 . \\ & 958 \end{aligned}$ |  |  |  | 1 | $\begin{aligned} & \text { Posit } \\ & \text { ive } \end{aligned}$ | 20.8 | 21.8 | 20 | NCE | $\begin{aligned} & \text { TAG 18:1- } \\ & \text { 18:1-26:0 } \end{aligned}$ |
| $\begin{aligned} & 896.7 \\ & 702 \end{aligned}$ |  |  |  | 1 | $\begin{aligned} & \text { Posit } \\ & \text { ive } \\ & \hline \end{aligned}$ | 17 | 18 | 20 | NCE | $\begin{aligned} & \text { TAG 18:1- } \\ & \text { 18:2-18:3 } \end{aligned}$ |
| $\begin{aligned} & 930.8 \\ & 484 \end{aligned}$ |  |  |  | 1 | Posit ive | 19.2 | 20.2 | 20 | NCE | TAG 18:1- 18:2-20:0 |
| $\begin{aligned} & 928.8 \\ & 328 \end{aligned}$ |  |  |  | 1 | Posit ive | 18.6 | 19.6 | 20 | NCE | $\begin{aligned} & \text { TAG 18:1- } \\ & \text { 18:2-20:1 } \\ & \hline \end{aligned}$ |
| $\begin{aligned} & 922.7 \\ & 858 \end{aligned}$ |  |  |  | 1 | Posit ive | 17.3 | 18.3 | 20 | NCE | $\begin{aligned} & \text { TAG 18:1- } \\ & \text { 18:2-20:4 } \end{aligned}$ |
| $\begin{aligned} & 958.8 \\ & 797 \end{aligned}$ |  |  |  | 1 | $\begin{array}{\|l} \text { Posit } \\ \text { ive } \\ \hline \end{array}$ | 19.7 | 20.7 | 20 | NCE | $\begin{aligned} & \text { TAG 18:1- } \\ & \text { 18:2-22:0 } \end{aligned}$ |
| $\begin{aligned} & 956.8 \\ & 641 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 19 | 20 | 20 | NCE | $\begin{aligned} & \text { TAG 18:1- } \\ & \text { 18:2-22:1 } \end{aligned}$ |
| $\begin{aligned} & 948.8 \\ & 015 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 17.3 | 18.3 | 20 | NCE | $\begin{aligned} & \text { TAG 18:1- } \\ & \text { 18:2-22:5 } \end{aligned}$ |
| $\begin{aligned} & 946.7 \\ & 858 \end{aligned}$ |  |  |  | 1 | Posit ive | 17.1 | 18.1 | 20 | NCE | $\begin{aligned} & \text { TAG } 18: 1- \\ & 18: 2-22: 6 \end{aligned}$ |
| $\begin{aligned} & 986.9 \\ & 11 \end{aligned}$ |  |  |  | 1 | Posit ive | 20.1 | 21.1 | 20 | NCE | $\begin{aligned} & \text { TAG 18:1- } \\ & \text { 18:2-24:0 } \end{aligned}$ |
| $\begin{aligned} & 984.8 \\ & 954 \end{aligned}$ |  |  |  | 1 | Posit ive | 19.5 | 20.5 | 20 | NCE | $\begin{aligned} & \text { TAG 18:1- } \\ & 18: 2-24: 1 \end{aligned}$ |
| $\begin{aligned} & 1014 . \\ & 942 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 20.5 | 21.5 | 20 | NCE | $\begin{aligned} & \text { TAG 18:1- } \\ & \text { 18:2-26:0 } \end{aligned}$ |
| $\begin{aligned} & 1012 . \\ & 927 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 19.9 | 20.9 | 20 | NCE | $\begin{aligned} & \text { TAG 18:1- } \\ & \text { 18:2-26:1 } \end{aligned}$ |


| $\begin{aligned} & 896.7 \\ & 702 \end{aligned}$ |  |  |  | 1 | Posit ive | 17 | 18 | 20 | NCE | $\begin{aligned} & \text { TAG 18:2- } \\ & \text { 18:2-18:2 } \end{aligned}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{aligned} & 894.7 \\ & 545 \end{aligned}$ |  |  |  | 1 | Posit ive | 16.4 | 17.4 | 20 | NCE | $\begin{aligned} & \text { TAG 18:2- } \\ & 18: 2-18: 3 \end{aligned}$ |
| $\begin{aligned} & 928.8 \\ & 328 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 18.6 | 19.6 | 20 | NCE | $\begin{aligned} & \hline \text { TAG 18:2- } \\ & \text { 18:2-20:0 } \end{aligned}$ |
| $\begin{aligned} & 920.7 \\ & 702 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 16.8 | 17.8 | 20 | NCE | $\begin{aligned} & \text { TAG 18:2- } \\ & \text { 18:2-20:4 } \\ & \hline \end{aligned}$ |
| $\begin{aligned} & 944.7 \\ & 702 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 16.5 | 17.5 | 20 | NCE | $\begin{aligned} & \text { TAG 18:2- } \\ & \text { 18:2-22:6 } \end{aligned}$ |
| $\begin{aligned} & \hline 892.7 \\ & 389 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 15.9 | 16.9 | 20 | NCE | $\begin{aligned} & \text { TAG 18:2- } \\ & \text { 18:3-18:3 } \\ & \hline \end{aligned}$ |
| $\begin{aligned} & 920.7 \\ & 702 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 16.8 | 17.8 | 20 | NCE | $\begin{aligned} & \text { TAG 18:2- } \\ & \text { 18:3-20:3 } \end{aligned}$ |
| $\begin{aligned} & 918.7 \\ & 545 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 16.3 | 17.3 | 20 | NCE | $\begin{aligned} & \text { TAG 18:2- } \\ & \text { 18:3-20:4 } \\ & \hline \end{aligned}$ |
| $\begin{aligned} & \hline 829.7 \\ & 985 \end{aligned}$ |  |  |  | 1 | Posit ive | 18.2 | 19.2 | 20 | NCE | $\begin{aligned} & \text { TG } \\ & \text { 15:0_18:1 } \\ & \text { D7_15:0 } \end{aligned}$ |
| $\begin{aligned} & \hline 720.5 \\ & 902 \end{aligned}$ |  |  |  | 1 | Posit ive | $\begin{array}{\|l\|} \hline 12.6 \\ 7 \\ \hline \end{array}$ | 14 | 30 | NCE | $\begin{aligned} & \text { PC(16:0e_ } \\ & 16: 0) \end{aligned}$ |
| $\begin{aligned} & \hline 768.5 \\ & 901 \end{aligned}$ |  |  |  | 1 | Posit ive | $\begin{aligned} & 11.8 \\ & 5 \end{aligned}$ | $\begin{aligned} & 12.8 \\ & 5 \end{aligned}$ | 30 | NCE | $\begin{aligned} & \mathrm{PC}\left(16: 0 \mathrm{e}_{-}\right. \\ & 20: 4) \end{aligned}$ |
| $\begin{aligned} & \hline 796.6 \\ & 215 \end{aligned}$ |  |  |  | 1 | Posit ive | 12.5 | 14 | 30 | NCE | $\begin{aligned} & \text { PC(16:0e_ } \\ & 22: 4) \end{aligned}$ |
| $\begin{aligned} & 748.6 \\ & 215 \end{aligned}$ |  |  |  | 1 | Posit ive | $\begin{aligned} & 13.5 \\ & 3 \end{aligned}$ | $\begin{aligned} & 14.5 \\ & 3 \end{aligned}$ | 30 | NCE | $\begin{aligned} & \text { PC(18:0e_ } \\ & 16: 0) \end{aligned}$ |
| $\begin{aligned} & \hline 774.6 \\ & 371 \end{aligned}$ |  |  |  | 1 | Posit ive | $\begin{array}{\|l} \hline 13.5 \\ 1 \\ \hline \end{array}$ | $14.5$ | 30 | NCE | $\begin{aligned} & \text { PC(18:0e_ } \\ & 18: 1) \end{aligned}$ |
| $\begin{aligned} & 798.6 \\ & 372 \end{aligned}$ |  |  |  | 1 | Posit ive | $\begin{aligned} & 13.0 \\ & 5 \end{aligned}$ | $\begin{aligned} & 14.0 \\ & 5 \end{aligned}$ | 30 | NCE | $\begin{aligned} & \mathrm{PC}\left(18: 0 \mathrm{e}_{-}\right. \\ & 20: 3) \end{aligned}$ |
| $\begin{aligned} & 824.6 \\ & 528 \end{aligned}$ |  |  |  | 1 | Posit ive | 13.5 | 14.5 | 30 | NCE | $\begin{aligned} & \text { PC(18:0e_ } \\ & 22: 4) \end{aligned}$ |
| $\begin{aligned} & \hline 820.6 \\ & 21 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | $\begin{aligned} & \hline 12.4 \\ & 7 \end{aligned}$ | $\begin{aligned} & 13.4 \\ & 7 \end{aligned}$ | 30 | NCE | $\begin{aligned} & \text { PC(18:0e_ } \\ & 22: 6) \end{aligned}$ |
| $\begin{aligned} & 702.5 \\ & 432 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | $\begin{array}{\|l\|} \hline 12.7 \\ 4 \\ \hline \end{array}$ | $\begin{array}{\|l\|} \hline 13.7 \\ 4 \\ \hline \end{array}$ | 30 | NCE | $\begin{aligned} & \text { PE(16:0p_ } \\ & 18: 1) \\ & \hline \end{aligned}$ |
| $\begin{array}{\|l\|} \hline 700.5 \\ 275 \\ \hline \end{array}$ |  |  |  | 1 | Posit ive | 12.1 | 13.1 | 30 | NCE | $\begin{aligned} & \text { PE(16:0p_ } \\ & 18: 2) \end{aligned}$ |
| $\begin{aligned} & 724.5 \\ & 275 \end{aligned}$ |  |  |  | 1 | Posit ive | $\begin{aligned} & 11.9 \\ & 5 \end{aligned}$ | $\begin{aligned} & 12.9 \\ & 5 \end{aligned}$ | 30 | NCE | $\begin{aligned} & \mathrm{PE}\left(16: 0 p_{-}\right. \\ & 20: 4) \end{aligned}$ |
| $\begin{aligned} & \hline 722.5 \\ & 119 \end{aligned}$ |  |  |  | 1 | Posit ive | $11.3$ | $\begin{array}{\|l\|} \hline 12.3 \\ 7 \end{array}$ | 30 | NCE | $\begin{aligned} & \mathrm{PE}\left(16: 0 \mathrm{p}_{-}\right. \\ & 20: 5) \end{aligned}$ |
| $\begin{aligned} & 752.5 \\ & 58 \end{aligned}$ |  |  |  | 1 | Posit ive | 12.5 | 14 | 30 | NCE | $\begin{aligned} & \mathrm{PE}\left(16: 0 p_{-}\right. \\ & 22: 4) \end{aligned}$ |


| $\begin{aligned} & \hline 748.5 \\ & 275 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | $11.7$ | $\begin{aligned} & 12.7 \\ & 1 \\ & \hline \end{aligned}$ | 30 | NCE |  | $\begin{aligned} & \text { PE(16:0p_ } \\ & 22: 6) \end{aligned}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{aligned} & 730.5 \\ & 745 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | $\begin{aligned} & \hline 13.5 \\ & 6 \\ & \hline \end{aligned}$ | $\begin{array}{\|l} \hline 14.5 \\ 6 \\ \hline \end{array}$ | 30 | NCE |  | $\begin{aligned} & \text { PE(18:0p_ } \\ & 18: 1) \\ & \hline \end{aligned}$ |
| $\begin{aligned} & \hline 728.5 \\ & 588 \end{aligned}$ |  |  |  | 1 | Posit <br> ive | 13.2 | 14.2 | 30 | NCE |  | $\begin{aligned} & \text { PE(18:0p } \\ & 18: 2) \\ & \hline \end{aligned}$ |
| $\begin{aligned} & 752.5 \\ & 587 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | 12.7 | 13.7 | 30 | NCE |  | $\begin{aligned} & \text { PE(18:0p_ } \\ & 20: 4) \\ & \hline \end{aligned}$ |
| $\begin{aligned} & 780.5 \\ & 902 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | $\begin{array}{\|l\|} \hline 13.3 \\ 1 \\ \hline \end{array}$ | $\begin{aligned} & 14.3 \\ & 1 \\ & \hline \end{aligned}$ | 30 | NCE |  | $\begin{aligned} & \text { PE(18:0p_ } \\ & 22: 4) \end{aligned}$ |
| $\begin{aligned} & 778.5 \\ & 745 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | $\begin{aligned} & 12.7 \\ & 9 \\ & \hline \end{aligned}$ | $\begin{array}{\|l\|} \hline 13.7 \\ 9 \\ \hline \end{array}$ | 30 | NCE |  | $\begin{aligned} & \text { PE(18:0p_ } \\ & 22: 5) \end{aligned}$ |
| $\begin{aligned} & 776.5 \\ & 588 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | $\begin{aligned} & \hline 12.5 \\ & 6 \\ & \hline \end{aligned}$ | $\begin{array}{\|l\|} \hline 13.5 \\ 6 \\ \hline \end{array}$ | 30 | NCE |  | $\begin{aligned} & \text { PE(18:0p_ } \\ & 22: 6) \\ & \hline \end{aligned}$ |
| $\begin{aligned} & 750.5 \\ & 432 \end{aligned}$ |  |  |  | 1 | Posit ive | 11.8 | 13 | 30 | NCE |  | $\begin{aligned} & \mathrm{PE}\left(18: 1 \mathrm{p}_{-}\right. \\ & 20: 4) \end{aligned}$ |
| $\begin{aligned} & 774.5 \\ & 411 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | $\begin{aligned} & \hline 11.6 \\ & 5 \\ & \hline \end{aligned}$ | $\begin{array}{\|l\|} \hline 12.6 \\ 5 \\ \hline \end{array}$ | 30 | NCE |  | $\begin{aligned} & \text { PE(18:1p_ } \\ & 22: 6) \end{aligned}$ |
| $\begin{aligned} & 753.6 \\ & 13 \\ & \hline \end{aligned}$ |  |  |  | 1 | Posit ive | $\begin{aligned} & 11.5 \\ & 5 \end{aligned}$ | 13 | 30 | NCE |  | $\begin{aligned} & \mathrm{PC}(18: 1 \mathrm{D} 7 \\ & -15: 0) \end{aligned}$ |
| $\begin{aligned} & 711.5 \\ & 664 \\ & \hline \end{aligned}$ |  |  |  | 1 | $\begin{array}{\|l} \hline \begin{array}{l} \text { Posit } \\ \text { ive } \end{array} \\ \hline \end{array}$ | 11.8 | 12.8 | 30 | NCE |  | $\begin{aligned} & \text { PE(18:1D7 } \\ & -15: 0) \end{aligned}$ |
| $\begin{aligned} & \text { Mass } \\ & {[\mathrm{m} / \mathrm{z}]} \end{aligned}$ | Form ula <br> [M] | Formu la type | Spe cies | $\begin{aligned} & \mathrm{CS} \\ & {[\mathrm{z}]} \end{aligned}$ | Polar ity | $\begin{aligned} & \text { Start } \\ & {[\mathrm{min}} \\ & ] \\ & \hline \end{aligned}$ | $\begin{array}{\|l} \text { End } \\ {[\mathrm{min}} \\ ] \\ \hline \end{array}$ | $\begin{aligned} & (\mathrm{N}) \\ & \mathrm{CE} \end{aligned}$ | $(\mathrm{N}) \mathrm{C}$ E type | $\begin{array}{\|l\|} \hline \text { MS } \\ \mathrm{X} \\ \mathrm{ID} \\ \hline \end{array}$ | Comment |
| $\begin{aligned} & \hline 599.3 \\ & 202 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | 4.5 | 6 |  |  |  | LPI (18:0) |
| $\begin{aligned} & 597.3 \\ & 045 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | 2.5 | 4.5 |  |  |  | LPI (18:1) |
| $\begin{aligned} & 595.2 \\ & 889 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | 1.5 | 3 |  |  |  | LPI (18:2) |
| $\begin{aligned} & \hline 621.3 \\ & 045 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | 2 | 3.5 |  |  |  | LPI (20:3) |
| $\begin{aligned} & \hline 619.2 \\ & 889 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | 1.5 | 3 |  |  |  | LPI (20:4) |
| $\begin{aligned} & 433.2 \\ & 361 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | 2.5 | 4 |  |  |  | LPA (18:2) |
| $\begin{aligned} & 903.4 \\ & 631 \\ & \hline \end{aligned}$ |  |  |  | 2 | Nega tive | 8.95 | 9.95 |  |  |  | $\begin{aligned} & \text { GD1a(d34: } \\ & \text { 1)-2H } \\ & \hline \end{aligned}$ |
| $\begin{aligned} & 917.4 \\ & 788 \end{aligned}$ |  |  |  | 2 | Nega tive | $\begin{aligned} & 10.0 \\ & 3 \end{aligned}$ | $\begin{array}{\|l\|} \hline 11.0 \\ \hline \end{array}$ |  |  |  | $\begin{aligned} & \text { GD1a(d36: } \\ & \text { 1)-2H } \end{aligned}$ |
| $\begin{aligned} & 720.8 \\ & 97 \\ & \hline \end{aligned}$ |  |  |  | 2 | Nega tive | 9.64 | $\begin{aligned} & 10.6 \\ & 4 \\ & \hline \end{aligned}$ |  |  |  | $\begin{aligned} & \text { GD3(d34:1 } \\ & \text { )-2H } \end{aligned}$ |
| $\begin{aligned} & 1123 . \\ & 675 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | 8.84 | 9.84 |  |  |  | $\begin{aligned} & \text { GM3(d32: } \\ & \text { 1)-H } \\ & \hline \end{aligned}$ |
| 1151. |  |  |  | 1 | Nega | 9.94 | 10.9 |  |  |  | GM3(d34: |


| 706 |  |  |  |  | tive |  | 4 |  |  |  | 1)-H |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{aligned} & 1149 . \\ & 69 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | 9 | 10 |  |  |  | $\begin{aligned} & \text { GM3(d34: } \\ & \text { 2)-H } \end{aligned}$ |
| $\begin{aligned} & 1179 . \\ & 737 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{aligned} & 10.9 \\ & 1 \\ & \hline \end{aligned}$ | $\begin{array}{\|l\|} \hline 11.9 \\ \hline \end{array}$ |  |  |  | $\begin{aligned} & \text { GM3(d36: } \\ & \text { 1)-H } \end{aligned}$ |
| $\begin{aligned} & 1235 . \\ & 8 \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{aligned} & 12.5 \\ & 1 \\ & \hline \end{aligned}$ | $\begin{aligned} & 13.5 \\ & 1 \\ & \hline \end{aligned}$ |  |  |  | $\begin{aligned} & \text { GM3(d40: } \\ & \text { 1)-H } \end{aligned}$ |
| $\begin{aligned} & 1263 . \\ & 831 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{aligned} & 13.1 \\ & 9 \\ & \hline \end{aligned}$ | $\begin{array}{\|l\|} \hline 14.1 \\ 9 \\ \hline \end{array}$ |  |  |  | $\begin{aligned} & \text { GM3(d42: } \\ & \text { 1)-H } \end{aligned}$ |
| $\begin{aligned} & 701.5 \\ & 127 \end{aligned}$ |  |  |  | 1 | Nega tive | $12.6$ | $\begin{array}{\|l\|} \hline 13.6 \\ \hline 8 \\ \hline \end{array}$ |  |  |  | $\begin{array}{lr} \hline \text { PA } & 18: 0- \\ 18: 1 \end{array}$ |
| $\begin{aligned} & 699.4 \\ & 97 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{aligned} & 11.9 \\ & 1 \end{aligned}$ | $\begin{aligned} & 12.9 \\ & 1 \end{aligned}$ |  |  |  | $\begin{array}{ll} \text { PA } \quad 18: 0- \\ 18: 2 & \\ \hline \end{array}$ |
| $\begin{aligned} & 723.4 \\ & 97 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{aligned} & 11.8 \\ & 6 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 12.8 \\ & 6 \\ & \hline \end{aligned}$ |  |  |  | $\begin{array}{ll} \hline \text { PA } & 18: 0- \\ 20: 4 & \\ \hline \end{array}$ |
| $\begin{aligned} & 747.4 \\ & 97 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | 11.6 | 12.6 |  |  |  | $\begin{array}{ll} \begin{array}{ll} \text { PA } & 18: 0- \\ 22: 6 \end{array} \\ \hline \end{array}$ |
| $\begin{aligned} & 666.5 \\ & 097 \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{aligned} & 11.2 \\ & 3 \end{aligned}$ | 13 |  |  |  | $\begin{aligned} & \text { PA(18:1D7 } \\ & 15: 0) \end{aligned}$ |
| $\begin{aligned} & 750.5 \\ & 291 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{aligned} & 11.0 \\ & 8 \end{aligned}$ | $\begin{array}{\|l\|} \hline 12.0 \\ 8 \end{array}$ |  |  |  | $\begin{array}{ll} \hline \text { PC } & 14: 0- \\ 16: 0 & \\ \hline \end{array}$ |
| $\begin{aligned} & 776.5 \\ & 447 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{aligned} & 11.1 \\ & 5 \end{aligned}$ | $\begin{aligned} & 12.1 \\ & 5 \end{aligned}$ |  |  |  | $\begin{array}{lr} \text { PC } & 14: 0- \\ 18: 1 \end{array}$ |
| $\begin{aligned} & 774.5 \\ & 291 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | 10.5 | 11.5 |  |  |  | $\begin{array}{\|lr} \hline \text { PC } & 14: 0- \\ 18: 2 & \\ \hline \end{array}$ |
| $\begin{aligned} & 798.5 \\ & 291 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{aligned} & 10.1 \\ & 9 \end{aligned}$ | $\begin{array}{\|l\|} \hline 11.1 \\ 9 \\ \hline \end{array}$ |  |  |  | $\begin{aligned} & \text { PC } 14: 0- \\ & 20: 4 \end{aligned}$ |
| $\begin{aligned} & 790.5 \\ & 604 \end{aligned}$ |  |  |  | 1 | Nega tive | 11.7 | 12.7 |  |  |  | $\begin{array}{lr} \hline \text { PC } & 15: 0- \\ 18: 1 & \\ \hline \end{array}$ |
| $\begin{aligned} & 788.5 \\ & 447 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | $10.8$ | $11.8$ |  |  |  | $\begin{array}{lr} \hline \text { PC } & 15: 0- \\ 18: 2 & \\ \hline \end{array}$ |
| $\begin{aligned} & 778.5 \\ & 604 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{aligned} & 12.0 \\ & 1 \end{aligned}$ | $\begin{array}{\|l} \hline 13.5 \\ 1 \\ \hline \end{array}$ |  |  |  | $\begin{array}{lr} \hline \text { PC } & 16: 0- \\ 16: 0 & \\ \hline \end{array}$ |
| $\begin{aligned} & 776.5 \\ & 447 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | 11.2 | 12.5 |  |  |  | $\begin{array}{lr} \hline \text { PC } & 16: 0- \\ 16: 1 & \end{array}$ |
| $\begin{aligned} & 806.5 \\ & 917 \end{aligned}$ |  |  |  | 1 | Nega tive | 13 | 14.5 |  |  |  | $\begin{array}{ll} \hline \text { PC } & 16: 0- \\ 18: 0 & \\ \hline \end{array}$ |
| $\begin{aligned} & 804.5 \\ & 76 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{aligned} & 12.0 \\ & 1 \end{aligned}$ | 13.5 |  |  |  | $\begin{array}{lr} \hline \text { PC } & 16: 0- \\ 18: 1 & \\ \hline \end{array}$ |
| $\begin{aligned} & 802.5 \\ & 604 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | 11.5 | 13 |  |  |  | $\begin{array}{lr} \text { PC } & 16: 0- \\ 18: 2 & \\ \hline \end{array}$ |
| $\begin{aligned} & 800.5 \\ & 447 \end{aligned}$ |  |  |  | 1 | Nega tive | 11 | 12 |  |  |  | $\begin{array}{ll} \hline \text { PC } & 16: 0- \\ 18: 3 & \\ \hline \end{array}$ |
| $\begin{aligned} & 832.6 \\ & 073 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{aligned} & 12.8 \\ & 3 \\ & \hline \end{aligned}$ | $\begin{array}{\|l\|} \hline 13.8 \\ \hline \end{array}$ |  |  |  | $\begin{array}{ll} \text { PC } & 16: 0- \\ 20: 1 & \\ \hline \end{array}$ |
| 830.5 |  |  |  | 1 | Nega | 12.2 | 13.2 |  |  |  | PC 16:0- |


| 917 |  |  |  |  | tive |  |  |  |  |  | 20:2 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{aligned} & 828.5 \\ & 76 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{aligned} & 11.5 \\ & 7 \\ & \hline \end{aligned}$ | $\begin{array}{\|l} \hline 12.5 \\ 7 \\ \hline \end{array}$ |  |  |  | $\begin{array}{lr} \text { PC } & 16: 0- \\ 20: 3 & \\ \hline \end{array}$ |
| $\begin{aligned} & \hline 826.5 \\ & 604 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{aligned} & 11.1 \\ & 8 \end{aligned}$ | $\begin{aligned} & \hline 12.5 \\ & 8 \end{aligned}$ |  |  |  | $\begin{array}{lr} \text { PC } & 16: 0- \\ 20: 4 & \\ \hline \end{array}$ |
| $\begin{aligned} & 824.5 \\ & 447 \end{aligned}$ |  |  |  | 1 | Nega tive | 10.8 | 11.8 |  |  |  | $\begin{array}{lr} \text { PC } & 16: 0- \\ 20: 5 \end{array}$ |
| $\begin{aligned} & 854.5 \\ & 917 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{aligned} & 11.8 \\ & 2 \end{aligned}$ | $\begin{aligned} & 12.8 \\ & 2 \end{aligned}$ |  |  |  | $\begin{array}{ll} \begin{array}{l} \text { PC } \\ 22: 4 \end{array} \\ & \\ \hline \end{array}$ |
| $\begin{aligned} & 852.5 \\ & 76 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{aligned} & 11.2 \\ & 4 \end{aligned}$ | $\begin{aligned} & \hline 12.2 \\ & 4 \end{aligned}$ |  |  |  | $\begin{array}{ll} \hline \text { PC } & 16: 0- \\ 22: 5 & \\ \hline \end{array}$ |
| $\begin{aligned} & 850.5 \\ & 604 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{aligned} & 10.9 \\ & 7 \end{aligned}$ | $\begin{array}{\|l} \hline 11.9 \\ 7 \\ \hline \end{array}$ |  |  |  | $\begin{array}{lr} \text { PC } & 16: 0- \\ 22: 6 \end{array}$ |
| $\begin{aligned} & 800.5 \\ & 447 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | 10.7 | 11.7 |  |  |  | $\begin{array}{lr} \hline \text { PC } & 16: 1- \\ 18: 2 & \\ \hline \end{array}$ |
| $\begin{aligned} & 824.5 \\ & 447 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{aligned} & 10.2 \\ & 7 \\ & \hline \end{aligned}$ | $\begin{array}{\|l} \hline 11.2 \\ 7 \\ \hline \end{array}$ |  |  |  | $\begin{array}{lr} \hline \text { PC } & 16: 1- \\ 20: 4 & \\ \hline \end{array}$ |
| $\begin{aligned} & 818.5 \\ & 917 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | 12.5 | 14 |  |  |  | $\begin{array}{lr} \hline \text { PC } & 17: 0- \\ 18: 1 & \\ \hline \end{array}$ |
| $\begin{aligned} & 816.5 \\ & 76 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{aligned} & 11.7 \\ & 9 \end{aligned}$ | 13 |  |  |  | $\begin{array}{ll} \text { PC } \quad 17: 0- \\ 18: 2 \end{array}$ |
| $\begin{aligned} & 840.5 \\ & 76 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{aligned} & 11.8 \\ & 6 \\ & \hline \end{aligned}$ | $12.8$ |  |  |  | $\begin{array}{lr} \text { PC } & 17: 0- \\ 20: 4 & \\ \hline \end{array}$ |
| $\begin{aligned} & 834.6 \\ & 23 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | 14 | 15 |  |  |  | $\begin{array}{lr} \hline \text { PC } & 18: 0- \\ 18: 0 & \end{array}$ |
| $\begin{aligned} & 832.6 \\ & 073 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{aligned} & 12.8 \\ & 3 \\ & \hline \end{aligned}$ | 14.5 |  |  |  | $\begin{array}{lr} \hline \text { PC } & 18: 0- \\ 18: 1 & \\ \hline \end{array}$ |
| $\begin{aligned} & 830.5 \\ & 917 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | 12.3 | 14 |  |  |  | $\begin{array}{lr} \hline \text { PC } & 18: 0- \\ 18: 2 & \end{array}$ |
| $\begin{aligned} & 828.5 \\ & 76 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | 12 | 13 |  |  |  | $\begin{array}{lr} \text { PC } & 18: 0- \\ 18: 3 & \\ \hline \end{array}$ |
| $\begin{aligned} & 858.6 \\ & 23 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | 13.2 | 14.2 |  |  |  | $\begin{array}{lr} \hline \text { PC } & 18: 0- \\ 20: 2 & \\ \hline \end{array}$ |
| $\begin{aligned} & \hline 856.6 \\ & 073 \end{aligned}$ |  |  |  | 1 | Nega tive | 12.7 | 13.7 |  |  |  | $\begin{array}{lr} \hline \text { PC } & 18: 0- \\ 20: 3 & \end{array}$ |
| $\begin{aligned} & 854.5 \\ & 917 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | 12.3 | 13.5 |  |  |  | $\begin{array}{ll} \hline \text { PC } & 18: 0- \\ 20: 4 & \\ \hline \end{array}$ |
| $\begin{aligned} & \hline 852.5 \\ & 76 \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{aligned} & 11.5 \\ & 4 \end{aligned}$ | $\begin{aligned} & 12.5 \\ & 4 \end{aligned}$ |  |  |  | $\begin{array}{lr} \hline \text { PC } & 18: 0- \\ 20: 5 & \\ \hline \end{array}$ |
| $\begin{aligned} & 882.6 \\ & 23 \end{aligned}$ |  |  |  | 1 | Nega tive | 13 | 14 |  |  |  | $\begin{array}{ll} \begin{array}{ll} \text { PC } & 18: 0- \\ 22: 4 \end{array} \\ \hline \end{array}$ |
| $\begin{aligned} & 880.6 \\ & 073 \end{aligned}$ |  |  |  | 1 | Nega tive | 12.3 | 13.5 |  |  |  | $\begin{array}{lr} \hline \text { PC } & 18: 0- \\ 22: 5 & \\ \hline \end{array}$ |
| $\begin{aligned} & 878.5 \\ & 917 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | 11.9 | 12.9 |  |  |  | $\begin{array}{lr} \text { PC } & 18: 0- \\ 22: 6 \end{array}$ |
| 830.5 |  |  |  | 1 | Nega | 12.0 | 13.0 |  |  |  | PC 18:1- |


| 917 |  |  |  |  | tive | 1 | 1 |  |  |  | 18:1 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{aligned} & 828.5 \\ & 76 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{aligned} & 11.5 \\ & 7 \\ & \hline \end{aligned}$ | $\begin{aligned} & 12.5 \\ & 7 \\ & \hline \end{aligned}$ |  |  |  | $\begin{array}{lr} \text { PC } & 18: 1- \\ 18: 2 & \\ \hline \end{array}$ |
| $\begin{aligned} & 846.6 \\ & 23 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{aligned} & 13.1 \\ & 6 \\ & \hline \end{aligned}$ | $\begin{aligned} & 14.1 \\ & 6 \\ & \hline \end{aligned}$ |  |  |  | $\begin{array}{lr} \text { PC } & 18: 1- \\ 19: 0 & \end{array}$ |
| $\begin{aligned} & 854.5 \\ & 917 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{aligned} & 11.8 \\ & 2 \\ & \hline \end{aligned}$ | $\begin{aligned} & 12.8 \\ & 2 \end{aligned}$ |  |  |  | $\begin{array}{ll} \text { PC } & 18: 1- \\ 20: 3 \end{array}$ |
| $\begin{aligned} & 852.5 \\ & 76 \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{aligned} & 11.2 \\ & 4 \\ & \hline \end{aligned}$ | $\begin{aligned} & 12.2 \\ & 4 \end{aligned}$ |  |  |  | $\begin{array}{ll} \begin{array}{l} \text { PC } \\ 20: 4 \end{array} \\ \hline \end{array}$ |
| $\begin{aligned} & 850.5 \\ & 604 \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{aligned} & 10.4 \\ & 9 \end{aligned}$ | $\begin{aligned} & 11.4 \\ & 9 \end{aligned}$ |  |  |  | $\begin{array}{ll} \hline \text { PC } & 18: 1- \\ 20: 5 & \end{array}$ |
| $\begin{aligned} & 878.5 \\ & 917 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | 11.9 | 12.9 |  |  |  | $\begin{array}{lr} \hline \text { PC } & 18: 1- \\ 22: 5 & \\ \hline \end{array}$ |
| $\begin{aligned} & 876.5 \\ & 76 \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{aligned} & 10.9 \\ & 6 \end{aligned}$ | $\begin{aligned} & 11.9 \\ & 6 \end{aligned}$ |  |  |  | $\begin{array}{lr} \hline \text { PC } & 18: 1- \\ 22: 6 & \\ \hline \end{array}$ |
| $\begin{aligned} & 826.5 \\ & 604 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{aligned} & 10.6 \\ & 3 \\ & \hline \end{aligned}$ | $\begin{aligned} & 11.6 \\ & 3 \\ & \hline \end{aligned}$ |  |  |  | $\begin{array}{lr} \hline \text { PC } & 18: 2- \\ 18: 2 & \\ \hline \end{array}$ |
| $\begin{aligned} & 824.5 \\ & 447 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | 9.97 | $\begin{aligned} & 10.9 \\ & 7 \end{aligned}$ |  |  |  | $\begin{array}{lr} \hline \text { PC } & 18: 2- \\ 18: 3 & \\ \hline \end{array}$ |
| $\begin{aligned} & 858.6 \\ & 23 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | 13.3 | 14.3 |  |  |  | $\begin{array}{ll} \text { PC } & 18: 2- \\ 20: 0 \end{array}$ |
| $\begin{aligned} & 852.5 \\ & 76 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{aligned} & 10.9 \\ & 7 \\ & \hline \end{aligned}$ | $\begin{aligned} & 11.9 \\ & 7 \end{aligned}$ |  |  |  | $\begin{array}{lr} \text { PC } & 18: 2- \\ 20: 3 & \\ \hline \end{array}$ |
| $\begin{aligned} & 850.5 \\ & 604 \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{aligned} & 10.4 \\ & 6 \end{aligned}$ | $\begin{aligned} & 11.4 \\ & 6 \\ & \hline \end{aligned}$ |  |  |  | $\begin{array}{lr} \hline \text { PC } & 18: 2- \\ 20: 4 & \\ \hline \end{array}$ |
| $\begin{aligned} & 876.5 \\ & 76 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | 10.7 | 11.7 |  |  |  | $\begin{array}{lr} \text { PC } 20: 3- \\ 20: 4 \end{array}$ |
| $\begin{aligned} & 874.5 \\ & 604 \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{aligned} & 10.2 \\ & 6 \end{aligned}$ | $\begin{aligned} & 11.2 \\ & 6 \end{aligned}$ |  |  |  | $\begin{array}{lr} \hline \text { PC } \quad 20: 4- \\ 20: 4 & \end{array}$ |
| $\begin{aligned} & 797.6 \\ & 043 \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{aligned} & 11.5 \\ & 5 \end{aligned}$ | 13 |  |  |  | $\begin{aligned} & \text { PC(18:1D7 } \\ & -15: 0) \end{aligned}$ |
| $\begin{aligned} & 718.5 \\ & 392 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{aligned} & 13.0 \\ & 9 \end{aligned}$ | $\begin{aligned} & 14.0 \\ & 9 \end{aligned}$ |  |  |  | $\begin{array}{ll} \text { PE } & 16: 0- \\ 18: 0 & \\ \hline \end{array}$ |
| $\begin{aligned} & 716.5 \\ & 236 \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{aligned} & 12.2 \\ & 7 \\ & \hline \end{aligned}$ | $\begin{aligned} & 13.2 \\ & 7 \\ & \hline \end{aligned}$ |  |  |  | $\begin{array}{lr} \hline \text { PE } & 16: 0- \\ 18: 1 & \end{array}$ |
| $\begin{aligned} & 714.5 \\ & 079 \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{aligned} & 11.5 \\ & 5 \end{aligned}$ | $\begin{aligned} & 12.5 \\ & 5 \end{aligned}$ |  |  |  | $\begin{array}{ll} \text { PE } & 16: 0- \\ 18: 2 \end{array}$ |
| $\begin{aligned} & 738.5 \\ & 079 \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{aligned} & 11.4 \\ & 7 \\ & \hline \end{aligned}$ | $\begin{aligned} & 12.4 \\ & 7 \end{aligned}$ |  |  |  | $\begin{array}{ll} \hline \text { PE } & 16: 0- \\ 20: 4 & \end{array}$ |
| $\begin{aligned} & 766.5 \\ & 392 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{aligned} & 12.0 \\ & 4 \\ & \hline \end{aligned}$ | $\begin{aligned} & 13.0 \\ & 4 \end{aligned}$ |  |  |  | $\begin{array}{ll} \text { PE } & 16: 0- \\ 22: 4 \end{array}$ |
| $\begin{aligned} & 764.5 \\ & 236 \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{aligned} & 11.4 \\ & 8 \end{aligned}$ | $\begin{aligned} & 12.4 \\ & 8 \end{aligned}$ |  |  |  | $\begin{array}{lr} \hline \text { PE } & 16: 0- \\ 22: 5 & \\ \hline \end{array}$ |
| $\begin{aligned} & 762.5 \\ & 079 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{aligned} & 11.2 \\ & 1 \\ & \hline \end{aligned}$ | $\begin{aligned} & 12.2 \\ & 1 \\ & \hline \end{aligned}$ |  |  |  | $\begin{aligned} & \text { PE } 16: 0- \\ & 22: 6 \end{aligned}$ |
| 744.5 |  |  |  | 1 | Nega | 13.0 | 14.0 |  |  |  | PE 18:0- |


| 549 |  |  |  |  | tive | 5 | 5 |  |  |  | 18:1 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{aligned} & 742.5 \\ & 392 \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{array}{\|l\|} \hline 12.4 \\ 5 \end{array}$ | $\begin{aligned} & 13.4 \\ & 5 \end{aligned}$ |  |  |  | $\begin{array}{lr} \hline \text { PE } & 18: 0- \\ 18: 2 & \end{array}$ |
| $\begin{aligned} & 768.5 \\ & 549 \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{array}{\|l\|} \hline 12.6 \\ 4 \end{array}$ | $\begin{aligned} & 13.6 \\ & 4 \end{aligned}$ |  |  |  | $\begin{array}{lr} \hline \text { PE } & 18: 0- \\ 20: 3 & \end{array}$ |
| $\begin{aligned} & 766.5 \\ & 392 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{array}{\|l} \hline 12.3 \\ 3 \end{array}$ | $13.3$ |  |  |  | $\begin{array}{lr} \text { PE } & 18: 0- \\ 20: 4 \end{array}$ |
| $\begin{aligned} & 794.5 \\ & 705 \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{array}{\|l\|} \hline 12.8 \\ 3 \end{array}$ | $\begin{aligned} & 13.8 \\ & 3 \end{aligned}$ |  |  |  | $\begin{array}{lr} \hline \text { PE } & 18: 0- \\ 22: 4 \end{array}$ |
| $\begin{aligned} & 792.5 \\ & 549 \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{array}{\|l\|} \hline 12.3 \\ 4 \\ \hline \end{array}$ | $\begin{aligned} & 13.3 \\ & 4 \end{aligned}$ |  |  |  | $\begin{array}{lr} \hline \text { PE } & 18: 0- \\ 22: 5 & \\ \hline \end{array}$ |
| $\begin{aligned} & 790.5 \\ & 392 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | 12.1 | 13.1 |  |  |  | $\begin{array}{ll} \text { PE } & 18: 0- \\ 22: 6 & \\ \hline \end{array}$ |
| $\begin{aligned} & 742.5 \\ & 392 \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{array}{\|l} \hline 12.2 \\ 3 \end{array}$ | $\begin{aligned} & 13.2 \\ & 3 \end{aligned}$ |  |  |  | $\begin{array}{lr} \hline \text { PE } & 18: 1- \\ 18: 1 & \\ \hline \end{array}$ |
| $\begin{array}{\|l\|} \hline 740.5 \\ 236 \\ \hline \end{array}$ |  |  |  | 1 | Nega tive | $\begin{array}{\|l} \hline 11.5 \\ 5 \\ \hline \end{array}$ | $\begin{aligned} & 12.5 \\ & 5 \\ & \hline \end{aligned}$ |  |  |  | $\begin{array}{lr} \hline \text { PE } & 18: 1- \\ 18: 2 & \\ \hline \end{array}$ |
| $\begin{aligned} & 764.5 \\ & 236 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{array}{\|l\|} \hline 11.4 \\ 8 \\ \hline \end{array}$ | $\begin{aligned} & 12.4 \\ & 8 \\ & \hline \end{aligned}$ |  |  |  | $\begin{array}{lr} \hline \text { PE } & 18: 1- \\ 20: 4 & \\ \hline \end{array}$ |
| $\begin{aligned} & \hline 738.5 \\ & 079 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{array}{\|l} \hline 10.8 \\ 5 \\ \hline \end{array}$ | $\begin{aligned} & 11.8 \\ & 5 \end{aligned}$ |  |  |  | $\begin{array}{lr} \text { PE } & 18: 2- \\ 18: 2 & \\ \hline \end{array}$ |
| $\begin{aligned} & 786.5 \\ & 079 \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{aligned} & 10.4 \\ & 9 \end{aligned}$ | $\begin{aligned} & 11.4 \\ & 9 \end{aligned}$ |  |  |  | $\begin{array}{ll} \text { PE } \quad 20: 4- \\ 20: 4 \end{array}$ |
| $\begin{aligned} & 709.5 \\ & 519 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | 11.8 | 12.8 |  |  |  | $\begin{aligned} & \text { PE(18:1D7 } \\ & 15: 0) \end{aligned}$ |
| $\begin{array}{\|l} \hline 788.5 \\ 447 \\ \hline \end{array}$ |  |  |  | 1 | Nega tive | 12.1 | 13.1 |  |  |  | $\begin{array}{ll} \hline \text { PS } & 18: 0- \\ 18: 1 & \\ \hline \end{array}$ |
| $\begin{aligned} & 810.5 \\ & 291 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{aligned} & 11.3 \\ & 2 \end{aligned}$ | $\begin{aligned} & 12.3 \\ & 2 \end{aligned}$ |  |  |  | $\begin{array}{lr} \hline \text { PS } & 18: 0- \\ 20: 4 & \\ \hline \end{array}$ |
| $\begin{aligned} & 838.5 \\ & 604 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{aligned} & 11.9 \\ & 1 \\ & \hline \end{aligned}$ | $\begin{aligned} & 12.9 \\ & 1 \end{aligned}$ |  |  |  | $\begin{array}{lr} \text { PS } & 18: 0- \\ 22: 4 \end{array}$ |
| $\begin{aligned} & \hline 836.5 \\ & 447 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | 11.1 | 12.1 |  |  |  | $\begin{array}{lr} \hline \text { PS } & 18: 1- \\ 22: 4 & \\ \hline \end{array}$ |
| $\begin{array}{\|l\|} \hline 830.4 \\ 978 \\ \hline \end{array}$ |  |  |  | 1 | Nega tive | 9.48 | $\begin{aligned} & 10.4 \\ & 8 \end{aligned}$ |  |  |  | $\begin{array}{lr} \hline \text { PS } \quad 20: 4- \\ 20: 4 \end{array}$ |
| $\begin{aligned} & 858.5 \\ & 291 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{aligned} & 10.2 \\ & 6 \end{aligned}$ | $\begin{aligned} & 11.2 \\ & 6 \end{aligned}$ |  |  |  | $\begin{aligned} & \text { PS 20:4- } \\ & 22: 4 \end{aligned}$ |
| $\begin{aligned} & 753.5 \\ & 417 \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{aligned} & 10.7 \\ & 1 \end{aligned}$ | $\begin{aligned} & 11.7 \\ & 1 \end{aligned}$ |  |  |  | $\begin{aligned} & \text { PS(18:1D7 } \\ & 15: 0) \end{aligned}$ |
| $\begin{aligned} & 828.5 \\ & 625 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | 10.6 | 11.6 |  |  |  | $\begin{aligned} & \mathrm{PI}(18: 1 \mathrm{D} 7 \\ & 15: 0) \end{aligned}$ |
| $\begin{aligned} & 861.5 \\ & 499 \\ & \hline \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{aligned} & 11.2 \\ & 7 \\ & \hline \end{aligned}$ | $12.2$ |  |  |  | $\begin{array}{ll} \hline \text { PI } & 18: 0- \\ 18: 2 & \\ \hline \end{array}$ |
| $\begin{aligned} & 859.5 \\ & 342 \end{aligned}$ |  |  |  | 1 | Nega tive | $\begin{aligned} & 10.6 \\ & 4 \\ & \hline \end{aligned}$ | $\begin{aligned} & 11.6 \\ & 4 \\ & \hline \end{aligned}$ |  |  |  | $\begin{aligned} & \text { PI } \quad 16: 0- \\ & 20: 3 \end{aligned}$ |
| 857.5 |  |  |  | 1 | Nega | 10.2 | 11.2 |  |  |  | PI 16:0- |


| 186 |  |  |  |  | tive | 7 | 7 |  |  |  | $20: 4$  <br> 871.5  |  |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- |

Supplementary Tables 5. Inclusion list for targeted proteomics (PRM).

| $\begin{gathered} \text { Mas } \\ \mathrm{s} \\ {[\mathrm{~m} /} \\ \mathrm{z}] \end{gathered}$ | For mul a [M] | $\begin{gathered} \text { For } \\ \text { mul } \\ \mathrm{a} \\ \text { typ } \\ \mathrm{e} \\ \hline \end{gathered}$ | Sp <br> eci <br> es | $\begin{aligned} & \mathrm{C} \\ & \mathrm{~S} \\ & {[ } \\ & \mathrm{Z} \\ & \mathrm{Z} \end{aligned}$ | $\begin{aligned} & \text { Pol } \\ & \text { arit } \\ & \text { y } \end{aligned}$ | $\begin{gathered} \mathrm{St} \\ \mathrm{art} \\ \text { [ } \\ \mathrm{mi} \\ \mathrm{n}] \end{gathered}$ | $\begin{gathered} \mathrm{E} \\ \mathrm{nd} \\ {[ } \\ \mathrm{mi} \\ \mathrm{n}] \end{gathered}$ | $\begin{aligned} & (\mathrm{N} \\ & \mathrm{r} \\ & \mathrm{E} \end{aligned}$ | $\begin{gathered} \text { (N } \\ \text { )C } \\ \text { E } \\ \text { typ } \\ \text { e } \end{gathered}$ | $\begin{gathered} \mathrm{M} \\ \mathrm{~S} \\ \mathrm{X} \\ \mathrm{I} \\ \mathrm{D} \end{gathered}$ | Comment |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{aligned} & 497 . \\ & 29 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & 13 \\ & .1 \end{aligned}$ | $\begin{aligned} & 15 \\ & .1 \end{aligned}$ |  |  |  | LLIYGASTR |
| $\begin{aligned} & 451 . \\ & 781 \\ & 5 \end{aligned}$ |  |  |  | 2 | $\begin{array}{\|l} \text { Pos } \\ \text { itiv } \\ \text { e } \end{array}$ | $\begin{array}{\|l\|} \hline 18 \\ .7 \end{array}$ | $\begin{array}{\|l\|} \hline 20 \\ .7 \end{array}$ |  |  |  | ELLLSSLK |
| $\begin{aligned} & 433 . \\ & 242 \\ & 5 \\ & \hline \end{aligned}$ |  |  |  | 2 | $\begin{array}{\|l} \hline \begin{array}{l} \text { Pos } \\ \text { itiv } \\ \mathrm{e} \end{array} \\ \hline \end{array}$ | $\begin{array}{\|l\|} \hline 12 \\ .5 \\ 3 \\ \hline \end{array}$ | $\begin{array}{\|l\|} \hline 14 \\ .1 \\ \hline \\ \hline \end{array}$ |  |  |  | FSGSLLGGK |
| $\begin{aligned} & 545 . \\ & 280 \\ & 4 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & 3 . \\ & 4 \end{aligned}$ | $\begin{aligned} & \hline 6 . \\ & 9 \end{aligned}$ |  |  |  | ASSLESGVPSR |
| $\begin{aligned} & 814 . \\ & 401 \\ & 8 \\ & \hline \end{aligned}$ |  |  |  | 2 | Pos <br> itiv <br> e | 15 <br> .7 <br> 4 | $\begin{array}{\|l} \hline 17 \\ .3 \\ 4 \\ \hline \end{array}$ |  |  |  | YSPSFQGQVTISADK |


| $\begin{aligned} & 644 . \\ & 314 \\ & 4 \\ & \hline \end{aligned}$ |  |  |  | 2 | $\begin{array}{\|l} \hline \text { Pos } \\ \text { itiv } \\ \mathrm{e} \\ \hline \end{array}$ | 14 .7 7 | $\begin{aligned} & 16 \\ & .3 \\ & 7 \\ & \hline \end{aligned}$ |  |  |  | FSGSGAGTDFTLK |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{aligned} & 532 . \\ & 790 \\ & 4 \end{aligned}$ |  |  |  | 2 | $\begin{array}{\|l} \hline \text { Pos } \\ \text { itiv } \\ \mathrm{e} \\ \hline \end{array}$ | $\begin{aligned} & 14 \\ & .0 \\ & 4 \end{aligned}$ | $\begin{aligned} & 15 \\ & .6 \\ & 4 \end{aligned}$ |  |  |  | LLIYDASNR |
| $\begin{aligned} & 538 . \\ & 798 \end{aligned}$ |  |  |  | 2 | $\begin{array}{\|l} \hline \text { Pos } \\ \text { itiv } \\ \mathrm{e} \\ \hline \end{array}$ | $\begin{aligned} & 25 \\ & .2 \\ & 4 \end{aligned}$ | $\begin{aligned} & 26 \\ & .8 \\ & 4 \end{aligned}$ |  |  |  | GLEWVGFIR |
| $\begin{aligned} & 408 . \\ & 721 \\ & 8 \\ & \hline \end{aligned}$ |  |  |  | 2 | $\begin{array}{\|l} \hline \text { Pos } \\ \text { itiv } \\ \mathrm{e} \\ \hline \end{array}$ | $\begin{aligned} & 13 \\ & .2 \end{aligned}$ | $\begin{aligned} & 15 \\ & .2 \end{aligned}$ |  |  |  | GLEWVGR |
| $\begin{aligned} & 519 . \\ & 284 \\ & 9 \end{aligned}$ |  |  |  | 2 | $\begin{array}{\|l\|} \hline \text { Pos } \\ \text { itiv } \\ \mathrm{e} \\ \hline \end{array}$ | $\begin{aligned} & 14 \\ & .1 \\ & 7 \\ & \hline \end{aligned}$ | $\begin{aligned} & 15 \\ & .7 \\ & 7 \end{aligned}$ |  |  |  | LLIYDASSR |
| $\begin{aligned} & 831 . \\ & 464 \\ & 7 \\ & \hline \end{aligned}$ |  |  |  | 2 | $\begin{array}{\|l} \hline \text { Pos } \\ \text { itiv } \\ \mathrm{e} \\ \hline \end{array}$ | $\begin{aligned} & 20 \\ & .9 \\ & 1 \\ & \hline \end{aligned}$ | $\begin{aligned} & 22 \\ & .5 \\ & 1 \\ & \hline \end{aligned}$ |  |  |  | LLIYAASSLQSGVPSR |
| $\begin{aligned} & 815 . \\ & 899 \\ & 6 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $\begin{aligned} & 10 \\ & .3 \\ & 6 \\ & \hline \end{aligned}$ | $\begin{aligned} & 11 \\ & .9 \\ & 6 \\ & \hline \end{aligned}$ |  |  |  | VTEPISAESGEQVER |
| $\begin{aligned} & 637 . \\ & 824 \\ & 1 \\ & \hline \end{aligned}$ |  |  |  | 2 | $\begin{array}{\|l} \hline \text { Pos } \\ \text { itiv } \\ \mathrm{e} \end{array}$ | $\begin{aligned} & 11 \\ & .4 \\ & 6 \end{aligned}$ | $\begin{aligned} & 13 \\ & .0 \\ & 6 \end{aligned}$ |  |  |  | VNEPSILEMSR |
| $\begin{aligned} & 766 . \\ & 694 \\ & 3 \end{aligned}$ |  |  |  | 3 | $\begin{array}{\|l} \hline \text { Pos } \\ \text { itiv } \\ \mathrm{e} \end{array}$ | $\begin{aligned} & 31 \\ & .9 \\ & 1 \\ & \hline \end{aligned}$ | $\begin{aligned} & 33 \\ & .5 \\ & 1 \\ & \hline \end{aligned}$ |  |  |  | ALPVFC[+57.0]DMDTEGGGW LVFQR |
| $\begin{aligned} & 512 . \\ & 746 \end{aligned}$ |  |  |  | 2 | $\begin{array}{\|l\|} \hline \text { Pos } \\ \text { itiv } \\ \mathrm{e} \\ \hline \end{array}$ | $\begin{aligned} & 14 \\ & .9 \\ & 5 \\ & \hline \end{aligned}$ | $\begin{aligned} & 16 \\ & .5 \\ & 5 \\ & \hline \end{aligned}$ |  |  |  | YGIDWASGR |
| $\begin{aligned} & 636 . \\ & 821 \\ & 9 \end{aligned}$ |  |  |  | 2 | $\begin{array}{\|l} \hline \text { Pos } \\ \text { itiv } \\ \mathrm{e} \\ \hline \end{array}$ | $\begin{aligned} & 11 \\ & .8 \\ & 5 \\ & \hline \end{aligned}$ | $\begin{aligned} & 13 \\ & .4 \\ & 5 \\ & \hline \end{aligned}$ |  |  |  | SEAAC[+57.0]LAAGPGIR |
| $\begin{aligned} & 795 . \\ & 899 \\ & 2 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \end{aligned}$ | $\begin{aligned} & 17 \\ & .9 \\ & 5 \end{aligned}$ | $\begin{aligned} & 19 \\ & .5 \\ & 5 \\ & \hline \end{aligned}$ |  |  |  | WIYHLTEGSTDLR |
| $\begin{aligned} & 409 . \\ & 250 \\ & 2 \\ & \hline \end{aligned}$ |  |  |  | 2 | $\begin{array}{\|l} \hline \text { Pos } \\ \text { itiv } \\ \mathrm{e} \end{array}$ | $\begin{aligned} & 16 \\ & .0 \\ & 3 \end{aligned}$ | $\begin{aligned} & 17 \\ & .6 \\ & 3 \\ & \hline \end{aligned}$ |  |  |  | AFLLTPR |
| $\begin{aligned} & 760 . \\ & 375 \end{aligned}$ |  |  |  | 2 | $\begin{array}{\|l\|} \hline \text { Pos } \\ \text { itiv } \\ \text { e } \\ \hline \end{array}$ | $\begin{aligned} & 20 \\ & .7 \\ & 6 \\ & \hline \end{aligned}$ | $\begin{aligned} & 22 \\ & .3 \\ & 6 \\ & \hline \end{aligned}$ |  |  |  | ALYLQYTDETFR |
| $\begin{aligned} & 602 . \\ & 267 \\ & 5 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & \hline 7 . \\ & 43 \end{aligned}$ | $\begin{aligned} & 10 \\ & .3 \\ & 5 \end{aligned}$ |  |  |  | EYTDASFTNR |
| 649. |  |  |  | 3 | Pos | 32 | 33 |  |  |  | GVNLQEFLNVTSVHLFK |


| $\begin{array}{\|l\|} \hline 022 \\ 9 \end{array}$ |  |  |  |  | itiv | .0 2 | . 6 |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{array}{\|l} \hline 763 . \\ 816 \\ 1 \\ \hline \end{array}$ |  |  |  | 2 | $\begin{array}{\|l} \hline \text { Pos } \\ \text { itiv } \\ \mathrm{e} \end{array}$ | $\begin{aligned} & 12 \\ & .6 \\ & 8 \end{aligned}$ | $\begin{aligned} & 14 \\ & .2 \\ & 8 \end{aligned}$ |  |  |  | GDAC[+57.0]EGDSGGPFVMK |
| $\begin{array}{\|l\|} \hline 601 . \\ 963 \\ 1 \\ \hline \end{array}$ |  |  |  | 3 | $\begin{array}{\|l} \hline \text { Pos } \\ \text { itiv } \\ \mathrm{e} \\ \hline \end{array}$ | $\begin{aligned} & 25 \\ & .9 \\ & 9 \end{aligned}$ | $28$ |  |  |  | MGNFPWQVFTNIHGR |
| $\begin{array}{\|l} \hline 783 . \\ 851 \\ 9 \\ \hline \end{array}$ |  |  |  | 2 | $\begin{array}{\|l} \hline \text { Pos } \\ \text { itiv } \\ \mathrm{e} \end{array}$ | $\begin{aligned} & 12 \\ & .5 \\ & 3 \\ & \hline \end{aligned}$ | $\begin{aligned} & 14 \\ & .1 \\ & 3 \\ & \hline \end{aligned}$ |  |  |  | QDAC[+57.0]QGDSGGVFAVR |
| $\begin{aligned} & 599 . \\ & 008 \\ & 6 \end{aligned}$ |  |  |  | 3 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \\ & \hline \end{aligned}$ | $\begin{aligned} & 21 \\ & .3 \\ & 4 \end{aligned}$ | $\begin{aligned} & 22 \\ & .9 \\ & 4 \\ & \hline \end{aligned}$ |  |  |  | VVLHPNYSQVDIGLIK |
| $\begin{array}{\|l} \hline 854 . \\ 413 \\ 3 \\ \hline \end{array}$ |  |  |  | 2 | Pos <br> itiv <br> e | $\begin{aligned} & 18 \\ & .9 \end{aligned}$ | $\begin{aligned} & 20 \\ & .5 \end{aligned}$ |  |  |  | YVMLPVADQDQC[+57.0]IR |
| $\begin{aligned} & 772 . \\ & 362 \\ & 4 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & 17 \\ & .3 \\ & 5 \end{aligned}$ | $\begin{aligned} & 18 \\ & .9 \\ & 5 \\ & \hline \end{aligned}$ |  |  |  | VGYVSGWGQSDNFK |
| $\begin{array}{\|l} \hline 531 . \\ 818 \\ 9 \\ \hline \end{array}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \\ & \hline \end{aligned}$ | $\begin{aligned} & 21 \\ & .5 \\ & 9 \\ & \hline \end{aligned}$ | $\begin{aligned} & 23 \\ & .1 \\ & 9 \\ & \hline \end{aligned}$ |  |  |  | SALVLQYLR |
| $\begin{aligned} & \hline 671 . \\ & 337 \\ & 9 \\ & \hline \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \hline \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $\begin{aligned} & 23 \\ & .7 \\ & 2 \\ & \hline \end{aligned}$ | $\begin{aligned} & 25 \\ & .3 \\ & 2 \\ & \hline \end{aligned}$ |  |  |  | ETYDFDIAVLR |
| $\begin{aligned} & 440 . \\ & 256 \end{aligned}$ |  |  |  | 4 | $\begin{aligned} & \hline \text { Pos } \\ & \text { itiv } \\ & \text { e } \\ & \hline \end{aligned}$ | $\begin{aligned} & 21 \\ & .5 \\ & 9 \\ & \hline \end{aligned}$ | $\begin{aligned} & 24 \\ & .3 \\ & 5 \\ & \hline \end{aligned}$ |  |  |  | RPDSLQHVLLPVLDR |
| $\begin{aligned} & \hline 544 . \\ & 763 \\ & 3 \\ & \hline \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \hline \text { Pos } \\ & \text { itiv } \\ & \text { e } \\ & \hline \end{aligned}$ | $\begin{aligned} & 18 \\ & .8 \\ & 3 \\ & \hline \end{aligned}$ | $\begin{aligned} & 20 \\ & .4 \\ & 3 \\ & \hline \end{aligned}$ |  |  |  | WELC[+57.0]DIPR |
| $\begin{aligned} & \hline 619 . \\ & 323 \\ & 5 \\ & \hline \end{aligned}$ |  |  |  | 2 | Pos <br> itiv <br> e | $\begin{aligned} & 25 \\ & .0 \\ & 2 \end{aligned}$ | $\begin{aligned} & 26 \\ & .6 \\ & 2 \\ & \hline \end{aligned}$ |  |  |  | FVTWIEGVMR |
| $\begin{array}{\|l\|} \hline 860 . \\ 427 \\ 8 \\ \hline \end{array}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \\ & \hline \end{aligned}$ | $\begin{aligned} & 28 \\ & .1 \\ & 7 \\ & \hline \end{aligned}$ | $\begin{aligned} & 29 \\ & .7 \\ & 7 \end{aligned}$ |  |  |  | LTLQGIISWGSGC[+57.0]GDR |
| $\begin{array}{\|l} \hline 677 . \\ 022 \\ 9 \\ \hline \end{array}$ |  |  |  | 3 | Pos <br> itiv <br> e | $\begin{aligned} & 30 \\ & .5 \\ & 6 \\ & \hline \end{aligned}$ | $\begin{aligned} & 32 \\ & .1 \\ & 6 \\ & \hline \end{aligned}$ |  |  |  | NKPGVYTDVAYYLAWIR |
| $\begin{aligned} & 754 . \\ & 846 \\ & 8 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & 10 \\ & .3 \\ & 5 \end{aligned}$ | $\begin{aligned} & 11 \\ & .9 \\ & 5 \end{aligned}$ |  |  |  | VSEADSSNADWVTK |
| $\begin{aligned} & 708 . \\ & 350 \end{aligned}$ |  |  |  | 3 | Pos itiv | $\begin{aligned} & 17 \\ & .2 \end{aligned}$ | $\begin{aligned} & 18 \\ & .8 \\ & \hline \end{aligned}$ |  |  |  | YGQTIRPIC[+57.0]LPC[+57.0]T EGTTR |


| 6 |  |  |  |  | e | 9 | 9 |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{aligned} & 752 . \\ & 685 \\ & 8 \end{aligned}$ |  |  |  | 3 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $\begin{aligned} & 15 \\ & .6 \\ & 4 \end{aligned}$ | $\begin{aligned} & 17 \\ & .2 \\ & 4 \\ & \hline \end{aligned}$ |  |  |  | EIINVGHSFHVNFEDNDNR |
| $\begin{aligned} & 715 . \\ & 898 \\ & 1 \\ & \hline \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \hline \text { Pos } \\ & \text { itiv } \\ & \text { e } \\ & \hline \end{aligned}$ | $\begin{aligned} & 23 \\ & .3 \\ & 7 \\ & \hline \end{aligned}$ | $\begin{aligned} & 24 \\ & .9 \\ & 7 \\ & \hline \end{aligned}$ |  |  |  | VAEGTQVLELPFK |
| $\begin{aligned} & 411 . \\ & 580 \\ & 3 \end{aligned}$ |  |  |  | 3 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \\ & \hline \end{aligned}$ | $\begin{aligned} & 21 \\ & .5 \end{aligned}$ | $\begin{aligned} & 23 \\ & .1 \end{aligned}$ |  |  |  | ANRPFLVFIR |
| $\begin{aligned} & 538 . \\ & 812 \\ & 3 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \hline \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $\begin{aligned} & 24 \\ & .2 \\ & 3 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 25 \\ & .8 \\ & 3 \end{aligned}$ |  |  |  | LSSWVLLMK |
| $\begin{aligned} & 508 . \\ & 311 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & 18 \\ & .7 \\ & 8 \end{aligned}$ | $\begin{aligned} & \hline 20 \\ & .3 \\ & 8 \\ & \hline \end{aligned}$ |  |  |  | SVLGQLGITK |
| $\begin{aligned} & 697 . \\ & 843 \\ & 5 \\ & \hline \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \\ & \hline \end{aligned}$ | $\begin{aligned} & 15 \\ & .9 \\ & 7 \\ & \hline \end{aligned}$ | $\begin{aligned} & 17 \\ & .5 \\ & 7 \\ & \hline \end{aligned}$ |  |  |  | NEDSLVFVQTDK |
| $\begin{aligned} & 636 . \\ & 840 \\ & 1 \\ & \hline \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & 11 \\ & .4 \\ & 3 \end{aligned}$ | $\begin{aligned} & 13 \\ & .0 \\ & 3 \\ & \hline \end{aligned}$ |  |  |  | VTAAPQSVC[+57.0]ALR |
| $\begin{aligned} & 531 . \\ & 297 \\ & 5 \\ & \hline \end{aligned}$ |  |  |  | 2 | Pos itiv <br> e | $\begin{aligned} & 18 \\ & .3 \\ & 5 \end{aligned}$ | $\begin{aligned} & 19 \\ & .9 \\ & 5 \end{aligned}$ |  |  |  | EIGELYLPK |
| $\begin{aligned} & 480 . \\ & 759 \\ & 1 \end{aligned}$ |  |  |  | 2 | Pos itiv e | $\begin{aligned} & 10 \\ & .2 \\ & 7 \end{aligned}$ | $\begin{aligned} & 11 \\ & .8 \\ & 7 \end{aligned}$ |  |  |  | ADLSGITGAR |
| $\begin{aligned} & 862 . \\ & 014 \\ & 9 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \\ & \hline \end{aligned}$ | $\begin{aligned} & 31 \\ & .8 \\ & 6 \\ & \hline \end{aligned}$ | $\begin{aligned} & 33 \\ & .4 \\ & 6 \\ & \hline \end{aligned}$ |  |  |  | VLSALQAVQGLLVAQGR |
| $\begin{aligned} & 719 . \\ & 359 \end{aligned}$ |  |  |  | 2 | Pos <br> itiv <br> e | $\begin{aligned} & 21 \\ & .8 \\ & 2 \\ & \hline \end{aligned}$ | $\begin{aligned} & 23 \\ & .4 \\ & 2 \\ & \hline \end{aligned}$ |  |  |  | SLDFTELDVAAEK |
| $\begin{aligned} & 443 . \\ & 765 \\ & 8 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \\ & \hline \end{aligned}$ | $\begin{aligned} & 15 \\ & .9 \\ & 2 \\ & \hline \end{aligned}$ | $\begin{aligned} & 17 \\ & .5 \\ & 2 \\ & \hline \end{aligned}$ |  |  |  | ISLPESLK |
| $\begin{aligned} & 701 . \\ & 421 \\ & 2 \end{aligned}$ |  |  |  | 2 | Pos itiv e | $\begin{aligned} & 25 \\ & .5 \\ & 2 \\ & \hline \end{aligned}$ | $\begin{aligned} & 27 \\ & .1 \\ & 2 \\ & \hline \end{aligned}$ |  |  |  | SSLSVPYVIVPLK |
| $\begin{aligned} & 724 . \\ & 344 \\ & 2 \\ & \hline \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \hline \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $\begin{aligned} & 10 \\ & .1 \\ & 9 \\ & \hline \end{aligned}$ | $\begin{aligned} & 12 \\ & .1 \\ & 9 \\ & \hline \end{aligned}$ |  |  |  | IDTQDIEASHYR |
| $\begin{aligned} & 768 . \\ & 437 \\ & 6 \end{aligned}$ |  |  |  | 2 | Pos itiv e | 25 .4 7 | 27 .0 7 |  |  |  | VSITSITVENVFVK |


| $\begin{aligned} & 692 . \\ & 334 \\ & 3 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | 23 .3 9 | $\begin{aligned} & 24 \\ & .9 \\ & 9 \\ & \hline \end{aligned}$ |  |  | ENFLFLTPDC[+57.0]K |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{array}{\|l} \hline 515 . \\ 771 \\ 5 \\ \hline \end{array}$ |  |  |  | 2 | $\begin{aligned} & \hline \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $\begin{aligned} & 22 \\ & .2 \\ & 1 \end{aligned}$ | $\begin{aligned} & 23 \\ & .8 \\ & 1 \end{aligned}$ |  |  | YFIDFVAR |
| $\begin{aligned} & 906 . \\ & 929 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \hline \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $\begin{aligned} & 21 \\ & .5 \\ & 4 \end{aligned}$ | $\begin{aligned} & \hline 23 \\ & .1 \\ & 4 \end{aligned}$ |  |  | SC[+57.0]DLALLETYC[+57.0] <br> ATPAK |
| $\begin{aligned} & 695 . \\ & 310 \\ & 1 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \hline \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $\begin{aligned} & 6 . \\ & 7 \end{aligned}$ | $\begin{aligned} & 9 . \\ & 4 . \end{aligned}$ |  |  | SSEDPNEDIVER |
| $\begin{array}{\|l} \hline 469 . \\ 792 \\ 7 \\ \hline \end{array}$ |  |  |  | 2 | Pos <br> itiv <br> e | $\begin{aligned} & 12 \\ & .9 \\ & 8 \\ & \hline \end{aligned}$ | $\begin{aligned} & 14 \\ & .7 \\ & 8 \\ & \hline \end{aligned}$ |  |  | IIVPLNNR |
| $\begin{aligned} & 874 . \\ & 464 \\ & 9 \\ & \hline \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & 21 \\ & .5 \\ & 8 \\ & \hline \end{aligned}$ | $\begin{aligned} & 23 \\ & .1 \\ & 8 \\ & \hline \end{aligned}$ |  |  | LLIYDASNLETGVPSR |
| $\begin{aligned} & 490 . \\ & 282 \\ & 2 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $\begin{aligned} & 12 \\ & .7 \\ & 2 \\ & \hline \end{aligned}$ | $\begin{aligned} & 14 \\ & .3 \\ & 2 \\ & \hline \end{aligned}$ |  |  | LLIYGASSR |
| $\begin{aligned} & 458 . \\ & 256 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $\begin{aligned} & 16 \\ & .1 \\ & 5 \end{aligned}$ | $\begin{aligned} & 17 \\ & .7 \\ & 5 \end{aligned}$ |  |  | IWLDNVR |
| $\begin{aligned} & \hline 721 . \\ & 429 \\ & 9 \\ & \hline \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $29$ | $\begin{aligned} & 30 \\ & .7 \end{aligned}$ |  |  | IALGGLLFPASNLR |
| $\begin{array}{\|l} \hline 702 . \\ 343 \\ 7 \\ \hline \end{array}$ |  |  |  | 2 | Pos <br> itiv <br> e | $\begin{aligned} & 23 \\ & .3 \\ & 3 \\ & \hline \end{aligned}$ | $\begin{aligned} & 24 \\ & .9 \\ & 3 \\ & \hline \end{aligned}$ |  |  | EATSTFTNITYR |
| $\begin{array}{\|l} \hline 727 . \\ 046 \\ 7 \\ \hline \end{array}$ |  |  |  | 3 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \end{aligned}$ | $\begin{aligned} & 21 \\ & .6 \\ & 5 \\ & \hline \end{aligned}$ | $\begin{aligned} & 23 \\ & .2 \\ & 5 \end{aligned}$ |  |  | GQIHLDPQQDYQLLQVQR |
| $\begin{aligned} & 624 . \\ & 335 \\ & 2 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $\begin{aligned} & 24 \\ & .1 \\ & 4 \end{aligned}$ | $\begin{aligned} & 25 \\ & .7 \\ & 4 \end{aligned}$ |  |  | ITLPDFTGDLR |
| $\begin{aligned} & \hline 646 . \\ & 011 \\ & 8 \end{aligned}$ |  |  |  | 3 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & 32 \\ & .1 \\ & 2 \end{aligned}$ | $\begin{aligned} & 33 \\ & .7 \\ & 2 \end{aligned}$ |  |  | SPVTLLAAVMSLPEEHNK |
| $\begin{aligned} & 900 . \\ & 458 \\ & 5 \end{aligned}$ |  |  |  | 3 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $\begin{aligned} & 34 \\ & .4 \\ & 3 \end{aligned}$ | $\begin{aligned} & 36 \\ & .0 \\ & 3 \end{aligned}$ |  |  | LGC[+57.0]EVLGVSVDSQFTH LAWINTPR |
| $\begin{aligned} & 741 . \\ & 354 \end{aligned}$ |  |  |  | 6 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \end{aligned}$ | $\begin{aligned} & 34 \\ & .4 \\ & 5 \end{aligned}$ | $\begin{aligned} & 36 \\ & .0 \\ & 5 \end{aligned}$ |  |  | LVQAFQYTDEHGEVC[+57.0]P AGWKPGSDTIKPNVDDSKEY FSK |
| 604. |  |  |  | 2 | Pos | 16 | 18 |  |  | TAAENDFVTLK |


| $\begin{aligned} & 811 \\ & 5 \\ & \hline \end{aligned}$ |  |  |  |  | $\begin{array}{\|l\|} \hline \text { itiv } \\ \mathrm{e} \end{array}$ | .9 6 | . 5 |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{aligned} & 730 . \\ & 903 \\ & 4 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \end{aligned}$ | $\begin{aligned} & 34 \\ & .5 \\ & 3 \\ & \hline \end{aligned}$ | $\begin{aligned} & 36 \\ & .1 \\ & 3 \end{aligned}$ |  |  |  | VDLLNQEIEFLK |
| $\begin{aligned} & 692 . \\ & 310 \\ & 8 \end{aligned}$ |  |  |  | 2 | $\begin{array}{\|l} \hline \text { Pos } \\ \text { itiv } \\ \mathrm{e} \\ \hline \end{array}$ | $\begin{aligned} & 21 \\ & .5 \\ & 9 \end{aligned}$ | $\begin{aligned} & 23 \\ & .1 \\ & 9 \end{aligned}$ |  |  |  | GASQAGMTGYGMPR |
| $\begin{aligned} & 807 . \\ & 387 \end{aligned}$ |  |  |  | 2 | Pos itiv e | $\begin{aligned} & 22 \\ & .9 \\ & 5 \end{aligned}$ | $\begin{aligned} & 24 \\ & .5 \\ & 5 \\ & \hline \end{aligned}$ |  |  |  | NALWHTGDTESQVR |
| $\begin{aligned} & 652 . \\ & 805 \\ & 6 \end{aligned}$ |  |  |  | 2 | $\begin{array}{\|l\|} \hline \text { Pos } \\ \text { itiv } \\ \mathrm{e} \\ \hline \end{array}$ | $\begin{aligned} & 12 \\ & .8 \\ & 3 \end{aligned}$ | $\begin{aligned} & 14 \\ & .4 \\ & 3 \\ & \hline \end{aligned}$ |  |  |  | S[+42.0]DKPDMAEIEK |
| $\begin{aligned} & 564 . \\ & 767 \\ & 6 \\ & \hline \end{aligned}$ |  |  |  | 2 | $\begin{array}{\|l} \hline \text { Pos } \\ \text { itiv } \\ \mathrm{e} \\ \hline \end{array}$ | $\begin{aligned} & 12 \\ & .8 \\ & 5 \\ & \hline \end{aligned}$ | $\begin{aligned} & 14 \\ & .6 \\ & 5 \\ & \hline \end{aligned}$ |  |  |  | ENAGEDPGLAR |
| $\begin{aligned} & 733 . \\ & 027 \\ & 1 \end{aligned}$ |  |  |  | 3 | Pos <br> itiv <br> e | $\begin{aligned} & 21 \\ & .5 \\ & 9 \end{aligned}$ | $\begin{aligned} & 23 \\ & .1 \\ & 9 \\ & \hline \end{aligned}$ |  |  |  | $\begin{aligned} & \text { STDTSC[+57.0]VNPPTVQNAH } \\ & \text { ILSR } \end{aligned}$ |
| $\begin{aligned} & 791 . \\ & 887 \\ & 8 \\ & \hline \end{aligned}$ |  |  |  | 2 | $\begin{array}{\|l\|} \hline \text { Pos } \\ \text { itiv } \\ \text { e } \\ \hline \end{array}$ | $\begin{aligned} & 15 \\ & .9 \\ & 5 \\ & \hline \end{aligned}$ | $\begin{aligned} & 17 \\ & .5 \\ & 5 \\ & \hline \end{aligned}$ |  |  |  | GQC[+57.0]LITQSPPYYR |
| $\begin{aligned} & 658 . \\ & 402 \\ & 8 \\ & \hline \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $\begin{aligned} & 30 \\ & .1 \\ & 9 \\ & \hline \end{aligned}$ | $\begin{aligned} & 31 \\ & .7 \\ & 9 \\ & \hline \end{aligned}$ |  |  |  | LTLLAPLNSVFK |
| $\begin{aligned} & 577 . \\ & 761 \end{aligned}$ |  |  |  | 2 | Pos <br> itiv <br> e | $\begin{aligned} & 10 \\ & .8 \end{aligned}$ | $\begin{aligned} & 12 \\ & .8 \end{aligned}$ |  |  |  | TGDAVEFQC[+57.0]K |
| $\begin{aligned} & 521 . \\ & 282 \\ & 4 \\ & \hline \end{aligned}$ |  |  |  | 2 | Pos itiv e | $\begin{aligned} & 25 \\ & .6 \\ & 2 \\ & \hline \end{aligned}$ | $\begin{aligned} & 27 \\ & .2 \\ & 2 \\ & \hline \end{aligned}$ |  |  |  | EAEPLVDIR |
| $\begin{aligned} & 883 . \\ & 993 \\ & 6 \\ & \hline \end{aligned}$ |  |  |  | 2 | $\begin{array}{\|l\|} \hline \text { Pos } \\ \text { itiv } \\ \text { e } \\ \hline \end{array}$ | $\begin{aligned} & 25 \\ & .2 \\ & 4 \\ & \hline \end{aligned}$ | $\begin{aligned} & 26 \\ & .8 \\ & 4 \\ & \hline \end{aligned}$ |  |  |  | IAIIGAGIGGTSAAYYLR |
| $\begin{aligned} & 646 . \\ & 285 \\ & 2 \end{aligned}$ |  |  |  | 2 | Pos itiv e | $\begin{aligned} & 22 \\ & .1 \\ & 8 \end{aligned}$ | $\begin{aligned} & 23 \\ & .7 \\ & 8 \end{aligned}$ |  |  |  | SPFAYC[+57.0]M[+16.0]MIR |
| $\begin{aligned} & 610 . \\ & 335 \\ & 7 \\ & \hline \end{aligned}$ |  |  |  | 2 | Pos <br> itiv <br> e | $\begin{aligned} & 15 \\ & .6 \\ & 2 \\ & \hline \end{aligned}$ | $\begin{aligned} & 17 \\ & .2 \\ & 2 \\ & \hline \end{aligned}$ |  |  |  | SGTSASLAISGLR |
| $\begin{aligned} & 786 . \\ & 055 \\ & 8 \\ & \hline \end{aligned}$ |  |  |  | 3 | Pos <br> itiv <br> e | $\begin{aligned} & 13 \\ & .9 \\ & 6 \end{aligned}$ | $\begin{aligned} & 15 \\ & .5 \\ & 6 \end{aligned}$ |  |  |  | $\begin{aligned} & \text { PGSAPTTVIYEDNQRPSGVPD } \\ & \text { R } \end{aligned}$ |
| $\begin{aligned} & 676 . \\ & 853 \\ & \hline \end{aligned}$ |  |  |  | 2 | $\begin{array}{\|l} \hline \text { Pos } \\ \text { itiv } \\ \hline \end{array}$ | $\begin{aligned} & 18 \\ & .9 \\ & \hline \end{aligned}$ | $\begin{aligned} & 20 \\ & .5 \\ & \hline \end{aligned}$ |  |  |  | NTLYLQMNSLR |


| 2 |  |  |  |  | e | 6 | 6 |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{aligned} & 645 . \\ & 787 \\ & 2 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $8 .$ | $\begin{aligned} & 10 \\ & .4 \end{aligned}$ |  |  |  | AEDTAVYYC[+57.0]AK |
| $\begin{aligned} & 515 . \\ & 29 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & 19 \\ & .8 \\ & 8 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 21 \\ & .4 \\ & 8 \\ & \hline \end{aligned}$ |  |  |  | GLEWVANIK |
| $\begin{aligned} & 659 . \\ & 790 \\ & 3 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & 7 . \\ & 9 \end{aligned}$ | $\begin{aligned} & 10 \\ & .9 \end{aligned}$ |  |  |  | AEDTAVYYC[+57.0]AR |
| $\begin{aligned} & 899 . \\ & 451 \\ & 3 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & 29 \\ & .1 \\ & 7 \\ & \hline \end{aligned}$ | $\begin{aligned} & 30 \\ & .7 \\ & 7 \\ & \hline \end{aligned}$ |  |  |  | SGTASVVC[+57.0]LLNNFYPR |
| $\begin{aligned} & 625 . \\ & 980 \\ & 5 \\ & \hline \end{aligned}$ |  |  |  | 3 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $\begin{aligned} & 12 \\ & .5 \\ & 2 \\ & \hline \end{aligned}$ | $\begin{aligned} & 14 \\ & .1 \\ & 2 \\ & \hline \end{aligned}$ |  |  |  | $\begin{aligned} & \text { VYAC[+57.0]EVTHQGLSSPVT } \\ & \text { K } \end{aligned}$ |
| $\begin{aligned} & 593 . \\ & 827 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & 17 \\ & .8 \\ & 6 \end{aligned}$ | $\begin{aligned} & 19 \\ & .4 \\ & 6 \end{aligned}$ |  |  |  | GPSVFPLAPSSK |
| $\begin{aligned} & 713 . \\ & 680 \\ & 7 \end{aligned}$ |  |  |  | 3 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \\ & \hline \end{aligned}$ | $\begin{aligned} & 19 \\ & .8 \\ & 9 \\ & \hline \end{aligned}$ | $\begin{aligned} & 21 \\ & .4 \\ & 9 \\ & \hline \end{aligned}$ |  |  |  | TPEVTC[+57.0]VVVDVSHEDP EVK |
| $\begin{aligned} & 598 . \\ & 668 \\ & 5 \\ & \hline \end{aligned}$ |  |  |  | 3 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & 25 \\ & .3 \\ & 1 \\ & \hline \end{aligned}$ | $\begin{aligned} & 26 \\ & .9 \\ & 1 \\ & \hline \end{aligned}$ |  |  |  | VVSVLTVVHQDWLNGK |
| $\begin{aligned} & 824 . \\ & 487 \\ & 6 \\ & \hline \end{aligned}$ |  |  |  | 1 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $\begin{aligned} & 10 \\ & .1 \end{aligned}$ | $\begin{aligned} & 12 \\ & .2 \end{aligned}$ |  |  |  | GLPAPIEK |
| $\begin{aligned} & 452 . \\ & 550 \\ & 6 \\ & \hline \end{aligned}$ |  |  |  | 3 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & 3 . \\ & 76 \end{aligned}$ | $\begin{aligned} & 5 . \\ & 36 \end{aligned}$ |  |  |  | TPLGDTTHTC[+57.0]PR |
| $\begin{aligned} & 805 . \\ & 389 \\ & 7 \\ & \hline \end{aligned}$ |  |  |  | 3 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \\ & \hline \end{aligned}$ | $\begin{aligned} & 22 \\ & .9 \\ & 8 \\ & \hline \end{aligned}$ | $\begin{aligned} & 24 \\ & .5 \\ & 8 \\ & \hline \end{aligned}$ |  |  |  | TPEVTC[+57.0]VVVDVSHEDP EVQFK |
| $\begin{aligned} & 415 . \\ & 734 \\ & 5 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & 7 . \\ & 6 \end{aligned}$ | $\begin{aligned} & 10 \\ & .4 \end{aligned}$ |  |  |  | GLPSSIEK |
| $\begin{aligned} & 639 . \\ & 358 \\ & 6 \\ & \hline \end{aligned}$ |  |  |  | 2 | Pos <br> itiv <br> e | $\begin{aligned} & 14 \\ & .2 \\ & 2 \\ & \hline \end{aligned}$ | $\begin{aligned} & 15 \\ & .8 \\ & 2 \\ & \hline \end{aligned}$ |  |  |  | YAATSQVLLPSK |
| $\begin{aligned} & 819 . \\ & 468 \\ & 7 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & 34 \\ & .1 \\ & 5 \end{aligned}$ | $\begin{aligned} & 35 \\ & .7 \\ & 5 \end{aligned}$ |  |  |  | VFAIPPSFASIFLTK |
| $\begin{aligned} & 770 . \\ & 867 \\ & 6 \end{aligned}$ |  |  |  | 2 | Pos <br> itiv <br> e | 18 <br> .5 <br> 5 | 20 .1 5 |  |  |  | DASGVTFTWTPSSGK |



| $\begin{aligned} & 870 \\ & 6 \end{aligned}$ |  |  |  |  | $\begin{aligned} & \text { itiv } \\ & \mathrm{e} \end{aligned}$ | .8 3 | .4 3 |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{aligned} & 815 . \\ & 416 \\ & 9 \\ & \hline \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $\begin{aligned} & 26 \\ & .1 \\ & 5 \end{aligned}$ | $\begin{aligned} & 27 \\ & .7 \\ & 5 \end{aligned}$ |  |  |  | DSHSLTTNIMEILR |
| $\begin{aligned} & 462 . \\ & 250 \\ & 9 \end{aligned}$ |  |  |  | 2 | $\begin{array}{\|l} \hline \text { Pos } \\ \text { itiv } \\ \mathrm{e} \\ \hline \end{array}$ | $\begin{aligned} & \hline 3 . \\ & 68 \end{aligned}$ | $\begin{aligned} & 5 . \\ & 28 \end{aligned}$ |  |  |  | TVIGPDGHK |
| $\begin{aligned} & 809 . \\ & 9 \end{aligned}$ |  |  |  | 2 | $\begin{array}{\|l\|} \hline \text { Pos } \\ \text { itiv } \\ \text { e } \\ \hline \end{array}$ | $\begin{aligned} & 15 \\ & .1 \\ & 6 \\ & \hline \end{aligned}$ | $\begin{aligned} & 16 \\ & .7 \\ & 6 \\ & \hline \end{aligned}$ |  |  |  | $\begin{aligned} & \hline \text { TPC[+57.0]TVSC[+57.0]NIPVV } \\ & \text { SGK } \end{aligned}$ |
| $\begin{aligned} & 893 . \\ & 398 \\ & 7 \\ & \hline \end{aligned}$ |  |  |  | 2 | Pos <br> itiv <br> e | $\begin{aligned} & 22 \\ & .0 \\ & 8 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 23 \\ & .6 \\ & 8 \\ & \hline \end{aligned}$ |  |  |  | NYC[+57.0]GLPGEYWLGNDK |
| $\begin{aligned} & 512 . \\ & 579 \\ & 4 \end{aligned}$ |  |  |  | 3 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \end{aligned}$ | $\begin{aligned} & 7 . \\ & 47 \end{aligned}$ | $\begin{aligned} & 9 . \\ & 9 \end{aligned}$ |  |  |  | AHYGGFTVQNEANK |
| $\begin{aligned} & 757 . \\ & 367 \\ & 7 \\ & \hline \end{aligned}$ |  |  |  | 2 | $\begin{array}{\|l\|} \hline \text { Pos } \\ \text { itiv } \\ \text { e } \\ \hline \end{array}$ | $\begin{aligned} & 11 \\ & .0 \\ & 8 \\ & \hline \end{aligned}$ | $\begin{aligned} & 12 \\ & .6 \\ & 8 \\ & \hline \end{aligned}$ |  |  |  | YLQEIYNSNNQK |
| $\begin{aligned} & 736 . \\ & 351 \\ & 6 \end{aligned}$ |  |  |  | 3 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $\begin{aligned} & 23 \\ & .2 \\ & 8 \\ & \hline \end{aligned}$ | $\begin{aligned} & 24 \\ & .8 \\ & 8 \\ & \hline \end{aligned}$ |  |  |  | EGFGHLSPTGTTEFWLGNEK |
| $\begin{aligned} & 745 . \\ & 903 \\ & 7 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $\begin{aligned} & 27 \\ & .4 \\ & 5 \end{aligned}$ | $\begin{aligned} & 29 \\ & .0 \\ & 5 \end{aligned}$ |  |  |  | ADFLEQPVLGFVR |
| $\begin{aligned} & 697 . \\ & 351 \\ & 5 \end{aligned}$ |  |  |  | 2 | $\begin{array}{\|l\|} \hline \text { Pos } \\ \text { itiv } \\ \mathrm{e} \\ \hline \end{array}$ | $\begin{aligned} & 10 \\ & .2 \\ & 8 \\ & \hline \end{aligned}$ | $\begin{aligned} & 11 \\ & .8 \\ & 8 \end{aligned}$ |  |  |  | IVLGQEQDSYG |
| $\begin{aligned} & 643 . \\ & 897 \\ & 2 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & 30 \\ & .2 \\ & 1 \end{aligned}$ | $\begin{aligned} & 31 \\ & .8 \\ & 1 \end{aligned}$ |  |  |  | GYVIIKPLVWV |
| $\begin{aligned} & 381 . \\ & 218 \\ & 9 \\ & \hline \end{aligned}$ |  |  |  | 2 | $\begin{array}{\|l} \hline \text { Pos } \\ \text { itiv } \\ \mathrm{e} \\ \hline \end{array}$ | $\begin{aligned} & 9 . \\ & 8 \end{aligned}$ | $\begin{aligned} & 11 \\ & .8 \end{aligned}$ |  |  |  | PAFSAIR |
| $\begin{aligned} & 571 . \\ & 761 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \\ & \hline \end{aligned}$ | $\begin{aligned} & 9 . \\ & 6 \end{aligned}$ | $\begin{aligned} & 11 \\ & .6 \end{aligned}$ |  |  |  | SLGFC[+57.0]DTTNK |
| $\begin{aligned} & 621 . \\ & 952 \\ & 9 \\ & \hline \end{aligned}$ |  |  |  | 3 | Pos <br> itiv <br> e | 14 .0 4 | $\begin{aligned} & 15 \\ & .6 \\ & 4 \\ & \hline \end{aligned}$ |  |  |  | FDHVITNMNNNYEPR |
| $\begin{aligned} & 538 . \\ & 770 \\ & 6 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \end{aligned}$ | $\begin{aligned} & 15 \\ & .9 \\ & 3 \end{aligned}$ | $\begin{aligned} & 17 \\ & .5 \\ & 3 \end{aligned}$ |  |  |  | GNLC[+57.0]VNLMR |
| $\begin{aligned} & 542 . \\ & 792 \\ & \hline \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \end{aligned}$ | 17 | 18 .6 |  |  |  | FQSVFTVTR |


| 9 |  |  |  |  | e |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{aligned} & 721 . \\ & 381 \end{aligned}$ |  |  |  | 2 | Pos itiv e | $\begin{aligned} & 13 \\ & .8 \\ & 8 \end{aligned}$ | $\begin{aligned} & 15 \\ & .4 \\ & 8 \end{aligned}$ |  |  |  | Q[-17.0]THQPPAPNSLIR |
| $\begin{aligned} & \hline 629 . \\ & 349 \\ & 1 \\ & \hline \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $\begin{aligned} & 11 \\ & .4 \\ & 8 \end{aligned}$ | $\begin{aligned} & \hline 13 \\ & .0 \\ & 8 \end{aligned}$ |  |  |  | TNQVNSGGVLLR |
| $\begin{aligned} & 516 . \\ & 272 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \hline \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | 4 | $\begin{aligned} & 5 . \\ & 6 \end{aligned}$ |  |  |  | VVEESELAR |
| $\begin{aligned} & \hline 788 . \\ & 927 \\ & 7 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $\begin{aligned} & 22 \\ & .3 \\ & 4 \end{aligned}$ | $\begin{aligned} & \hline 23 \\ & .9 \\ & 4 \end{aligned}$ |  |  |  | RPWNVASLIYETK |
| $\begin{aligned} & \hline 728 . \\ & 359 \\ & 4 \\ & \hline \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \hline \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $\begin{aligned} & 23 \\ & .3 \\ & 7 \\ & \hline \end{aligned}$ | $\begin{aligned} & 24 \\ & .9 \\ & 7 \end{aligned}$ |  |  |  | AIEDYINEFSVR |
| $\begin{aligned} & 886 . \\ & 992 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $\begin{aligned} & 33 \\ & .1 \\ & 5 \\ & \hline \end{aligned}$ | $\begin{aligned} & 34 \\ & .7 \\ & 5 \\ & \hline \end{aligned}$ |  |  |  | FIC[+57.0]PLTGLWPINTLK |
| $\begin{aligned} & \hline 796 . \\ & 003 \\ & 6 \\ & \hline \end{aligned}$ |  |  |  | 3 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | 17 | $\begin{aligned} & 18 \\ & .6 \end{aligned}$ |  |  |  | $\begin{aligned} & \text { ATFGC[+57.0]HDGYSLDGPEEI } \\ & \text { EC }[+57.0] \mathrm{TK} \end{aligned}$ |
| $\begin{aligned} & 740 . \\ & 655 \\ & 5 \end{aligned}$ |  |  |  | 4 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & 28 \\ & .3 \\ & 7 \\ & \hline \end{aligned}$ | $\begin{aligned} & 29 \\ & .9 \\ & 7 \\ & \hline \end{aligned}$ |  |  |  | LQELHLSSNGLESLSPEFLRPV PQLR |
| $\begin{aligned} & 590 . \\ & 340 \\ & 2 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $\begin{aligned} & 21 \\ & .8 \\ & 9 \\ & \hline \end{aligned}$ | $\begin{aligned} & 23 \\ & .4 \\ & 9 \\ & \hline \end{aligned}$ |  |  |  | DLLLPQPDLR |
| $\begin{aligned} & \hline 829 . \\ & 041 \\ & 1 \\ & \hline \end{aligned}$ |  |  |  | 3 | $\begin{aligned} & \hline \text { Pos } \\ & \text { itiv } \\ & \text { e } \\ & \hline \end{aligned}$ | $\begin{aligned} & 29 \\ & .3 \end{aligned}$ | $\begin{aligned} & 30 \\ & .9 \end{aligned}$ |  |  |  | $\begin{aligned} & \text { DGFDISGNPWIC[+57.0]DQNL } \\ & \text { SDLYR } \end{aligned}$ |
| $\begin{aligned} & 904 . \\ & 456 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \\ & \hline \end{aligned}$ | $\begin{aligned} & 23 \\ & .3 \\ & 7 \\ & \hline \end{aligned}$ | $\begin{aligned} & 24 \\ & .9 \\ & 7 \\ & \hline \end{aligned}$ |  |  |  | VTIMWTPPESAVTGYR |
| $\begin{aligned} & 555 . \\ & 774 \\ & 9 \\ & \hline \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \\ & \hline \end{aligned}$ | $\begin{aligned} & 10 \\ & .2 \\ & 7 \\ & \hline \end{aligned}$ | $\begin{aligned} & 11 \\ & .8 \\ & 7 \\ & \hline \end{aligned}$ |  |  |  | STTPDITGYR |
| $\begin{array}{\|l} \hline 678 . \\ 351 \\ 3 \\ \hline \end{array}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \\ & \hline \end{aligned}$ | $\begin{aligned} & 18 \\ & .0 \\ & 9 \\ & \hline \end{aligned}$ | $\begin{aligned} & 19 \\ & .6 \\ & 9 \\ & \hline \end{aligned}$ |  |  |  | IYLYTLNDNAR |
| $\begin{aligned} & \hline 898 . \\ & 378 \\ & 5 \\ & \hline \end{aligned}$ |  |  |  | 3 | $\begin{aligned} & \hline \text { Pos } \\ & \text { itiv } \\ & \text { e } \\ & \hline \end{aligned}$ | $\begin{aligned} & 21 \\ & .5 \\ & 7 \\ & \hline \end{aligned}$ | $\begin{aligned} & 23 \\ & .1 \\ & 7 \\ & \hline \end{aligned}$ |  |  |  | GNDDHWIVDTDYDTYAVQYS C [ +57.0$] \mathrm{R}$ |
| 688. <br> 994 <br> 7 |  |  |  | 3 | Pos <br> itiv <br> e | 27 <br> .4 <br> 2 | 29 .0 2 |  |  |  | $\begin{aligned} & \text { LLNLDGTC[+57.0]ADSYSFVF } \\ & \text { SR } \end{aligned}$ |


| $\begin{aligned} & 704 . \\ & 884 \\ & 8 \end{aligned}$ |  |  |  | 2 | $\begin{array}{\|l} \hline \text { Pos } \\ \text { itiv } \\ \mathrm{e} \\ \hline \end{array}$ | $\begin{aligned} & 30 \\ & .2 \\ & 8 \end{aligned}$ | $\begin{aligned} & \hline 31 \\ & .8 \\ & 8 \end{aligned}$ |  |  | AFIQLWAFDAVK |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{aligned} & 854 . \\ & 877 \\ & 8 \\ & \hline \end{aligned}$ |  |  |  | 2 | Pos <br> itiv <br> e | $\begin{aligned} & 17 \\ & .3 \end{aligned}$ | $\begin{aligned} & 18 \\ & .9 \end{aligned}$ |  |  | EYC[+57.0]GVPGDGDEELLR |
| $\begin{aligned} & 876 . \\ & 980 \\ & 8 \end{aligned}$ |  |  |  | 2 | $\begin{array}{\|l} \hline \text { Pos } \\ \text { itiv } \\ \mathrm{e} \\ \hline \end{array}$ | $\begin{aligned} & 19 \\ & .9 \end{aligned}$ | $\begin{aligned} & 21 \\ & .5 \end{aligned}$ |  |  | YVGGQEHFAHLLILR |
| $\begin{aligned} & 871 . \\ & 906 \\ & 3 \\ & \hline \end{aligned}$ |  |  |  | 2 | Pos itiv e | $\begin{aligned} & 27 \\ & .4 \\ & 3 \end{aligned}$ | $\begin{aligned} & 29 \\ & .0 \\ & 3 \\ & \hline \end{aligned}$ |  |  | EQLGEFYEALDC[+57.0]L |
| $\begin{aligned} & 598 . \\ & 817 \\ & 1 \end{aligned}$ |  |  |  | 2 | $\begin{array}{\|l\|} \hline \text { Pos } \\ \text { itiv } \\ \text { e } \\ \hline \end{array}$ | $\begin{aligned} & 3 . \\ & 98 \end{aligned}$ | $\begin{aligned} & 6 . \\ & 98 \end{aligned}$ |  |  | HTLNQIDEVK |
| $\begin{aligned} & 672 . \\ & 694 \\ & 7 \\ & \hline \end{aligned}$ |  |  |  | 3 | $\begin{array}{\|l\|} \hline \text { Pos } \\ \text { itiv } \\ \mathrm{e} \\ \hline \end{array}$ | $\begin{aligned} & 17 \\ & .1 \end{aligned}$ | $\begin{aligned} & 19 \\ & .1 \end{aligned}$ |  |  | TVVQPSVGAAAGPVVPPC[+5 7.0]PGR |
| $\begin{aligned} & 789 . \\ & 427 \\ & 1 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $\begin{aligned} & 18 \\ & .0 \\ & 8 \\ & \hline \end{aligned}$ | $\begin{aligned} & 19 \\ & .6 \\ & 8 \\ & \hline \end{aligned}$ |  |  | AGPHC[+57.0]PTAQLIATL |
| $\begin{aligned} & 683 . \\ & 883 \\ & 1 \end{aligned}$ |  |  |  | 2 | $\begin{array}{\|l\|} \hline \text { Pos } \\ \text { itiv } \\ \mathrm{e} \\ \hline \end{array}$ | $\begin{aligned} & 18 \\ & .7 \\ & 2 \\ & \hline \end{aligned}$ | $\begin{aligned} & 20 \\ & .3 \\ & 2 \\ & \hline \end{aligned}$ |  |  | GSPAINVAVHVFR |
| $\begin{aligned} & 697 . \\ & 814 \\ & 8 \\ & \hline \end{aligned}$ |  |  |  | 2 | Pos <br> itiv <br> e | $\begin{aligned} & 17 \\ & .5 \\ & 3 \\ & \hline \end{aligned}$ | $\begin{aligned} & 19 \\ & .1 \\ & 3 \\ & \hline \end{aligned}$ |  |  | AADDTWEPFASGK |
| $\begin{aligned} & 476 . \\ & 224 \\ & 5 \\ & \hline \end{aligned}$ |  |  |  | 2 | Pos <br> itiv <br> e | $\begin{aligned} & 9 . \\ & 3 . \end{aligned}$ | $\begin{aligned} & \hline 11 \\ & .3 \end{aligned}$ |  |  | DLGEENFK |
| $\begin{aligned} & 829 . \\ & 38 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \end{aligned}$ | $\begin{aligned} & 21 \\ & .1 \\ & 4 \end{aligned}$ | $\begin{aligned} & 22 \\ & .7 \\ & 4 \end{aligned}$ |  |  | QNC[+57.0]ELFEQLGEYK |
| $\begin{aligned} & 500 . \\ & 805 \\ & 5 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \end{aligned}$ | $\begin{aligned} & 16 \\ & .5 \\ & 6 \end{aligned}$ | $\begin{aligned} & 18 \\ & .1 \\ & 6 \end{aligned}$ |  |  | QTALVELVK |
| $\begin{aligned} & 840 . \\ & 010 \\ & 4 \end{aligned}$ |  |  |  | 3 | Pos itiv e | $\begin{aligned} & 17 \\ & .2 \\ & 3 \end{aligned}$ | $\begin{aligned} & 18 \\ & .8 \\ & \hline \end{aligned}$ |  |  | EVVSLTEAC[+57.0]C[+57.0]AE GADPDC[+57.0]YDTR |
| $\begin{aligned} & 789 . \\ & 428 \\ & 2 \\ & \hline \end{aligned}$ |  |  |  | 3 | Pos <br> itiv <br> e | $\begin{aligned} & 35 \\ & .0 \\ & 9 \\ & \hline \end{aligned}$ | $\begin{aligned} & 36 \\ & .6 \\ & 9 \\ & \hline \end{aligned}$ |  |  | VPTADLEDVLPLAEDITNILSK |
| $\begin{aligned} & 550 . \\ & 819 \\ & 1 \\ & \hline \end{aligned}$ |  |  |  | 2 | Pos itiv e | 16 | $\begin{aligned} & 17 \\ & .6 \end{aligned}$ |  |  | NIQSLEVIGK |
| 708. |  |  |  | 2 | Pos | 14 | 16 |  |  | SVIPSDGPSVAC[+57.0]VK |


| $\begin{aligned} & 363 \\ & 6 \\ & \hline \end{aligned}$ |  |  |  |  | $\begin{aligned} & \text { itiv } \\ & \text { e } \end{aligned}$ | . 9 | . 5 |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{aligned} & 815 . \\ & 411 \\ & 6 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & 23 \\ & .0 \\ & 7 \\ & \hline \end{aligned}$ | $\begin{aligned} & 24 \\ & .6 \\ & 7 \\ & \hline \end{aligned}$ |  |  |  | EDPQTFYYAVAVVK |
| $\begin{aligned} & 748 . \\ & 343 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \\ & \hline \end{aligned}$ | $\begin{aligned} & 19 \\ & .2 \\ & 2 \\ & \hline \end{aligned}$ | $\begin{aligned} & 20 \\ & .8 \\ & 2 \\ & \hline \end{aligned}$ |  |  |  | YYC[+57.0]FQGNQFLR |
| $\begin{aligned} & 487 . \\ & 278 \\ & 9 \\ & \hline \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & 28 \\ & .5 \\ & 7 \\ & \hline \end{aligned}$ | $\begin{aligned} & 30 \\ & .1 \\ & 7 \\ & \hline \end{aligned}$ |  |  |  | LWWLDLK |
| $\begin{aligned} & 462 . \\ & 250 \\ & 9 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & 13 \\ & .9 \\ & 4 \\ & \hline \end{aligned}$ | $\begin{aligned} & 15 \\ & .5 \\ & 4 \end{aligned}$ |  |  |  | GGISGYTLR |
| $\begin{aligned} & 730 . \\ & 362 \\ & 4 \\ & \hline \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \\ & \hline \end{aligned}$ | $\begin{aligned} & 12 \\ & .2 \\ & 7 \\ & \hline \end{aligned}$ | $\begin{aligned} & 13 \\ & .8 \\ & 7 \\ & \hline \end{aligned}$ |  |  |  | IAYGTQGSSGYSLR |
| $\begin{aligned} & 703 . \\ & 348 \\ & 3 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \\ & \hline \end{aligned}$ | $\begin{aligned} & 18 \\ & .2 \\ & 9 \\ & \hline \end{aligned}$ | $\begin{aligned} & 19 \\ & .8 \\ & 9 \\ & \hline \end{aligned}$ |  |  |  | LVGITSWGEGC[+57.0]AR |
| $\begin{aligned} & 791 . \\ & 359 \\ & 4 \\ & \hline \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \\ & \hline \end{aligned}$ | $\begin{aligned} & 15 \\ & .8 \\ & 9 \\ & \hline \end{aligned}$ | $\begin{aligned} & 17 \\ & .4 \\ & 9 \\ & \hline \end{aligned}$ |  |  |  | FSAIC[+57.0]QGDGTWSPR |
| $\begin{aligned} & 735 . \\ & 911 \\ & 8 \\ & \hline \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \\ & \hline \end{aligned}$ | $\begin{aligned} & 23 \\ & .5 \end{aligned}$ | $\begin{aligned} & 25 \\ & .1 \end{aligned}$ |  |  |  | LSLEIEQLELQR |
| $\begin{aligned} & 652 . \\ & 776 \\ & 8 \\ & \hline \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \hline \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $\begin{aligned} & 10 \\ & .2 \\ & 8 \\ & \hline \end{aligned}$ | $\begin{aligned} & 11 \\ & .8 \\ & 8 \\ & \hline \end{aligned}$ |  |  |  | GQYC[+57.0]YELDE |
| $\begin{aligned} & 823 . \\ & 912 \\ & 3 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & 28 \\ & .6 \\ & 4 \\ & \hline \end{aligned}$ | $\begin{aligned} & 30 \\ & .2 \\ & 4 \\ & \hline \end{aligned}$ |  |  |  | DVWGIEGPIDAAFTR |
| $\begin{aligned} & 745 . \\ & 025 \\ & 9 \end{aligned}$ |  |  |  | 3 | Pos <br> itiv <br> e | $\begin{aligned} & 17 \\ & .9 \\ & 8 \\ & \hline \end{aligned}$ | $\begin{aligned} & 19 \\ & .5 \\ & 8 \\ & \hline \end{aligned}$ |  |  |  | ELNQAGQETLVTGWGYHSSR |
| $\begin{aligned} & 328 . \\ & 175 \\ & 5 \end{aligned}$ |  |  |  | 4 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & 17 \\ & .2 \\ & 3 \end{aligned}$ | $\begin{aligned} & 18 \\ & .8 \\ & 3 \\ & \hline \end{aligned}$ |  |  |  | YLDWIHGHIR |
| $\begin{aligned} & 506 . \\ & 823 \\ & 7 \\ & \hline \end{aligned}$ |  |  |  | 2 | Pos <br> itiv <br> e | $\begin{aligned} & 23 \\ & .2 \\ & 8 \\ & \hline \end{aligned}$ | $\begin{aligned} & 24 \\ & .8 \\ & 8 \\ & \hline \end{aligned}$ |  |  |  | TGISPLALIK |
| $\begin{aligned} & 654 . \\ & 845 \\ & 4 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & 28 \\ & .6 \\ & 2 \end{aligned}$ | $\begin{aligned} & 30 \\ & .2 \\ & 2 \end{aligned}$ |  |  |  | GFEPTLEALFGK |
| $\begin{aligned} & 715 . \\ & 391 \\ & \hline \end{aligned}$ |  |  |  | 3 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \hline \end{aligned}$ | $\begin{aligned} & 28 \\ & .7 \\ & \hline \end{aligned}$ | $\begin{aligned} & 30 \\ & .3 \\ & \hline \end{aligned}$ |  |  |  | LAGYLHTLVQNLVNNGYVR |


| 9 |  |  |  |  | e | 3 | 3 |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{aligned} & 712 . \\ & 355 \\ & 6 \\ & \hline \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & 21 \\ & .2 \\ & 8 \\ & \hline \end{aligned}$ | $\begin{aligned} & 22 \\ & .8 \\ & 8 \\ & \hline \end{aligned}$ |  |  |  | ITTTSPWMFPSR |
| $\begin{aligned} & 876 . \\ & 468 \\ & 2 \\ & \hline \end{aligned}$ |  |  |  | 3 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & 34 \\ & .7 \\ & 4 \\ & \hline \end{aligned}$ | $\begin{aligned} & 36 \\ & .3 \\ & 4 \\ & \hline \end{aligned}$ |  |  |  | DLLAGLPAPGVEVYC[+57.0]L YGVGLPTPR |
| $\begin{aligned} & 872 . \\ & 444 \\ & 3 \\ & \hline \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & 32 \\ & .5 \\ & 2 \\ & \hline \end{aligned}$ | $\begin{aligned} & 34 \\ & .1 \\ & 2 \\ & \hline \end{aligned}$ |  |  |  | AIWNVINWENVTER |
| $\begin{aligned} & 562 . \\ & 808 \\ & 6 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & 27 \\ & .9 \\ & 2 \end{aligned}$ | $\begin{aligned} & 29 \\ & .5 \\ & 2 \end{aligned}$ |  |  |  | DGYLFQLLR |
| $\begin{aligned} & 745 . \\ & 849 \\ & 2 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \\ & \hline \end{aligned}$ | $\begin{aligned} & 21 \\ & .8 \\ & 2 \\ & \hline \end{aligned}$ | $\begin{aligned} & 23 \\ & .4 \\ & 2 \end{aligned}$ |  |  |  | GGEGTGYFVDFSVR |
| $\begin{aligned} & 686 . \\ & 852 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & 11 \\ & .4 \end{aligned}$ | 13 |  |  |  | HQFLLTGDTQGR |
| $\begin{aligned} & 544 . \\ & 796 \end{aligned}$ |  |  |  | 2 | Pos itiv e | $\begin{aligned} & 14 \\ & .9 \\ & 6 \\ & \hline \end{aligned}$ | $\begin{aligned} & 16 \\ & .5 \\ & 6 \\ & \hline \end{aligned}$ |  |  |  | ATWSGAVLAGR |
| $\begin{aligned} & 437 . \\ & 753 \\ & 3 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \hline \text { Pos } \\ & \text { itiv } \\ & \text { e } \\ & \hline \end{aligned}$ | $\begin{aligned} & 12 \\ & .1 \\ & 7 \end{aligned}$ | $\begin{aligned} & 13 \\ & .7 \\ & 7 \end{aligned}$ |  |  |  | SLVNLGGSK |
| $\begin{aligned} & 720 . \\ & 372 \\ & 5 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $\begin{aligned} & 35 \\ & .0 \\ & 1 \\ & \hline \end{aligned}$ | $\begin{aligned} & 36 \\ & .6 \\ & 1 \\ & \hline \end{aligned}$ |  |  |  | YAGSQVASTSEVLK |
| $\begin{aligned} & 807 . \\ & 454 \\ & 1 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \\ & \hline \end{aligned}$ | $\begin{aligned} & 25 \\ & .5 \end{aligned}$ | $27$ |  |  |  | LVINGNPITIFQER |
| $\begin{aligned} & 812 . \\ & 414 \\ & 9 \\ & \hline \end{aligned}$ |  |  |  | 1 | Pos <br> itiv <br> e | $\begin{aligned} & 17 \\ & .3 \\ & 5 \\ & \hline \end{aligned}$ | $\begin{aligned} & 18 \\ & .9 \\ & 5 \\ & \hline \end{aligned}$ |  |  |  | Q[-17.0]ASEGPLK |
| $\begin{aligned} & 829 . \\ & 385 \\ & 6 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & 13 \\ & .6 \\ & 2 \\ & \hline \end{aligned}$ | $\begin{aligned} & 15 \\ & .2 \\ & 2 \\ & \hline \end{aligned}$ |  |  |  | C[+57.0]PNPPVQENFDVNK |
| $\begin{aligned} & 615 . \\ & 838 \\ & 1 \\ & \hline \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \\ & \hline \end{aligned}$ | $\begin{aligned} & 14 \\ & .9 \\ & 6 \\ & \hline \end{aligned}$ | $\begin{aligned} & 16 \\ & .5 \\ & 6 \\ & \hline \end{aligned}$ |  |  |  | NILTSNNIDVK |
| $\begin{aligned} & 779 . \\ & 898 \\ & 7 \\ & \hline \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{gathered} \hline 24 \\ .6 \end{gathered}$ | $\begin{aligned} & 26 \\ & .6 \end{aligned}$ |  |  |  | TLYLADTFPTNFR |
| $\begin{aligned} & 613 . \\ & 83 \end{aligned}$ |  |  |  | 2 | Pos itiv e | 19 .8 2 | 21 .4 2 |  |  |  | AAAATGTIFTFR |


| $\begin{aligned} & 558 . \\ & 798 \\ & 4 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | 13 <br> .9 <br> 5 | $\begin{aligned} & 15 \\ & .5 \\ & 5 \\ & \hline \end{aligned}$ |  |  | LLDSLPSDTR |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{aligned} & 593 . \\ & 353 \\ & 2 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \hline \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 23 \\ & .0 \\ & 5 \end{aligned}$ | $\begin{aligned} & \hline 24 \\ & .6 \\ & 5 \end{aligned}$ |  |  | FQPTLLTLPR |
| $\begin{array}{\|l\|} \hline 728 . \\ 853 \\ 1 \\ \hline \end{array}$ |  |  |  | 2 | $\begin{aligned} & \hline \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $\begin{array}{\|l\|} \hline 17 \\ .9 \\ 8 \\ \hline \end{array}$ | $\begin{aligned} & 19 \\ & .5 \\ & 8 \\ & \hline \end{aligned}$ |  |  | GLETSLAEC[+57.0]TFTK |
| $\begin{aligned} & 596 . \\ & 821 \\ & 7 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \hline \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $\begin{aligned} & 22 \\ & .1 \\ & 3 \end{aligned}$ | $\begin{aligned} & 23 \\ & .7 \\ & 3 \\ & \hline \end{aligned}$ |  |  | VFSLQWGEVK |
| $\begin{aligned} & 574 . \\ & 273 \\ & 9 \end{aligned}$ |  |  |  | 3 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & 12 \\ & .6 \\ & 3 \\ & \hline \end{aligned}$ | $\begin{aligned} & 14 \\ & .2 \\ & 3 \\ & \hline \end{aligned}$ |  |  | SGYLLHGSNEITC[+57.0]NR |
| $\begin{array}{\|l} \hline 759 . \\ 710 \\ 8 \\ \hline \end{array}$ |  |  |  | 3 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \\ & \hline \end{aligned}$ | $\begin{array}{\|l} \hline 20 \\ .8 \\ 2 \\ \hline \end{array}$ | $\begin{array}{\|l} \hline 22 \\ .4 \\ 2 \\ \hline \end{array}$ |  |  | QGYDLSPLTPLSELSVQC[+57. 0]NR |
| $\begin{aligned} & 884 . \\ & 959 \\ & 4 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $\begin{aligned} & 26 \\ & .6 \\ & 7 \end{aligned}$ | $\begin{aligned} & \hline 28 \\ & .2 \\ & 7 \\ & \hline \end{aligned}$ |  |  | GDTYPAELYITGSILR |
| $\begin{array}{\|l} \hline 657 . \\ 387 \\ 4 \\ \hline \end{array}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $\begin{aligned} & 24 \\ & .1 \\ & 7 \\ & \hline \end{aligned}$ | $\begin{aligned} & 25 \\ & .7 \\ & 7 \\ & \hline \end{aligned}$ |  |  | LDTLAQEVALLK |
| $\begin{aligned} & 748 . \\ & 025 \\ & 6 \end{aligned}$ |  |  |  | 3 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 22 \\ & .6 \end{aligned}$ | $\begin{aligned} & \hline 24 \\ & .2 \end{aligned}$ |  |  | GGTLGTPQTGSENDALYEYL R |
| $\begin{array}{\|l\|} \hline 742 . \\ 323 \\ 8 \\ \hline \end{array}$ |  |  |  | 2 | Pos <br> itiv <br> e | $\begin{aligned} & \hline 14 \\ & .3 \\ & 4 \\ & \hline \end{aligned}$ | $\begin{aligned} & 15 \\ & .9 \\ & 4 \\ & \hline \end{aligned}$ |  |  | EGQMESVEAAMSSK |
| $\begin{aligned} & 561 . \\ & 323 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \end{aligned}$ | $\begin{aligned} & 29 \\ & .2 \\ & 6 \\ & \hline \end{aligned}$ | $\begin{array}{\|l} \hline 30 \\ .8 \\ 6 \\ \hline \end{array}$ |  |  | SFMLLILER |
| $\begin{aligned} & 410 . \\ & 252 \\ & 4 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $\begin{array}{\|l\|} \hline 21 \\ .5 \\ 9 \\ \hline \end{array}$ | $\begin{aligned} & 23 \\ & .1 \\ & 9 \\ & \hline \end{aligned}$ |  |  | IAIDLFK |
| $\begin{aligned} & 651 . \\ & 684 \\ & 2 \end{aligned}$ |  |  |  | 3 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & \hline 28 \\ & .3 \end{aligned}$ | $\begin{aligned} & \hline 29 \\ & .9 \end{aligned}$ |  |  | FTVDRPFLFLIYEHR |
| $\begin{aligned} & 542 . \\ & 767 \\ & 5 \\ & \hline \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $\begin{aligned} & 18 \\ & .7 \\ & 8 \end{aligned}$ | $\begin{aligned} & \hline 20 \\ & .3 \\ & 8 \\ & \hline \end{aligned}$ |  |  | TSC[+57.0]LLFMGR |
| $\begin{aligned} & \hline 646 . \\ & 552 \\ & 9 \\ & \hline \end{aligned}$ |  |  |  | 4 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $\begin{array}{\|l\|} \hline 23 \\ .1 \\ 3 \\ \hline \end{array}$ | $\begin{array}{\|l} 24 \\ .7 \\ 3 \\ \hline \end{array}$ |  |  | ESILFHYTDWVDDQRPENYR |
| 599. |  |  |  | 2 | Pos | 11 | 13 |  |  | YLTLNTESTR |


| $\begin{array}{\|l\|} \hline 309 \\ 1 \end{array}$ |  |  |  |  | itiv | .4 <br> 8 | .0 8 |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{array}{\|l} \hline 607 . \\ 303 \\ 7 \\ \hline \end{array}$ |  |  |  | 2 | Pos <br> itiv <br> e | $\begin{aligned} & 16 \\ & .5 \\ & 8 \end{aligned}$ | $\begin{aligned} & 18 \\ & .1 \\ & 8 \end{aligned}$ |  |  |  | NYLAWYQQK |
| $\begin{aligned} & \hline 561 . \\ & 818 \\ & 9 \\ & \hline \end{aligned}$ |  |  |  | 2 | Pos <br> itiv <br> e | $\begin{aligned} & \hline 21 \\ & .8 \\ & 1 \\ & \hline \end{aligned}$ | $\begin{aligned} & 23 \\ & .4 \\ & 1 \end{aligned}$ |  |  |  | LLIYWASTR |
| $\begin{aligned} & 475 . \\ & 263 \\ & 7 \end{aligned}$ |  |  |  | 2 | Pos <br> itiv <br> e | $\begin{aligned} & 7 . \\ & 55 \end{aligned}$ | $\begin{aligned} & 9 . \\ & 15 \end{aligned}$ |  |  |  | VTISVDTSK |
| $\begin{aligned} & 882 . \\ & 456 \\ & 7 \end{aligned}$ |  |  |  | 1 | $\begin{array}{\|l} \hline \text { Pos } \\ \text { itiv } \\ \mathrm{e} \\ \hline \end{array}$ | $\begin{aligned} & \hline 7 . \\ & 02 \end{aligned}$ | $\begin{aligned} & 10 \\ & .0 \\ & 2 \end{aligned}$ |  |  |  | TASDFITK |
| $\begin{aligned} & 660 . \\ & 351 \\ & 3 \end{aligned}$ |  |  |  | 2 | Pos itiv e | $\begin{array}{\|l\|} \hline 17 \\ .6 \\ 2 \\ \hline \end{array}$ | $\begin{aligned} & 19 \\ & .2 \\ & 2 \\ & \hline \end{aligned}$ |  |  |  | AGALNSNDAFVLK |
| $\begin{aligned} & \hline 879 . \\ & 938 \\ & 6 \end{aligned}$ |  |  |  | 2 | $\begin{array}{\|l} \hline \text { Pos } \\ \text { itiv } \\ \mathrm{e} \\ \hline \end{array}$ | $\begin{aligned} & \hline 24 \\ & .1 \\ & 2 \\ & \hline \end{aligned}$ | $\begin{aligned} & 25 \\ & .7 \\ & 2 \end{aligned}$ |  |  |  | PIC[+57.0]LPC[+57.0]TMEANL ALR |
| $\begin{aligned} & \hline 786 . \\ & 724 \\ & 4 \\ & \hline \end{aligned}$ |  |  |  | 3 | Pos <br> itiv <br> e | $\begin{aligned} & 31 \\ & .9 \\ & 8 \end{aligned}$ | $\begin{aligned} & 33 \\ & .5 \\ & 8 \end{aligned}$ |  |  |  | FFQVGLVSWGLYNPC[+57.0]L GSADK |
| $\begin{aligned} & 817 . \\ & 922 \\ & 9 \\ & \hline \end{aligned}$ |  |  |  | 2 | $\begin{array}{\|l\|} \hline \text { Pos } \\ \text { itiv } \\ \mathrm{e} \\ \hline \end{array}$ | $\begin{aligned} & \hline 26 \\ & .1 \\ & 6 \\ & \hline \end{aligned}$ | $\begin{aligned} & 27 \\ & .7 \\ & 6 \\ & \hline \end{aligned}$ |  |  |  | SELTQQLNALFQDK |
| $\begin{aligned} & 598 . \\ & 782 \\ & 8 \end{aligned}$ |  |  |  | 2 | Pos <br> itiv <br> e | $\begin{aligned} & \hline 7 . \\ & 99 \end{aligned}$ | $\begin{aligned} & 9 . \\ & 59 \end{aligned}$ |  |  |  | VEPYGENFNK |
| $\begin{aligned} & \hline 611 . \\ & 274 \\ & 7 \\ & \hline \end{aligned}$ |  |  |  | 4 | Pos itiv e | $\begin{aligned} & \hline 13 \\ & .6 \\ & 1 \end{aligned}$ | $\begin{aligned} & 15 \\ & .2 \\ & 1 \end{aligned}$ |  |  |  | $\begin{aligned} & \text { DC[+57.0]KDVDEC[+57.0]SLK } \\ & \text { PSIC[+57.0]GTAVC }[+57.0] \mathrm{K} \end{aligned}$ |
| $\begin{array}{\|l} \hline 875 . \\ 472 \\ 7 \\ \hline \end{array}$ |  |  |  | 2 | Pos <br> itiv <br> e | $\begin{aligned} & 28 \\ & .0 \\ & 3 \end{aligned}$ | $\begin{aligned} & 29 \\ & .6 \\ & 3 \end{aligned}$ |  |  |  | SQDILLSVENTVIYR |
| $\begin{aligned} & \hline 890 . \\ & 921 \\ & \hline \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \end{aligned}$ | $\begin{aligned} & \hline 22 \\ & .6 \\ & 1 \end{aligned}$ | $\begin{aligned} & 24 \\ & .2 \\ & 1 \end{aligned}$ |  |  |  | VDATEESDLAQQYGVR |
| $\begin{aligned} & 497 . \\ & 255 \\ & 3 \end{aligned}$ |  |  |  | 2 | Pos <br> itiv <br> e | $\begin{aligned} & 10 \\ & .9 \\ & 4 \end{aligned}$ | $\begin{aligned} & 12 \\ & .5 \\ & 4 \end{aligned}$ |  |  |  | MESLGITSR |
| $\begin{aligned} & 860 . \\ & 912 \\ & 2 \end{aligned}$ |  |  |  | 2 | Pos itiv e | $\begin{aligned} & 8 . \\ & 7 \end{aligned}$ | $\begin{aligned} & \hline 10 \\ & .7 \\ & 6 \end{aligned}$ |  |  |  | $\underset{\mathrm{K}}{\text { LGSLGAAC[+57.0]EQTQTEGA }}$ K |
| $\begin{aligned} & \hline 438 . \\ & 716 \\ & \hline \end{aligned}$ |  |  |  | 2 | Pos itiv | $\begin{aligned} & 18 \\ & .7 \\ & \hline \end{aligned}$ | $\begin{aligned} & 20 \\ & .3 \\ & \hline \end{aligned}$ |  |  |  | SGFSFGFK |


| 2 |  |  |  |  | e | 5 | 5 |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{aligned} & 809 . \\ & 925 \\ & 4 \\ & \hline \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & 24 \\ & .4 \\ & 6 \\ & \hline \end{aligned}$ | $\begin{aligned} & 26 \\ & .0 \\ & 6 \end{aligned}$ |  |  |  | IPGIFELGISSQSDR |
| $\begin{array}{\|l\|} \hline 720 . \\ 368 \\ 6 \\ \hline \end{array}$ |  |  |  | 3 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & 18 \\ & .6 \\ & 3 \\ & \hline \end{aligned}$ | $\begin{aligned} & 20 \\ & .2 \\ & 3 \\ & \hline \end{aligned}$ |  |  |  | AEATTLHVAPQGTAMAVSTFR |
| $\begin{array}{\|l} \hline 685 . \\ 979 \\ 2 \\ \hline \end{array}$ |  |  |  | 3 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \\ & \hline \end{aligned}$ | $\begin{aligned} & 23 \\ & .5 \\ & 6 \\ & \hline \end{aligned}$ | $\begin{aligned} & 25 \\ & .1 \\ & 6 \\ & \hline \end{aligned}$ |  |  |  | $\begin{aligned} & \text { YGFC[+57.0]EAADQFHVLDE } \\ & \text { VR } \end{aligned}$ |
| $\begin{aligned} & 697 . \\ & 869 \\ & 4 \\ & \hline \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \\ & \hline \end{aligned}$ | $\begin{aligned} & 34 \\ & .9 \\ & 5 \\ & \hline \end{aligned}$ | $\begin{aligned} & 36 \\ & .5 \\ & 5 \\ & \hline \end{aligned}$ |  |  |  | FVFGTTPEDILR |
| $\begin{array}{\|l\|} \hline 538 . \\ 300 \\ 1 \\ \hline \end{array}$ |  |  |  | 2 | $\begin{aligned} & \hline \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $\begin{aligned} & 18 \\ & .1 \end{aligned}$ | $19$ |  |  |  | MNTVIAALSR |
| $\begin{array}{\|l} 882 . \\ 962 \end{array}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & 23 \\ & .8 \\ & 7 \\ & \hline \end{aligned}$ | $\begin{aligned} & 25 \\ & .4 \\ & 7 \\ & \hline \end{aligned}$ |  |  |  | WSAGLTSSQVDLYIPK |
| $\begin{array}{\|l} \hline 749 . \\ 343 \\ 2 \\ \hline \end{array}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $\begin{aligned} & 12 \\ & .5 \\ & 2 \end{aligned}$ | $\begin{aligned} & 14 \\ & .1 \\ & 2 \end{aligned}$ |  |  |  | DAVAAP |
| $\begin{aligned} & 555 . \\ & 304 \end{aligned}$ |  |  |  | 3 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & 16 \\ & .2 \end{aligned}$ | $\begin{aligned} & 17 \\ & .8 \end{aligned}$ |  |  |  | LPETIDLGALYLSMK |
| $\begin{array}{\|l\|} \hline 889 . \\ 038 \\ 4 \\ \hline 77 \\ \hline \end{array}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \\ & \hline \end{aligned}$ | $\begin{aligned} & 28 \\ & .5 \\ & 2 \\ & \hline \end{aligned}$ | $\begin{aligned} & 30 \\ & .1 \\ & 2 \\ & \hline \end{aligned}$ |  |  |  | LTVGAAQVPAQLLVGALR |
| $\begin{array}{\|l\|} \hline 776 . \\ 060 \\ 9 \\ \hline \end{array}$ |  |  |  | 3 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \\ & \hline \end{aligned}$ | $\begin{aligned} & 23 \\ & .1 \\ & 6 \\ & \hline \end{aligned}$ | $\begin{aligned} & 24 \\ & .7 \\ & 6 \\ & \hline \end{aligned}$ |  |  |  | SITC[+57.0]IHGVWTQLPQC[+ 57.0]VAIDK |
| $\begin{array}{\|l} \hline 827 . \\ 874 \\ 5 \\ \hline \end{array}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \\ & \hline \end{aligned}$ | $\begin{aligned} & 12 \\ & .2 \\ & 6 \\ & \hline \end{aligned}$ | $\begin{aligned} & 13 \\ & .8 \\ & 6 \\ & \hline \end{aligned}$ |  |  |  | AGEQVTYTC[+57.0]ATYYK |
| $\begin{array}{\|l} \hline 617 . \\ 305 \\ 9 \\ \hline \end{array}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \\ & \hline \end{aligned}$ | $\begin{aligned} & 14 \\ & .8 \\ & 9 \\ & \hline \end{aligned}$ | $\begin{aligned} & 16 \\ & .4 \\ & 9 \\ & \hline \end{aligned}$ |  |  |  | LC[+57.0]QDLGPGAFR |
| $\begin{array}{\|l\|} \hline 760 . \\ 685 \\ 6 \\ \hline \end{array}$ |  |  |  | 3 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $\begin{aligned} & 27 \\ & .5 \\ & 3 \\ & \hline \end{aligned}$ | $\begin{aligned} & 29 \\ & .1 \\ & 3 \\ & \hline \end{aligned}$ |  |  |  | DSFHLDEQFTVPVEMMQAR |
| $\begin{aligned} & 739 . \\ & 393 \\ & 5 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \end{aligned}$ | $\begin{aligned} & 30 \\ & .1 \\ & 9 \end{aligned}$ | 31 .7 9 |  |  |  | FSLVSGWGQLLDR |
| $\begin{array}{\|l} \hline 882 . \\ 462 \\ 3 \\ \hline \end{array}$ |  |  |  | 2 | Pos <br> itiv <br> e | 28 .5 3 | 30 .1 3 |  |  |  | SNALDIIFQTDLTGQK |


| $\begin{aligned} & 686 . \\ & 822 \\ & 6 \end{aligned}$ |  |  |  | 2 | $\begin{array}{\|l} \hline \text { Pos } \\ \text { itiv } \\ \mathrm{e} \\ \hline \end{array}$ | 12 .4 1 | 14 .0 1 |  |  |  | EDTPNSVWEPAK |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{aligned} & 814 . \\ & 474 \\ & 5 \end{aligned}$ |  |  |  | 2 | Pos itiv e | $\begin{aligned} & 25 \\ & .2 \\ & 4 \end{aligned}$ | $\begin{aligned} & 26 \\ & .8 \\ & 4 \\ & \hline \end{aligned}$ |  |  |  | PVAFSVVPTAAAAVSLK |
| $\begin{aligned} & 684 . \\ & 363 \\ & 9 \\ & \hline \end{aligned}$ |  |  |  | 2 | $\begin{array}{\|l} \hline \text { Pos } \\ \text { itiv } \\ \mathrm{e} \\ \hline \end{array}$ | $\begin{aligned} & 30 \\ & .2 \\ & 8 \end{aligned}$ | $\begin{aligned} & \hline 31 \\ & .8 \\ & 8 \\ & \hline \end{aligned}$ |  |  |  | DSSTWLTAFVLK |
| $\begin{aligned} & 655 . \\ & 361 \\ & 2 \end{aligned}$ |  |  |  | 2 | Pos itiv e | $\begin{aligned} & 28 \\ & .7 \\ & 9 \\ & \hline \end{aligned}$ | $\begin{aligned} & 30 \\ & .3 \\ & 9 \\ & \hline \end{aligned}$ |  |  |  | GSSTWLTAFVLK |
| $\begin{aligned} & 717 . \\ & 345 \\ & 7 \end{aligned}$ |  |  |  | 2 | $\begin{array}{\|l\|} \hline \text { Pos } \\ \text { itiv } \\ \text { e } \\ \hline \end{array}$ | $\begin{aligned} & 20 \\ & .9 \end{aligned}$ | $\begin{aligned} & 22 \\ & .5 \end{aligned}$ |  |  |  | AEMADQAAAWLTR |
| $\begin{aligned} & 495 . \\ & 758 \\ & 8 \end{aligned}$ |  |  |  | 2 | $\begin{array}{\|l\|} \hline \text { Pos } \\ \text { itiv } \\ \mathrm{e} \\ \hline \end{array}$ | $\begin{aligned} & 3 . \\ & 63 \end{aligned}$ | $\begin{aligned} & 5 . \\ & 23 \end{aligned}$ |  |  |  | AGVETTTPSK |
| $\begin{aligned} & 652 . \\ & 303 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $\begin{aligned} & 19 \\ & .1 \\ & 5 \\ & \hline \end{aligned}$ | $\begin{aligned} & 20 \\ & .7 \\ & 5 \\ & \hline \end{aligned}$ |  |  |  | NSLESYAFNMK |
| $\begin{aligned} & 652 . \\ & 795 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | 7 | $\begin{aligned} & 9 . \\ & 9 \end{aligned}$ |  |  |  | AEDTALYYC[+57.0]AK |
| $\begin{aligned} & 903 . \\ & 475 \\ & 3 \\ & \hline \end{aligned}$ |  |  |  | 2 | Pos <br> itiv <br> e | $\begin{aligned} & 25 \\ & .3 \\ & 1 \\ & \hline \end{aligned}$ | $\begin{aligned} & 26 \\ & .9 \\ & 1 \\ & \hline \end{aligned}$ |  |  |  | YSAWAESVTNLPQVIK |
| $\begin{aligned} & 902 . \\ & 946 \\ & 5 \\ & \hline \end{aligned}$ |  |  |  | 2 | Pos <br> itiv <br> e | $\begin{aligned} & 15 \\ & .5 \\ & 8 \\ & \hline \end{aligned}$ | $\begin{aligned} & 17 \\ & .1 \\ & 8 \\ & \hline \end{aligned}$ |  |  |  | QSISVTSIRPC[+57.0]AAETQ |
| $\begin{aligned} & 697 . \\ & 351 \\ & 5 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \end{aligned}$ | $\begin{aligned} & 26 \\ & .7 \\ & 5 \end{aligned}$ | $\begin{aligned} & 28 \\ & .3 \\ & 5 \end{aligned}$ |  |  |  | ASSIIDELFQDR |
| $\begin{aligned} & 477 . \\ & 733 \\ & 7 \\ & \hline \end{aligned}$ |  |  |  | 2 | $\begin{array}{\|l\|} \hline \text { Pos } \\ \text { itiv } \\ \text { e } \\ \hline \end{array}$ | $\begin{aligned} & 7 . \\ & 11 \end{aligned}$ | $\begin{aligned} & 9 . \\ & 4 \end{aligned}$ |  |  |  | FMETVAEK |
| $\begin{aligned} & 476 . \\ & 268 \\ & 6 \end{aligned}$ |  |  |  | 2 | Pos <br> itiv <br> e | $\begin{aligned} & 23 \\ & .0 \\ & 7 \\ & \hline \end{aligned}$ | $\begin{aligned} & 24 \\ & .6 \\ & 7 \\ & \hline \end{aligned}$ |  |  |  | WLTFSLGK |
| $\begin{aligned} & 630 . \\ & 832 \\ & 8 \end{aligned}$ |  |  |  | 2 | Pos itiv e | $\begin{aligned} & 32 \\ & .3 \\ & 4 \end{aligned}$ | $\begin{aligned} & 33 \\ & .9 \\ & 4 \end{aligned}$ |  |  |  | FTVNNLAEPQK |
| $\begin{aligned} & 629 . \\ & 821 \\ & 7 \\ & \hline \end{aligned}$ |  |  |  | 2 | Pos itiv e | $\begin{aligned} & 11 \\ & .5 \\ & 4 \\ & \hline \end{aligned}$ | $\begin{aligned} & 13 \\ & .1 \\ & 4 \\ & \hline \end{aligned}$ |  |  |  | DGLGFC[+57.0]ALIHR |
| 647. |  |  |  | 2 | Pos | 28 | 30 |  |  |  | LAILGIHNEVSK |


| $\begin{aligned} & 379 \\ & 9 \end{aligned}$ |  |  |  |  | itiv <br> e | .9 3 | .9 3 |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{aligned} & 557 . \\ & 342 \\ & 6 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & 25 \\ & .4 \\ & 5 \end{aligned}$ | $\begin{aligned} & 27 \\ & .0 \\ & 5 \end{aligned}$ |  |  |  | VPLALFALNR |
| $\begin{aligned} & 854 . \\ & 389 \\ & 7 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \\ & \hline \end{aligned}$ | $\begin{aligned} & 18 \\ & .1 \\ & 6 \\ & \hline \end{aligned}$ | $\begin{aligned} & 19 \\ & .7 \\ & 6 \\ & \hline \end{aligned}$ |  |  |  | GSLGGGFSSGGFSGGSFSR |
| $\begin{aligned} & 763 . \\ & 912 \\ & 3 \\ & \hline \end{aligned}$ |  |  |  | 4 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $\begin{aligned} & 34 \\ & .7 \\ & 6 \\ & \hline \end{aligned}$ | $\begin{aligned} & 36 \\ & .3 \\ & 6 \\ & \hline \end{aligned}$ |  |  |  | TIDDLKNQILNLTTDNANILLQ IDNAR |
| $\begin{aligned} & 748 . \\ & 856 \\ & 1 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & 17 \\ & .3 \\ & 4 \\ & \hline \end{aligned}$ | $\begin{aligned} & 18 \\ & .9 \\ & 4 \\ & \hline \end{aligned}$ |  |  |  | GEVLDNSFTGGIC[+57.0]K |
| $\begin{aligned} & 613 . \\ & 308 \\ & 6 \\ & \hline \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \\ & \hline \end{aligned}$ | $\begin{aligned} & 23 \\ & .0 \\ & 5 \\ & \hline \end{aligned}$ | $\begin{aligned} & 24 \\ & .6 \\ & 5 \\ & \hline \end{aligned}$ |  |  |  | TFSEWLESVK |
| $\begin{aligned} & 647 . \\ & 081 \\ & 3 \end{aligned}$ |  |  |  | 4 | $\begin{aligned} & \hline \text { Pos } \\ & \text { itiv } \\ & \text { e } \\ & \hline \end{aligned}$ | $\begin{aligned} & 21 \\ & .5 \\ & 9 \\ & \hline \end{aligned}$ | $\begin{aligned} & 23 \\ & .1 \\ & 9 \\ & \hline \end{aligned}$ |  |  |  | $\begin{aligned} & \text { HLYVLEFSDHPGIHEPLEPEV } \\ & \text { K } \end{aligned}$ |
| $\begin{aligned} & 491 . \\ & 787 \\ & 6 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \\ & \hline \end{aligned}$ | $\begin{aligned} & 11 \\ & .4 \\ & 2 \end{aligned}$ | $\begin{aligned} & 13 \\ & .0 \\ & 2 \\ & \hline \end{aligned}$ |  |  |  | SIPQVSPVR |
| $\begin{aligned} & 462 . \\ & 922 \\ & 5 \end{aligned}$ |  |  |  | 3 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & 18 \\ & .6 \\ & 7 \end{aligned}$ | $\begin{aligned} & 20 \\ & .2 \\ & 7 \\ & \hline \end{aligned}$ |  |  |  | YGFIEGHVVIPR |
| $\begin{aligned} & 473 . \\ & 279 \\ & 5 \\ & \hline \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \hline \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $\begin{aligned} & 18 \\ & .4 \\ & 5 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 20 \\ & .0 \\ & 5 \\ & \hline \end{aligned}$ |  |  |  | FLNVLSPR |
| $\begin{aligned} & 412 . \\ & 734 \\ & 9 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & \hline 3 . \\ & 82 \end{aligned}$ | $\begin{aligned} & 5 . \\ & 42 \end{aligned}$ |  |  |  | AAVHLEGK |
| $\begin{aligned} & 878 . \\ & 930 \\ & 7 \\ & \hline \end{aligned}$ |  |  |  | 2 | Pos <br> itiv <br> e | $\begin{aligned} & 18 \\ & .7 \\ & 3 \\ & \hline \end{aligned}$ | $\begin{aligned} & 20 \\ & .3 \\ & 3 \\ & \hline \end{aligned}$ |  |  |  | NWGLSFYADKPETTK |
| $\begin{aligned} & 704 . \\ & 995 \\ & 8 \end{aligned}$ |  |  |  | 3 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & 30 \\ & .7 \\ & 5 \end{aligned}$ | $\begin{aligned} & 32 \\ & .3 \\ & 5 \end{aligned}$ |  |  |  | $\begin{aligned} & \text { EQLGEFYEALDC[+57.0]LC[+5 } \\ & \text { 7.0]IPR } \end{aligned}$ |
| $\begin{aligned} & 423 . \\ & 745 \\ & 3 \\ & \hline \end{aligned}$ |  |  |  | 2 | Pos <br> itiv <br> e | $\begin{aligned} & 7 . \\ & 3 \end{aligned}$ | $\begin{aligned} & 9 . \\ & 9 \end{aligned}$ |  |  |  | IYLQPGR |
| $\begin{aligned} & 669 . \\ & 364 \\ & 2 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & 18 \\ & .4 \\ & 6 \end{aligned}$ | $\begin{aligned} & 20 \\ & .0 \\ & 6 \end{aligned}$ |  |  |  | FYNQVSTPLLR |
| $\begin{aligned} & 669 . \\ & 341 \\ & \hline \end{aligned}$ |  |  |  | 3 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \hline \end{aligned}$ | $\begin{aligned} & 15 \\ & .6 \\ & \hline \end{aligned}$ | $\begin{array}{r} 17 \\ .2 \\ \hline \end{array}$ |  |  |  | FAHYVVTSQVVNTANEAR |


| 2 |  |  |  |  | e | 3 | 3 |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{aligned} & 781 . \\ & 453 \\ & 1 \\ & \hline \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $\begin{aligned} & 33 \\ & .9 \\ & 2 \\ & \hline \end{aligned}$ | $\begin{aligned} & 35 \\ & .5 \\ & 2 \\ & \hline \end{aligned}$ |  |  |  | LWAYLTIQELLAK |
| $\begin{aligned} & 561 . \\ & 805 \\ & 7 \\ & \hline \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & 23 \\ & .3 \\ & 2 \\ & \hline \end{aligned}$ | $\begin{aligned} & 24 \\ & .9 \\ & 2 \end{aligned}$ |  |  |  | SLFTDLVAEK |
| $\begin{aligned} & 620 . \\ & 837 \\ & 9 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \hline \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $\begin{aligned} & 16 \\ & .2 \\ & 7 \\ & \hline \end{aligned}$ | $\begin{aligned} & 17 \\ & .8 \\ & 7 \\ & \hline \end{aligned}$ |  |  |  | AVGYLITGYQR |
| $\begin{aligned} & 503 . \\ & 782 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $\begin{aligned} & 15 \\ & .1 \\ & 8 \\ & \hline \end{aligned}$ | $\begin{aligned} & 16 \\ & .7 \\ & 8 \\ & \hline \end{aligned}$ |  |  |  | ALLAFQESK |
| $\begin{aligned} & 577 . \\ & 757 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \hline \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $\begin{aligned} & 11 \\ & .6 \\ & 7 \end{aligned}$ | $\begin{aligned} & 13 \\ & .2 \\ & 7 \end{aligned}$ |  |  |  | ESGMTMEELK |
| $\begin{aligned} & 817 . \\ & 378 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & 14 \\ & .1 \\ & 6 \\ & \hline \end{aligned}$ | $\begin{aligned} & 15 \\ & .7 \\ & 6 \\ & \hline \end{aligned}$ |  |  |  | NSC[+57.0]PPTSELLGTSDR |
| $\begin{aligned} & 657 . \\ & 865 \\ & 6 \\ & \hline \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \hline \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $\begin{aligned} & 24 \\ & .3 \\ & 6 \\ & \hline \end{aligned}$ | $\begin{aligned} & 25 \\ & .9 \\ & 6 \\ & \hline \end{aligned}$ |  |  |  | FLVGPDGIPIMR |
| $\begin{aligned} & 366 . \\ & 222 \end{aligned}$ |  |  |  | 3 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \\ & \hline \end{aligned}$ | $\begin{aligned} & 16 \\ & .0 \\ & 9 \end{aligned}$ | $\begin{aligned} & 17 \\ & .6 \\ & 9 \\ & \hline \end{aligned}$ |  |  |  | LFQPLTHLK |
| $\begin{aligned} & 801 . \\ & 435 \\ & 9 \\ & \hline \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $\begin{aligned} & 22 \\ & .4 \\ & 4 \end{aligned}$ | $\begin{aligned} & 24 \\ & .0 \\ & 4 \end{aligned}$ |  |  |  | LSNNALSGLPQGVFGK |
| $\begin{aligned} & 511 . \\ & 779 \\ & 5 \\ & \hline \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \hline \text { Pos } \\ & \text { itiv } \\ & \text { e } \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 18 \\ & .7 \\ & 3 \\ & \hline \end{aligned}$ | $\begin{aligned} & 20 \\ & .3 \\ & 3 \\ & \hline \end{aligned}$ |  |  |  | ENFVLTTAK |
| $\begin{aligned} & 635 . \\ & 784 \\ & 6 \\ & \hline \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $\begin{aligned} & 10 \\ & .2 \\ & 2 \\ & \hline \end{aligned}$ | $\begin{aligned} & 11 \\ & .8 \\ & 2 \\ & \hline \end{aligned}$ |  |  |  | DC[+57.0]SLPYATESK |
| $\begin{aligned} & 589 . \\ & 777 \\ & 5 \\ & \hline \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & 15 \\ & .9 \end{aligned}$ | $\begin{aligned} & 17 \\ & .5 \end{aligned}$ |  |  |  | TGYYFDGISR |
| $\begin{aligned} & 801 . \\ & 741 \\ & 2 \\ & \hline \end{aligned}$ |  |  |  | 3 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \end{aligned}$ | $\begin{aligned} & 32 \\ & .5 \\ & 2 \\ & \hline \end{aligned}$ | $\begin{aligned} & 34 \\ & .1 \\ & 2 \\ & \hline \end{aligned}$ |  |  |  | HVEDVPAFQALGSLNDLQFFR |
| $\begin{aligned} & 564 . \\ & 288 \\ & 2 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & 7 . \\ & 92 \end{aligned}$ | $\begin{aligned} & 9 . \\ & 92 \end{aligned}$ |  |  |  | AGEVQEPELR |
| $\begin{aligned} & 796 . \\ & 883 \\ & 4 \\ & \hline \end{aligned}$ |  |  |  | 4 | Pos <br> itiv <br> e | 30 .0 6 | 31 .6 6 |  |  |  | GTELQHLLHAVVPGPWQEDV ADAEEC[+57.0]AGR |



| $\begin{array}{\|l\|} \hline 345 \\ 4 \end{array}$ |  |  |  |  | $\begin{aligned} & \text { itiv } \\ & \mathrm{e} \end{aligned}$ | . 5 | . 9 |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{array}{\|l} \hline 537 . \\ 774 \\ 9 \\ \hline \end{array}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $\begin{aligned} & 3 . \\ & 75 \end{aligned}$ | $\begin{aligned} & 5 . \\ & 35 \end{aligned}$ |  |  |  | LGGSQEDQIK |
| $\begin{aligned} & 540 . \\ & 332 \\ & 2 \end{aligned}$ |  |  |  | 2 | $\begin{array}{\|l\|} \hline \text { Pos } \\ \text { itiv } \\ \text { e } \\ \hline \end{array}$ | $\begin{aligned} & 10 \\ & .1 \end{aligned}$ | $\begin{aligned} & 12 \\ & .2 \end{aligned}$ |  |  |  | SHLIIAQVAK |
| $\begin{aligned} & \hline 654 . \\ & 369 \\ & 5 \end{aligned}$ |  |  |  | 2 | $\begin{array}{\|l\|} \hline \text { Pos } \\ \text { itiv } \\ \mathrm{e} \\ \hline \end{array}$ | $\begin{aligned} & \hline 20 \\ & .6 \\ & 9 \\ & \hline \end{aligned}$ | $\begin{aligned} & 22 \\ & .2 \\ & 9 \\ & \hline \end{aligned}$ |  |  |  | LSSGLVTAALYGR |
| $\begin{aligned} & \hline 573 . \\ & 785 \\ & 9 \end{aligned}$ |  |  |  | 2 | Pos <br> itiv <br> e | $\begin{aligned} & 12 \\ & .2 \\ & 6 \end{aligned}$ | $\begin{aligned} & 13 \\ & .8 \\ & 6 \end{aligned}$ |  |  |  | IC[+57.0]AMEGLPQK |
| $\begin{array}{\|l} \hline 857 . \\ 467 \\ 1 \\ \hline \end{array}$ |  |  |  | 2 | $\begin{array}{\|l\|} \hline \text { Pos } \\ \text { itiv } \\ \mathrm{e} \\ \hline \end{array}$ | $\begin{aligned} & 22 \\ & .9 \end{aligned}$ | $\begin{aligned} & 24 \\ & .5 \end{aligned}$ |  |  |  | IAPQLSTEELVSLGEK |
| $\begin{array}{\|l\|} \hline 684 . \\ 814 \\ 3 \\ \hline \end{array}$ |  |  |  | 2 | Pos <br> itiv <br> e | $\begin{aligned} & 12 \\ & .2 \\ & 7 \\ & \hline \end{aligned}$ | $\begin{aligned} & 14 \\ & .4 \end{aligned}$ |  |  |  | VEC[+57.0]SDNLFTQR |
| $\begin{aligned} & 816 . \\ & 917 \end{aligned}$ |  |  |  | 2 | $\begin{array}{\|l\|} \hline \text { Pos } \\ \text { itiv } \\ \mathrm{e} \\ \hline \end{array}$ | $\begin{aligned} & 19 \\ & .7 \\ & 8 \\ & \hline \end{aligned}$ | $\begin{aligned} & 21 \\ & .3 \\ & 8 \\ & \hline \end{aligned}$ |  |  |  | TGVITSPDFPNPYPK |
| $\begin{array}{\|l} \hline 861 . \\ 801 \\ 4 \\ \hline \end{array}$ |  |  |  | 3 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \\ & \hline \end{aligned}$ | $\begin{aligned} & 34 \\ & .8 \\ & 2 \\ & \hline \end{aligned}$ | $\begin{aligned} & 36 \\ & .4 \\ & 2 \\ & \hline \end{aligned}$ |  |  |  | LVYHLGLPFSFLTFPYVEEAIK |
| $\begin{array}{\|l} \hline 549 . \\ 793 \\ 1 \\ \hline \end{array}$ |  |  |  | 2 | $\begin{array}{\|l\|} \hline \text { Pos } \\ \text { itiv } \\ \mathrm{e} \\ \hline \end{array}$ | $\begin{aligned} & 11 \\ & .3 \\ & 7 \\ & \hline \end{aligned}$ | $\begin{aligned} & 12 \\ & .9 \\ & 7 \end{aligned}$ |  |  |  | LPTDSELAPR |
| $\begin{aligned} & 834 . \\ & 933 \\ & 2 \\ & \hline \end{aligned}$ |  |  |  | 2 | Pos <br> itiv <br> e | $\begin{aligned} & 26 \\ & .9 \\ & 6 \\ & \hline \end{aligned}$ | $\begin{aligned} & 28 \\ & .5 \\ & 6 \\ & \hline \end{aligned}$ |  |  |  | SLEYLDLSFNQIAR |
| $\begin{array}{\|l} \hline 846 . \\ 090 \\ 4 \\ \hline \end{array}$ |  |  |  | 3 | $\begin{array}{\|l\|} \hline \text { Pos } \\ \text { itiv } \\ \mathrm{e} \\ \hline \end{array}$ | $\begin{aligned} & 27 \\ & .1 \\ & 4 \end{aligned}$ | $\begin{array}{\|l} 28 \\ .7 \\ 4 \\ \hline \end{array}$ |  |  |  | NIPTVNENLENYYLEVNQLEK |
| $\begin{aligned} & 850 . \\ & 386 \\ & 2 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & 32 \\ & .3 \end{aligned}$ | $\begin{aligned} & 33 \\ & .9 \end{aligned}$ |  |  |  | DGWQWFWSPSTFR |
| $\begin{array}{\|l} \hline 782 . \\ 956 \\ 5 \\ \hline \end{array}$ |  |  |  | 2 | Pos <br> itiv <br> e | $\begin{aligned} & 35 \\ & .0 \\ & 7 \\ & \hline \end{aligned}$ | 36 <br> .6 <br> 7 |  |  |  | SIVVSPILIPENQR |
| $\begin{aligned} & \hline 874 . \\ & 428 \\ & 5 \end{aligned}$ |  |  |  | 2 | Pos <br> itiv <br> e | $\begin{aligned} & 23 \\ & .1 \\ & 7 \end{aligned}$ | 24 .7 7 |  |  |  | GPDGLTAFEATDNQAIK |
| $\begin{aligned} & 652 . \\ & 026 \\ & \hline \end{aligned}$ |  |  |  | 3 | $\begin{array}{\|l} \hline \begin{array}{l} \text { Pos } \\ \text { itiv } \end{array} \\ \hline \end{array}$ | $\begin{aligned} & 19 \\ & .4 \\ & \hline \end{aligned}$ | $\begin{aligned} & 21 \\ & .0 \\ & \hline \end{aligned}$ |  |  |  | VAPEEHPVLLTEAPLNPK |


| 3 |  |  |  |  | e | 4 | 4 |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{aligned} & 796 . \\ & 659 \end{aligned}$ |  |  |  | 4 | Pos itiv e | 26 | $\begin{aligned} & 27 \\ & .6 \end{aligned}$ |  |  |  | $\begin{aligned} & \text { TTGIVMDSGDGVTHTVPIYEG } \\ & \text { YALPHAILR } \end{aligned}$ |
| $\begin{aligned} & 747 . \\ & 901 \\ & 2 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & 32 \\ & .5 \\ & 1 \\ & \hline \end{aligned}$ | $\begin{aligned} & 34 \\ & .1 \\ & 1 \end{aligned}$ |  |  |  | INVNEIFYDLVR |
| $\begin{aligned} & 852 . \\ & 080 \\ & 9 \end{aligned}$ |  |  |  | 3 | $\begin{aligned} & \hline \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $\begin{aligned} & 30 \\ & .3 \\ & 7 \\ & \hline \end{aligned}$ | $\begin{aligned} & 31 \\ & .9 \\ & \hline 7 \\ & \hline \end{aligned}$ |  |  |  | SNFLNC[+57.0]YVSGFHPSDIE VDLLK |
| $\begin{aligned} & 654 . \\ & 308 \\ & 5 \\ & \hline \end{aligned}$ |  |  |  | 3 | $\begin{aligned} & \hline \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $\begin{aligned} & 19 \\ & .7 \\ & 5 \end{aligned}$ | $\begin{aligned} & 21 \\ & .3 \\ & 5 \end{aligned}$ |  |  |  | YPIEHGIITNWDDMEK |
| $\begin{aligned} & 652 . \\ & 686 \\ & 1 \\ & \hline \end{aligned}$ |  |  |  | 3 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & 18 \\ & .4 \\ & 3 \\ & \hline \end{aligned}$ | $\begin{aligned} & 20 \\ & .0 \\ & 3 \\ & \hline \end{aligned}$ |  |  |  | VAPEEHPTLLTEAPLNPK |
| $\begin{aligned} & 649 . \\ & 338 \\ & 8 \\ & \hline \end{aligned}$ |  |  |  | 3 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \end{aligned}$ | $\begin{aligned} & 31 \\ & .1 \\ & 4 \\ & \hline \end{aligned}$ | $\begin{aligned} & 32 \\ & .7 \\ & 4 \\ & \hline \end{aligned}$ |  |  |  | VNPTVFFDIAVDGEPLGR |
| $\begin{aligned} & 799 . \\ & 876 \\ & 3 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \\ & \hline \end{aligned}$ | $\begin{aligned} & 21 \\ & .0 \\ & 7 \\ & \hline \end{aligned}$ | $\begin{aligned} & 22 \\ & .6 \\ & 7 \\ & \hline \end{aligned}$ |  |  |  | IIPGFMC[+57.0]QGGDFTR |
| $\begin{aligned} & 652 . \\ & 845 \\ & 9 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \\ & \hline \end{aligned}$ | $\begin{aligned} & 15 \\ & .0 \\ & 7 \end{aligned}$ | $\begin{aligned} & 16 \\ & .6 \\ & 7 \\ & \hline \end{aligned}$ |  |  |  | FLIPNASQAESK |
| $\begin{aligned} & 780 . \\ & 709 \\ & 4 \end{aligned}$ |  |  |  | 3 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $\begin{aligned} & 28 \\ & .9 \\ & 9 \end{aligned}$ | $\begin{aligned} & 30 \\ & .5 \\ & 9 \end{aligned}$ |  |  |  | EENVGLHQTLDQTLNELNC[+ \| 57.0]I |
| $\begin{aligned} & 657 . \\ & 836 \\ & 1 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \hline \text { Pos } \\ & \text { itiv } \\ & \text { e } \\ & \hline \end{aligned}$ | $\begin{aligned} & 14 \\ & .4 \\ & 5 \\ & \hline \end{aligned}$ | $\begin{aligned} & 16 \\ & .0 \\ & 5 \\ & \hline \end{aligned}$ |  |  |  | VNVDEVGGEALGR |
| $\begin{aligned} & 445 . \\ & 004 \end{aligned}$ |  |  |  | 4 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \\ & \hline \end{aligned}$ | $\begin{aligned} & 28 \\ & .9 \\ & 2 \\ & \hline \end{aligned}$ | $\begin{aligned} & 30 \\ & .5 \\ & 2 \\ & \hline \end{aligned}$ |  |  |  | $\begin{aligned} & \text { LLGNVLVC[+57.0]VLAHHFG } \\ & \text { K } \end{aligned}$ |
| $\begin{aligned} & 765 . \\ & 370 \\ & 8 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & 9 . \\ & 6 \end{aligned}$ | $\begin{aligned} & 11 \\ & .6 \end{aligned}$ |  |  |  | VGAHAGEYGAEALER |
| $\begin{aligned} & 536 . \\ & 280 \\ & 8 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \end{aligned}$ | $\begin{aligned} & 21 \\ & .8 \\ & 1 \\ & \hline \end{aligned}$ | $\begin{aligned} & 23 \\ & .4 \\ & 1 \\ & \hline \end{aligned}$ |  |  |  | MFLSFPTTK |
| $\begin{aligned} & 648 . \\ & 000 \\ & 1 \end{aligned}$ |  |  |  | 3 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & 28 \\ & .9 \end{aligned}$ | $\begin{aligned} & 30 \\ & .5 \end{aligned}$ |  |  |  | HVSSPLASYFLSFPYAR |
| $\begin{aligned} & 730 . \\ & 373 \end{aligned}$ |  |  |  | 2 | Pos <br> itiv <br> e | 16 .9 5 | 18 .5 5 |  |  |  | IADVTSGLIGGEDGR |




| 3 |  |  |  |  | e |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{array}{\|l} \hline 603 . \\ 802 \\ 1 \\ \hline \end{array}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & 14 \\ & .1 \\ & 4 \end{aligned}$ | $\begin{aligned} & 15 \\ & .7 \\ & 4 \\ & \hline \end{aligned}$ |  |  |  | MMAVAADTLQR |
| $\begin{aligned} & 409 . \\ & 549 \\ & 9 \\ & \hline \end{aligned}$ |  |  |  | 3 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \\ & \hline \end{aligned}$ | $\begin{array}{\|l\|} \hline 22 \\ .1 \\ 1 \\ \hline \end{array}$ | $\begin{aligned} & 23 \\ & .7 \\ & 1 \\ & \hline \end{aligned}$ |  |  |  | EEILMHLWR |
| $\begin{aligned} & \hline 606 . \\ & 988 \\ & 1 \\ & \hline \end{aligned}$ |  |  |  | 3 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & \hline 22 \\ & .3 \\ & 4 \end{aligned}$ | $\begin{aligned} & 23 \\ & .9 \\ & 4 \\ & \hline \end{aligned}$ |  |  |  | PSLSHLLSQYYGAGVAR |
| $\begin{aligned} & 746 . \\ & 858 \\ & 7 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & 29 \\ & .5 \\ & 6 \\ & \hline \end{aligned}$ | $\begin{aligned} & 31 \\ & .1 \\ & 6 \end{aligned}$ |  |  |  | TDC[+57.0]PGDALFDLLR |
| $\begin{aligned} & 879 . \\ & 806 \end{aligned}$ |  |  |  | 3 | $\begin{aligned} & \hline \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $\begin{array}{\|l\|} \hline 23 \\ .1 \\ 7 \end{array}$ | $\begin{aligned} & 24 \\ & .7 \\ & 7 \\ & \hline \end{aligned}$ |  |  |  | LQDIPYNIFNLPNIVELSVGHN K |
| $\begin{aligned} & 420 . \\ & 222 \\ & 1 \\ & \hline \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 3 . \\ & 71 \end{aligned}$ | $\begin{aligned} & 5 . \\ & 31 \end{aligned}$ |  |  |  | EHVDALR |
| $\begin{array}{\|l} \hline 826 . \\ 761 \\ 4 \\ \hline \end{array}$ |  |  |  | 3 | Pos itiv e | $\begin{aligned} & \hline 32 \\ & .3 \\ & 3 \\ & \hline \end{aligned}$ | $\begin{aligned} & 33 \\ & .9 \\ & 3 \\ & \hline \end{aligned}$ |  |  |  | GGLGSLFYLTLDVLETDC[+57 .0]HVLR |
| $\begin{aligned} & 456 . \\ & 799 \\ & 5 \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \end{aligned}$ | $\begin{aligned} & 22 \\ & .6 \\ & 4 \\ & \hline \end{aligned}$ | $\begin{aligned} & 24 \\ & .2 \\ & 4 \end{aligned}$ |  |  |  | LVVLPFPK |
| $\begin{array}{\|l} \hline 855 . \\ 938 \\ 5 \\ \hline \end{array}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \mathrm{e} \\ & \hline \end{aligned}$ | $\begin{aligned} & 29 \\ & .0 \\ & 2 \\ & \hline \end{aligned}$ | $\begin{aligned} & 30 \\ & .6 \\ & 2 \end{aligned}$ |  |  |  | IFSPFADLSELSATGR |
| $\begin{aligned} & 602 . \\ & 852 \\ & 1 \\ & \hline \end{aligned}$ |  |  |  | 2 | $\begin{aligned} & \text { Pos } \\ & \text { itiv } \\ & \text { e } \\ & \hline \end{aligned}$ | $\begin{aligned} & 21 \\ & .6 \end{aligned}$ | $\begin{aligned} & 23 \\ & .2 \end{aligned}$ |  |  |  | VMVTNVTSLLK |
| $\begin{array}{\|l\|} \hline 630 . \\ 834 \\ 8 \\ \hline \end{array}$ |  |  |  | 2 | Pos <br> itiv <br> e | $\begin{array}{\|l\|} \hline 20 \\ .8 \\ 6 \\ \hline \end{array}$ | $\begin{aligned} & 22 \\ & .8 \\ & 6 \\ & \hline \end{aligned}$ |  |  |  | VAYDLVYYVR |
| $\begin{array}{\|l} \hline 784 . \\ 443 \\ 8 \\ \hline \end{array}$ |  |  |  | 2 | Pos <br> itiv <br> e | $\begin{array}{\|l\|} \hline 35 \\ .0 \\ 7 \\ \hline \end{array}$ | $\begin{aligned} & 36 \\ & .6 \\ & 7 \\ & \hline \end{aligned}$ |  |  |  | VNGVLTALPVSVADGR |

